Curriculum Vitae Trisha Suppes, M.D., Ph.D. BIOGRAPHICAL

Trisha Suppes, M.D., Ph.D.

Page 1 of 68

04.17.19

Curriculum Vitae


BIOGRAPHICAL AND PERSONAL INFORMATION

Place of Birth: Palo Alto, California

Nationality: U.S. Citizen

ACADEMIC BACKGROUND

Stanford University, Stanford, California 09/69 – 06/73

B.A., Human Biology

University of California, Los Angeles, California 09/74 – 12/80

Ph.D., Department of Anatomy

Dartmouth Medical School, Hanover, New Hampshire 08/83 – 06/87

Medical Degree Program

CERTIFICATION

National Board of Medical Examiners

July, 1988

American Board of Psychiatry and Neurology

November, 1992

Massachusetts State Board of Medical Examiners

Currently Inactive

Texas State Board of Medical Examiners

Currently Closed

California State Board of Medical Examiners

G87908

Current

Drug Enforcement Administration

United States Department of Justice

BS0900767

Current


Page 2 of 68

04.17.19

PROFESSIONAL EXPERIENCE

Appointments Held

01/71 – 06/71 & Undergraduate Research Assistant, Dr. Donald Kennedy's

01/72 – 06/73 Laboratory, Department of Biology, Stanford University

09/73 – 06/74 Research Assistant, Institute for Mathematical Studies in the Social Sciences, Stanford

University

09/74 – 12/80 Graduate Student, Department of Anatomy, University of California, Los Angeles

09/77 – 12/80 Doctoral Candidate, Dr. Paul O'Lague's laboratory, Department of Biology, University of

California, Los Angeles

06/81 – 08/83 Postdoctoral Fellow, Dr. David Prince's laboratory, Department of Neurology, Stanford

University School of Medicine, Stanford, California

07/84 – 08/84 Research Associate, Neurochemical Pharmacology Unit of Medical Research at

Addenbrooke's Hospital, Cambridge, England

07/87 – 06/91 Resident in Adult Psychiatry, McLean Hospital, Belmont, MA

07/87 – 06/92 Clinical Fellow in Psychiatry, Harvard Medical School, Boston, MA

07/90 – 06/91 Research Associate, Dr. Paul Rosenberg, Department of Neurology, Children's Hospital,

Boston, MA

7/90 – 06/92 Neuroscience Fellow, Department of Psychiatry, Harvard Medical School and McLean

Hospital, Belmont, MA

07/92 – 10/94 Medical Director, Mental Health Mental Retardation Day Treatment Center, Dallas,

Texas

07/92 – 08/98 Assistant Professor, Department of Psychiatry, UT Southwestern Medical Center, Dallas,

Texas

10/97 – 06/00 Director, Bipolar Disorder Module, Texas Medication Algorithm Project (TMAP)

07/00 – 08/04 Director, Bipolar Disorder Module, Texas Implementation of Medication Algorithms

(TIMA)

10/00 – 09/02 Project Director, Systematic Treatment Enhancement Program for Bipolar Disorder

(STEP-BD) Women’s Studies, NIMH Contract

04/96 – 05/2008 Director, Bipolar Disorder Research Program, Department of Psychiatry, UT

Southwestern Medical Center, Dallas, Texas

09/98 – 08/05 Associate Professor, Department of Psychiatry, UT Southwestern Medical Center, Dallas,

Texas

09/05 – 05/08 Professor, Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.

6/08- 05/09 Adjunct Professor, Department of Psychiatry, UT Southwestern Medical Center, Dallas,

Texas

06/08 – Present Professor, Department of Psychiatry and Behavioral Sciences, Stanford School of

Medicine, Stanford, CA.

06/08 –10/18 Director, Bipolar and Depression Research Program, VA Palo Alto Health Care System,

Palo Alto, CA.

10/12 – Present Director, Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites

(NODES), VA Palo Alto Health Care System, Palo Alto, CA

02/13 – 08/14 Director, Center for Clinical Research, VA Palo Alto Health Care System, Palo Alto, CA

11/18 – Present Director, Exploratory Therapeutics Laboratory

Appointments Held – Committee

1977 – 1978 Mental Health Training Program Executive Committee, Graduate Student

Representative, Brain Research Institute, University of California, Los Angeles


Page 3 of 68

04.17.19

1985 – 1986 Committee on Graduate Housing, Dartmouth College, Student Representative for

Dartmouth Medical School, Hanover

1988 – 1989 Committee on Emergency Medical Care, McLean Hospital, Resident Representative

1989 – 1990 Treasurer, Resident's Association, McLean Hospital

1992 – 1998 Pharmacy Therapeutics Committee, Dallas County Mental Health Mental Retardation

Department

1993 – 1994 Membership Committee for the Society of Biological Psychiatry

1994 – 1995 Co-chair, Membership Committee, Society of Biological Psychiatry.

1994 – 2000 Research Committee, Department of Psychiatry, UT Southwestern Medical Center,

Dallas, TX.

1994 – Present Scientific Advisory Board (SAB), Depression and Bipolar Support Alliance (DBSA)

formerly National Depressive and Manic-Depressive Association (NDMDA).

1995 – 1996 Chair, Membership Committee, Society of Biological Psychiatry.

1997 – 1999 Member, Committee to Revise DSM-IV Mood Disorders, American Psychiatric

Association.

1997 – 2003 Member, Committee on Research on Psychiatric Treatments, Council on Research,

American Psychiatric Association (CCRPT).

1998 – 1999 Member, Committee on Psychiatric Knowledge and Skills Assessment Program

(PKSAP), American Psychiatric Association.

1998 – 2001 Member, Executive Committee, Scientific Advisory Board, National Depressive and

Manic-Depressive Association (NDMDA).

2000 – 2000 Committee Chair, Update on Texas Medication Algorithms, Dallas, TX.

2000 – 2001 Member, Bipolar Educational Awareness Material (BEAM) 4th & 5th Initiative

Educational Panel, Janssen Pharmaceutica Research Foundation.

2000 – 2003 Member, Committee on Practice Guidelines for the Treatment of Patients with Bipolar

Disorder, American Psychiatric Association.

2000 – 2001 Member, Task Force on Defining Response and Remission for Major Psychiatric

Disorders, American College of Neuropsychopharmacology (ACNP).

2000 – 2005 Member, Advisory Council on STEP-BD Women Studies, National Institute of Mental

Health (NIMH).

2001 Participant, Pharmacological and Somatic Treatment Development Workgroup,

Molecular and Cellular Neuroscience Research Division, National Institute of Mental

Health (NIMH).

2003 Chair, Bipolar Section on Co-occurring Disorders, COMAP: The Consensus Conference,

Dallas, Texas.

2004 – 2005 Committee Chair, Updates on Texas Medication Algorithms, Dallas, Texas.

2004 – 2005 Member, Biostatistics and Clinical Science Advisory Committee, University of Texas

Southwestern Medical Center at Dallas.

2005 – 2008 Member, Program Planning Committee, Society of Biological Psychiatry.

2005 – 2008 Member, Nomenclature Committee Project Development Meeting, International Society

for Bipolar Disorder, Pittsburgh, PA.

2005 – 2008 Member, Outline for Diagnostic Committee Task Force Groups Meeting, International

Society for Bipolar Disorder, Pittsburgh, PA.

2005 – 2008 Member, Departmental Appointments and Promotions Committee, Department of

Psychiatry, UT Southwestern Medical Center, Dallas, TX.

2006 – 2007 Member, Membership Committee, International Society of Bipolar Disorder.

2006 Member, Diagnostic Committee, Bipolar II Workgroup, Course and Outcome

Nomenclature (CON), International Society of Bipolar Disorder.


Page 4 of 68

04.17.19

2006 Member, Ad hoc Committee, Poster Judging, 2nd Biennial Conference of the International

Society for Bipolar Disorders, Edinburgh, Scotland.

2006 – 2011 Member, Data Safety Monitoring Board for collaborative R01 grant [R01 MH 071762]

Bipolar Disorder in Pregnancy and the Postpartum Period: Predictors of Morbidity (PI:

Viguera and Newport).

2006 –2007 Member, UT Southwestern Medical Center at Dallas Institutional Review Board 4.

2006 – 2009 Member, Work Group for the Practice Guidelines for Bipolar Disorder, American

Psychiatric Association.

2007 – 2012 Member, Workgroup for Mood Disorders, American Psychiatric Association Diagnostic

and Statistical Manual for Mental Disorders 5 (DSM5).

2007 – 2012 Chair, Sub Workgroup for Bipolar Disorder, American Psychiatric Association

Diagnostic and Statistical Manual for Mental Disorders 5 (DSM5).

2008 – 2011 Member, History Committee, American College of Neuropsychopharmacology.

2008 – 2014 Chair, Search Committees for two positions, Faculty for Psychiatry and Behavioral

Sciences, Stanford University School of Medicine, Stanford, CA.

2008 – 2012 Chair for Veterans Affairs and Department of Defense Bipolar Disorder Treatment

Guidelines.

2009 – Present Member, Industry Academia Liaison Committee, International Society for Bipolar

Disorders.

2009 – Present Member, Research Committee, International Society for Bipolar Disorders.

2009 – Present Member, Clinical Trials Working Group, International Society for Bipolar Disorders.

2009 – Present Member, Strategic Planning Committee, International Society for Bipolar Disorders.

2009 – Present Member, Scientific Planning Committee, International Society for Bipolar Disorders.

2007 – 2010 Member, Institutional Review Board, Panel 7, Stanford University, Stanford, CA.

2010 – Present Alternate, Faculty Senate, Department of Psychiatry and Behavioral Sciences, Stanford

University School of Medicine, Stanford, CA.

2010 – Present Member, Academic Progress—Appointments and Promotions Committee, Stanford

University School of Medicine, Stanford, CA.

2011 - 2014 Member, Program Committee, American College of Neuropsychopharmacology

(ACNP).

2011 – Present Member, R&D Committee, VA Palo Alto Health Care System, Palo Alto, CA.

2011 – Present Member, Scientific Advisory Board, International Forum on Mood and Anxiety

Disorders (IFMAD).

2011 – Present Member, Executive Committee, Stanford Mood Disorders Center, Stanford University

School of Medicine, Stanford, CA. 2010 – 2015 Member, Data Safety Monitoring Board for AHRQ R01 grant: Comparative

Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (PI: Perlis)

2011 – 2014 Member, Membership Committee, Society of Biological Psychiatry (SOBP) 2011 – 2017 Member, Program Committee, Society of Biological Psychiatry (SOBP) 2011 – 2015 Co-Chair, Service Members, Veterans & Military Families Task Group, National

Network of Depression Centers (NNDC) 2011 – Present Member, Bipolar Disorder Task Force, National Network of Depression Centers (NNDC) 2012 – 2013 Member, Selection Committee for Acting Chief of Staff (ACOS) of R&D, VA Palo Alto

Health Care System, Palo Alto, CA.

2013 – Present Member, Research Planning Council (RPC), VA Palo Alto Health Care System, Palo

Alto, CA.

2013 – Present Collaborator, Clinical Research Task Force, VA Palo Alto Health Care System, Palo

Alto, CA.


Page 5 of 68

04.17.19

2013 – 2015 Member, Scientific Program Committee, American College of Psychiatrists (ACP)

2014 – 2017,2019 Mentor, Research Colloquium for Junior Investigators, APA Annual Meeting

2015 – Present Member, Professioriate Committee, Stanford University, Department of Psychiatrity and

Behaviorial Health

2015 – Present Member, Executive Research Advisory Council, VA Palo Alto Health Care System, Palo

Alto, CA.

2015 – Present ISBD Women’s Initiative, founder and continuing member

2016 – Present Member, Executive Committee, Veteran Affairs, Cooperative Studies Program (CSP)

Network of Dedicated Enrollment Sites (NODES)

2017 – Present Alternate, A&P Committee, Stanford University, School of Medicine

2017 – 2019 Member, VA CSP Coordinating Center Palo Alto director search committee

2018 Member, VA Professoriate search committee focused on brain stimulation

2017-2019 ASCP CME Committee

2019 Member, International Scientific Program Committee for the World Congress of

Biological Psychiatry

Awards

09/74 –08/78 Appointed to the Mental Health Training Program, Brain Research Institute, University

of California, Los Angeles

06/80 – 12/80 Chancellor’s Patent Fund Grant, University of California, Los Angeles

06/81 – 06/83 McCormick Fellowship, Stanford University School of Medicine, Stanford

07/84 – 08/84 Summer Research Fellowship, Scottish Rite Foundation for Schizophrenic Research at

Addenbrooke’s Hospital, Cambridge, England

07/90 – 06/92 Neuroscience Fellowship in Psychiatry, McLean and Massachusetts General Hospitals in

the Department of Psychiatry, Harvard Medical School

05/91 Stanley Cobb Prize, Boston Society

05/92 Dista Travel Fellowship Award, Society of Biological Psychiatry

12/92 Outstanding Team Effort, AMH Contract Services, Dallas County Mental Health and

Mental Retardation Center

07/93 – 06/95 Young Investigator Award, National Alliance for Research on Schizophrenia and

Depression (NARSAD)

05/94 Outstanding PGY-III Teacher of the Year Award 1993-94, Department of Psychiatry, UT

Southwestern Medical Center

06/94 McCurley Award for Treatment of Patients with Rapid Cycling Bipolar Disorder

08/94 – 07/96 Scientist Development Award (1-K2-MH-01221-01), Principal Investigator, National

Institute of Mental Health (NIMH)

07/95 – 06/97 Young Investigator Award, National Alliance for Research on Schizophrenia and

Depression (NARSAD)

05/95 Nominated for Outstanding PGY-III Teacher of the Year 1994-95, Department of

Psychiatry, UT Southwestern Medical Center

1996 Co-recipient, 1996 Gerald L. Klerman Young Investigator Award, National Depressive

and Manic-Depressive Association

1996-2010 Elected by peers for inclusion in the Best Doctors in America®

05/96 Outstanding PGY-III Teacher of the Year Award 1995-96, Department of Psychiatry, UT

Southwestern Medical Center

05/02 Nominated PGY-IV Outstanding Teacher of the Year 2001-02, Department of



Page 6 of 68

04.17.19

05/04 Nominated PGY-IV Outstanding Teacher of the Year 2003-2004, Department of


2005 – Present Elected to Distinguished Fellow, American Psychiatric Association

05/05 Nominated for Outstanding PGY-IV Teacher of the Year 2004-2005, Department of


2006 – 2008 Councilor, Board of Councilors, International Society for Bipolar Disorders.

2007 2007 Texas Super Doctors, Texas Monthly

2008 Recipient, 2008 Gerald L. Klerman Senior Investigator Award, Depression and Bipolar

Support Alliance.

2009 – 2013 Councilor, Board of Councilors, International Society for Bipolar Disorders.

12/09 Elected to Fellow, American College of Neuropsychopharmacology (ACNP)

2010 Selected by the Consumers' Research Council of American Psychiatric Association as

one of America’s Top Psychiatrists.

2013 Elected as a member, American College of Psychiatrists

2014-2015 Elected as Treasurer/Secretary to International Society of Bipolar Disorders

2014 Reuter’s Top 1% Globally Influential Psychiatrists Over Last 10 Years

2014-2017 Chair, Finance Committee, International Society for Bipolar Disorder

2016 Elected to Distinguished Life Fellow, American Psychiatric Association

2016 Chair, Program Committee, Washington DC meeting, International Society for Bipolar

Disorders

2016-2017 Reelected as Treasurer/Secretary to International Society of Bipolar Disorders

2017-2025 Elected to American Society of Clinical Psychopharmacology (ASCP) Board Member

2018-2020 Elected President to International Society of Bipolar Disorders

Pharmaceutical Advisory Board

1999 – 2001 Bipolar Disorder Advisory Board, Pharmaceutical Research Institute

06/98 – 2006 US Bipolar Advisory Board Committee, Eli Lilly and Company, Indianapolis, IN

1998 – 2006 Bipolar Disorder Advisory Board, GlaxoSmithKline

1998 – 04/07 Bipolar Disorder Advisory Board, Abbott Laboratories

1998 – 2005 Bipolar Disorder Advisory Board, Janssen Pharmaceutica Products

1999 – 2006 Bipolar Disorder and National Advisory Board, AstraZeneca

2000 – 2003 Bipolar Advisory Board, Johnson and Johnson Pharmaceutical Research and

Development

2000 – 2006 Bipolar Advisory Board, Novartis Pharmaceuticals

2000 – 2006 Bipolar Advisory Board, Bristol-Myers Squibb

2001 – 2006 Geodon Bipolar Disorder Advisory Board, Pfizer US Pharmaceuticals

2002 – 2005 Bipolar Disorder Advisory Board, UCB Pharmaceutical

2004 – 2005 Bipolar Disorder Advisory Board, Shire Inc.

2008 – 2008 Bipolar Disorder Advisory Board, Orexigin Therapeutics Inc.

2012 –2015 Bipolar Disorder Advisory Board, Sunovion Pharmaceuticals Inc.

2014 -2015 Merck, Clinical Insomnia US Advisory Board

2018 Allergan Advisory Board

Editorial Boards

9/99 – 7/00 Section Editor, Nonschizophrenic Psychotic Disorders, Current Science

4/00 – 2001 Editorial Board Member, Psychiatric Practice Success Newsletters


Page 7 of 68

04.17.19

10/00 – Present Editorial Board, Bipolar Disorders – An International Journal of Psychiatry and

Neurosciences

02/01 – Present Editorial Board, Clinical Approaches in Bipolar Disorders Journal

2007 – 2014 Associate Editor, American Journal of Psychiatry

2007 – Present Advisory Board Member, bp Magazine

2012 – Present Editorial Board Member, Depression and Anxiety

2012—2016 Editorial Board Member, International Journal of Bipolar Disorders

2016 – Present Associate Editor, International Journal of Bipolar Disorders

2018 Editorial Board Member, Bipolar Disorders

Ad-Hoc Editorial Review

1993 The Medical Letter

1995 – Present The Journal of Psychiatric Research

2003 – Present Neuropsychopharmacology & Biological Psychiatry

1993 – Present The Journal of Clinical Psychiatry

1993 – Present Biological Psychiatry

1996 – Present Psychiatric Services

1996 – Present Neuropsychopharmacology

1996 – Present Journal of Clinical Psychopharmacology

1998 – Present Psychological Medicine

1998 – Present Comprehensive Psychiatry

1999 – Present Journal of Affective Disorders

1999 – Present International Clinical Psychopharmacology

1999 – Present Bipolar Disorders

1999 – Present American Journal of Psychiatry

2004 − Present Expert Consensus Guidelines

2004 – Present Archives of General Psychiatry (JAMA, Psychiatry)

2005 – Present CNS Drugs

2007 – Present Schizophrenia Bulletin

2007 – Present International Journal of Neuropsychopharmacology

2009 – Present Journal of Psychopharmacology

2009 – Present Journal of Traumatic Stress

2015 – Present Nordic Journal of Psychiatry

Review Committee Duties

1995 Scientific Abstract Reviewer, 35th Annual New Clinical Drug Evaluation Unit (NCDEU)

1999 Reviewer (one of 10 invited experts nationally), National Clinical Treatment Guidelines

for Bipolar Disorder, Department of Veterans Affairs

2001 Reviewer, National Institute of Mental Health Intramural Program

2003 – Present Scientific Abstract Reviewer, 43rd Annual New Clinical Drug Evaluation Unit (NCDEU)

2002-2005 Secretarial Appointee, Department of Veterans Affairs Medical Research Service Merit

Review Subcommittee for Mental Health and Behavioral Science

2005-2007 Member, Special Emphasis Panel, National Institutes of Health Extramural Loan

Repayment Program

10/19/06-10/20/06 Chairperson, National Institutes of Health, Special Emphasis Panel, Child

Psychopathology and Developmental Disabilities study section


Page 8 of 68

04.17.19

11/20/06-11/21/06 Reviewer, National Institute of Mental Health, Mental Health Centers for Intervention

Development & Applied Research (CIDAR)

2007 Reviewer, National Institute of Mental Health, Loan Repayment Program

10/18/07 Reviewer, National Institute of Mental Health, Mental Health Centers for Intervention

Development & Applied Research (CIDAR)

2010 Reviewer, National Institute of Mental Health, Loan Repayment Program (LRP)

2010 Reviewer, National Institute of Mental Health, Special Emphasis Panel/ Scientific

Review Group

2012 Reviewer, National Institute of Mental Health, Loan Repayment Program (LRP)

2013-present Reviewer, National Institute of Mental Health, Special Emphasis Panel/ Scientific

Review Group

2016 Reviewer, National Institute of Mental Health, Fellowship

Professional Society Memberships

1973 – 1999 Member, Society of Neuroscience

1981 – 1998, Member, American Association for the Advancement of Science

2016 – 2018

1986 – 1997 Member, New York Academy of Science

1997 – 2001 Associate Member, American College of Neuropsychopharmacology (ACNP)

1996 – 2002 Member, Texas Society of Psychiatric Physicians

1998 – 2014 Member, American Medical Association

1984 – 2016 Distinguished Fellow, American Psychiatric Association (APA)

1995 − 2008 Member, Dallas Area Women Psychiatrists

1995 – Present Member, Society of Biological Psychiatry (SOBP)

1998 – 2008 Member, Dallas County Medical Association

2000 – 2008 Member, International Society for Affective Disorders

2001 – Present Member, International Society for Bipolar Disorders

2005 – 2009 Member, American College of Neuropsychopharmacology (ACNP)

2009 – Present Fellow, American College of Neuropsychopharmacology (ACNP)

2010 – 2014 Member, World Federation of Societies of Biological Psychiatry (WFSBP)

2010 – 2016 Distinguished Fellow, Northern California Psychiatric Society (NCPS)

2016 – Present Lifetime Distinguished Fellow, American Psychiatric Association (APA)

2018 American College of Neuropsychopharmacology (ACNP)

2019 Emeritus Member, American College of Psychiatrists (ACP)

Teaching

09/75 – 03/76 Gross Anatomy, Department of Anatomy, School of Medicine, University of California,

Los Angeles, California

03/76 – 05/76 Neurology for Medical Students, Department of Anatomy, School of Medicine,

University of California, Los Angeles, California

09/76 – 12/76 Microscopic Anatomy, Department of Anatomy, School of Medicine, University of

California, Los Angeles, California

09/77 – 12/77 Introduction to Neurobiology, Department of Biology, University of California, Los

Angeles, California

09/91 – 11/91 Human Nervous System and Behavior, Harvard Medical School, Boston, Massachusetts

12/92 PGY-II Clinical Neuroscience Mood Disorders Module: Biology of Mania, UT



Page 9 of 68

04.17.19

06/93 – 06/95 Introductory Lecture on Psychopharmacology – PGY-II Level – six times per year, UT


12/93 Mental Health Mental Retardation Training Session, Schizoaffective Disorders, UT


03/94 – 2000 Yearly PGY-III Advanced Clinical Neuroscience Section on Bipolar Disorder, UT

Southwestern Medical Center, Department of Psychiatry, Dallas, Texas (4-5 lectures per

year)

08/94 Schizoaffective and Bipolar Mood Disorders, Psychopathology and Treatment Course,

UT Southwestern Medical Center, Dallas, Texas

1994 Quarterly Case Conference, Mental Health Connection, St. Paul's Hospital, UT

Southwestern Medical Center, Department of Psychiatry, Dallas, Texas

1994 – 5/2008 Case Conference, Parkland Psychiatry Outpatient Service

08/95 Lecture on Treatment-Resistant Bipolar Disorder, Parkland Memorial Hospital, Dallas,

Texas

12/6/96 Update on Medication Treatment for Bipolar Disorder Workshop, Texas Medication

Algorithm Project (TMAP), San Antonio (see various lectures in Texas on Medication

Algorithms for Bipolar Disorder Center), Dallas, Texas

1998 – 2003 PGY-IV Advanced Complicated Bipolar Disorder, UT Southwestern Medical, Dallas,

Texas, 1 lecture/year.

11/00 Consultation Liaison Medical Update, UT Southwestern Medical Center, Dallas, Texas

2001 “How to Integrate a Clinical and Research Career”, Faculty Workshop, UT Southwestern

Medical Center, Dallas, Texas

01/2001 – 07/2007 Course Co-Director, PGY-II – PGY-III (18-month) of Clinical Neuroscience at UT

Southwestern Medical Center, Department of Psychiatry, Dallas, Texas

01/2001 – 05/2008 PGY-II Lecturer on Bipolar Disorder (4-5 lectures each year) at UT Southwestern

Medical Center, Department of Psychiatry, Dallas, Texas

2002 Suppes T, Cullum M. “How to Integrate a Clinical and Research Career”, Faculty

Workshop, UT Southwestern Medical Center, Dallas, Texas

2002 PGY-IV Lecture on Psychopharmacology II: Bipolar Disorder, UT Southwestern


2002 Lecture on Bipolar Disorder for Neurology Residents, UT Southwestern Medical Center,

Dallas, Texas

2003 Lecture on Research in Bipolar Disorders, UT Southwestern Medical Center, Dallas,

Texas

2003 MS3 Summer Internship Lecture on Research in BP Disorders, UT Southwestern


2003 – 05/2008 Yearly lectures for Research Track, Psychiatric Residents, UT Southwestern Medical

Center, Dallas, Texas

2003 – 05/2008 Yearly PGY-IV Lecture: “Mechanisms of Action of Mood Stabilizers,” UT Southwestern


2004 – 05/2008 MS3 Yearly Lecture on Bipolar Disorders, UT Southwestern Medical Center, Dallas,

Texas

Mentees

1993 – 1994 Psychopharmacology Supervision of Catherine Fontaine, M.D., Ava Lee, M.D., and

Charles Mathis, M.D., PGY-III UTSW Psychiatric Residents.

1994 – 1995 Supervision of Ray Clark, M.D. and Valerie Meshack, M.D., PGY-III UTSW Psychiatric

Residents.


Page 10 of 68

04.17.19

1994 – 1995 Louis Costello, M.D., PGY-III – A clinically significant interaction between clozapine

and valproate (Letter). Journal of Clinical Psychopharmacology, 1995,15(2):139-141.

1994 – 1995 E. Sherwood Brown, Ph.D., M.D., PGY-II – Development of scientific interest and

completion of publication: Capgras’ and Fregoli’s syndromes in one family (Letter).

Journal of Clinical Psychiatry, 1995; 57(3):137-138.

1995 Psychotherapy Supervision of Esther Cooper, M.D. and Ray Clark, M.D., PGY-IV

Psychiatric Residents (6 months Psychotherapy).

1995 – 1996 Psychopharmacology Supervision of Antonio Roman, M.D. and Vidyasagar Vangala,

M.D., PGY-III Psychiatric Residents.

1996 – 1997 Research and Psychopharmacology Supervision of E. Sherwood Brown, Ph.D., M.D.,

PGY-IV Psychiatric Resident (Research Track).

1996 – 1997 Psychopharmacology Supervision of James Knoll, M.D., PGY-III Psychiatric Resident.

1996 – 1998 Research Supervision of E. Sherwood Brown, Ph.D., M.D., Mentorship of NIMH

Fellowship (see references for publications)

1997 – 1998 Research and Psychopharmacology Supervision of Phyll Zuberi, M.D., PGY-IV

Psychiatric Resident (Research Track).

1999 – 2003 Mentorship of Ellen B. Dennehy, Ph.D., NARSAD Young Investigator Award.

2000 Supervision of Melissa de la Garza, Stanley Summer Scholars Program, Southern

Methodist University.

2001 – 2002 Research Mentorship of Robert Gonzalez, PGY-I Psychiatric Resident.

2001 – 2002 Clinical Supervision of PGY-IV Psychiatric Resident: Daralynn Deardorff and R. Surya

2001 – 2003 Research Supervision of Mehmet Ozcan, M.D., Psychopharmacology Fellowship,

Department of Psychiatry, UT Southwestern Medical Center

2002 Clinical Supervision of PGY-IV Psychiatric Resident: Laura Beard

2002 Research and Clinical Supervision of Southern Methodist University Department of

Psychology master’s level psychology students; Fallon Cluxton and Lori Cohen

2002 Research and Clinical Supervision of Michael Lutter, Medical Student IV, Medical

electives.

2002 Clinical Supervision of Michael Shiekh, PGY-IV Psychiatric Resident.

2003 Eric Curley, MS I Summer Internship Program.

2003 – 2004 Mentorship of Lisa Monteggia, Ph.D., Assistant Professor, Department of Psychiatry, UT

Southwestern Medical Center.

2003 – 2004 Research and Clinical Supervision of Geetha Shivakumar, PGY-IV Psychiatric Resident.

2003 – 2004 Clinical Supervision of Rob Garrett, PGY-IV Psychiatric Resident.

2000 – 2004 Research Mentorship of PGY Resident: Paul Carlson, M.D. and mentor for APA Janssen

Fellowship for Research in Severe Mental Illness, New Clinical Drug Evaluation Unit

(NCDEU) New Investigator Award, 2003.

2003 – 2008 Mentorship of Kathleen Saine, Ph.D., UT Southwestern Medical Center.

2003 – 2005 Mentorship of Heidi Jacobe, M.D., Assistant Professor of Dermatology, UT


2003 – 2006 Mentorship of Laura Lacritz, Ph.D., Assistant Professor of Psychology, UT Southwestern

Medical Center.

2003 – 2005 Mentorship of Vicki Nejtek, Ph.D., Assistant Professor, Department of Psychiatry, UT


2003 – 2006 Research and Clinical Supervision of Guohua Xia and Robert Gonzales (July 2004, PGY-

III), PGY-II Psychiatric Residents.

2003 – 2006 Research and Clinical Supervision of Kevin Majeres, PGY-III Psychiatric Resident (July

2004, PGY-IV, Research Track).


Page 11 of 68

04.17.19

2004 – 2006 Research Supervision of Geetha Shivakumar, M.D., Mood Disorders Clinical

Intervention Training Program, NIMH Fellowship.

2004 – 2005 Research and Clinical Supervision of Erich Swafford and Scott Bartley, PGY-IV

Psychiatric Residents.

2004 – 2006 Research and Clinical Supervision of Ryan Estevez, PGY-III Psychiatric Resident;

Stanley Medical Research Institute Grant to pursue his research interests in his PGY-IV

year.

2005 – 2006 Mentorship of Ryan Estevez: Janssen Resident Psychiatric Research Scholar.

2005 – Present Research and Clinical Supervision of F. Andrew Kozel, M.D., M.S.C.R., Director of

TMS Clinic & Staff Psychiatrist in Mental Health and Behavioral Sciences, Associate

Investigator in HSR&D Center of Innovation on Disability and Rehabilitation Research,

James A. Haley VAH; Associate Professor, Department of Psychiatry and Behavioral

Sciences, University of South Florida

2006 – 2008 Research and Clinical Supervision of Robert Gonzalez, M.D. NIMH Research Fellow.

2006 – Present Research and Clinical Supervision of Robert Gonzalez, M.D. Supervision as Medical

Student; Resident; Research Fellow; and continued mentorship of his academic work.

Dr. Gonzalez is currently an Associate Professor, Tenure-Track Department of Psychiatry

and Neural and Behavioral Sciences, Penn State College of Medicine, Milton S. Hershey

Medical Center

2006 – 2008 Research and Clinical Supervision of Ryan Estevez, M.D., Ph.D., Instructor in

Psychiatry, UT Southwestern Medical Center.

2006 – 2008 Mentorship of Kirti Saxena, M.D., Assistant Professor of Psychiatry, UT Southwestern

Medical Center.

2006 – present Mentorship of Geetha Shivakumar, M.D., Assistant Professor of Psychiatry, UT

Southwestern Medical Center, currently at the rank of Associat Professor.

2007 MS I Summer Internship Program, Xi Luo.

2007 MS I Summer Internship Program, Elizabeth Carroll.

2009 – 2012 Research and Clinical Supervision of Huaiyu Yang, M.D., MIRECC Fellow.

2009 – 2010 Mentorship of Jeong Seok Seo, M.D., Visiting Associate Professor, Department of

Psychiatry and Behavioral Sciences, Stanford University.

2011 – 2013 Jennifer Dore, Pgy II Resident

2011 – 2014 Michael Ostacher, MD, MPH, MMSc, Assistant Professor, Psychiatry and Behavioral

Sciences, Stanford University School of Medicine, Staff Physician at VA Palo Alto

Health Care System

2014 - Present Michael Ostacher, MD, MPH, MMSc, Associate Professor, Psychiatry and Behavioral

Sciences, Stanford University School of Medicine, currently at the rank of Professor.

2009 – Present Victoria Cosgrove, PhD, Postdoctoral Fellow War Related Illness and Injury Center, VA

Health Sciences Center Palo Alto (2009-2012); Instructor, Psychiatry and Behavioral

Sciences, Stanford University School of Medicine (2012-2014); and currently Clinical

Assistant Professor, Psychiatry and Behavioral Sciences, Stanford University School of

Medicine

2012 – 2014 Shefali Miller, MD, MIREC PostDoctoral Fellow, VA Palo Alto Health Care System

2014 – 2018 Shefali Miller, MD, Clinical Assistant Professor, Psychiatry and Behavioral Sciences,

Stanford University School of Medicine

2011-2017 Natalie Feldman, Research Assistant

2011-2018 Emma Gliddon, Research Assistant

2013-2016 David Grimm, Research Assistant

2015 Kaegan Engstrom-Garner, Research Assistant


Page 12 of 68

04.17.19

2016-2017 Talya Feldman, Research Assistant

2016-Present Allyson Rosen, PhD, ABPP Clinical Associate Professor (Affiliated)

Department of Psychiatry and Behavioral Sciences, Stanford University School of

Medicine

2017-Present Nicole Kramer-Lange, Research Assistant and Psy-D student Palo Alto University

2017-Present Jihun “Jay” Lyu, graduate student at Palo Alto University

2017-2019 Ben Hambro, MD, pre-residency in Psychiatry

2017-Present Serena Tally, pre-medical student

2018-2019 Mette Fredskild, Lundbeck Foundation Scholar, Psychiatry and Behavioral Sciences

RESEARCH SUPPORT

Current Research Support (Principal Investigator)

Merck&Co.9760

A double-blind, randomized, placebo-controlled trial of adjunctive suvorexant for treatment-resistant insomnia

in patients with bipolar disorder, (PI)

2018- present

PRIME Care (Precision Medicine in Mental Health)

This project is designed to evaluate the utility of PGx testing in treating Major Depressive Disorder, (PI)

6/21/17- present

VA Cooperative Studies Program

NODES (Network of Dedicated Enrollment Sites) Renewal (Director)

2016-2019

Current Research Support (Co-investigator/other)

APP1169845

The Candesartan Adjunctive bipolar DEpression Trial – CADET (CI)

MRFF - Research Grants

2019-2024

PI-Berk

Palo Alto Health Sciences, Inc.

Investigation of the Freespira Breathing System in the Treatment of PTSD

Goal: Trial of a novel breathing device to treat PTSD. (Co-I)

11/2016 - present

VA Cooperative Studies Program

CSP 590, Lithium for Suicidal Behavior in Mood Disorders (Li+) (Co-I)

2015- present

1UH2AG052163-01

Engaging self-regulation targets to understand the mechanisms of behavior

change and improve mood and weight outcomes (Consultant)

Goal: To assess if measures tailored to specific brain mechanisms would

improve behavior change.

08/2015 - present


Page 13 of 68

04.17.19

NIDA 1R34DA040119

Web-based ACT for smoking cessation in bipolar disorder (Co-I)

Goal: To test an internet intervention using motivational interviewing to

support smoking cessation

05/2015 – present

NIMH ROI MH1010496

Neural Dimensions of Threat Reactivity and Regulation for Understanding

Anxiety (Co-I)

Goal: Identifying the neural basis of anxiety.

08/2013-present

1 I01 RX003152-01

Targeting Functional Improvement in rTMS Therapy (Co-I)

01/01/2019 till 12/31/2022

PI- Rosen

Pending Research Support (Principal Investigator/other)

RX002652

Improving Implementation of Clinical rTMS Targeting, (Consultant)

7/1/18-6/30/22

PI-Rosen

Past Research Support (Principal Investigator)

NIH - Grant: 1R34MH091284 - 01A1

A Randomized trial of internet based interventions for bipolar disorder (PI)

2012 - 2018

Stanley Medical Research Institute

A Multisite, Randomized, Double Blind Placebo controlled 12 weeks Study Evaluating the Efficacy, Safety and

Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression, (PI)

2015 – 2018

Pathway Genomics

Pharmacogenetics in Treatment Refractory Depression, Replication Study, (PI)

Goal: If genetics information of medication side effects was available will

prescriber patterns be impacted?

2015- 2018

Year Initiated – 2012

NIH - Grant: 1R34MH091284 - 01A1

A Randomized trial of internet based interventions for bipolar disorder (PI)

2012-2018

Industry Funding

Sunovion Pharmaceuticals Inc.

March 2012 – 2016


Page 14 of 68

04.17.19

D1050296 – A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of

Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects with Bipolar I

Disorder.


August 2012 – 2016

D1050308 – A multicenter, open-label, flexible-dose extension study of lurasidone adjunctive to lithium or

divalproex in subjects with bipolar I disorder.

Elan Pharmaceuticals, Inc.

September 2012 –2014

ELND005-BPD201: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and

Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder

Federal/State Funding

National Institute of Mental Health

April 2011 – March 2014

Collaborative R34 (NIMH # MH091284) – A Randomized Trial of Internet-based Interventions for Bipolar

Disorder.

Federal Funding

Veterans Administrations Cooperative Studies Program

Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES)


August 2012 – 20161

CSP #576: VA Augmentation and Switching Strategies for Improvement of Depression Treatment (VAST

Improvement-D).


August 2012 –2014

CSP #572: Genetics of Functional Disability in Bipolar Illness and Schizophrenia

Foundation

Marriott Award in Individualized Medicine

Fall 2008

(Mark Frye, MD and Joanna Biernacka, Ph.D., PIs)

The Mayo Bipolar Collaborative NetworkCore Biorepository (Consultant).

Federal Funding


December 2010 – November 2012

(Roy H. Perlis, MD MSc, PI)

AHRQ R01 – Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic

Mood Stabilizer for Bipolar Disorder (DSMB Consultant).


December 2007 – November 2012


Page 15 of 68

04.17.19

(C. Tamminga, MD, PI)

Collaborative R01 – Bipolar & Schizophrenia Consortium for Parsing Endophenotypes (Consultant).


Industry Funding


August 2011 – 2016

D1050304 – A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study

of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features.


August 2011 – 20116

D1050306 – A 12-Week, Open-Label Extension Study for the Treatment of Major Depressive Disorder with

Mixed Features


Industry Funding

Pfizer, Inc.

December 2009 – June 2011

A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder with Comorbid

Lifetime Panic or Generalized Anxiety Disorder.


Federal Funding

National Institute of Mental Health (NIMH)

July 2004 – June 2009

NIMH # R01 MH69801-01 – Bipolar I Mania: Open label Divalproex and Randomized, Double-Blind Placebo,

Lithium, or Quetiapine for Treatment of Mania.

Industry Funding

AstraZeneca

August 2007 – July 2009

A Randomized, Double-Blind, Placebo-Controlled Study of Quetiapine SR Monotherapy and Divalproex

Sodium ER Monotherapy in Ambulatory Bipolar Disorder with Current at least Moderately Severe Anxiety and

Lifetime Panic or Generalized Anxiety Disorder.

AstraZeneca

February 1, 2007 – May 31, 2007

A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy

and Safety of Quetiapine Fumarate Sustained-release as Monotherapy in Adult Patients with Acute Bipolar

Depression.


Foundation Funding


July 2006 – December 2007

rTMS for Acute Treatment of Depressed Phase of Bipolar Disorder Type II (A. Kozel, M.D., PI).

Industry Funding


Page 16 of 68

04.17.19

Pfizer, Inc.

September 2006 – August 2007

A Phase 3, Randomized, 6-month, Double Blind Trial in Subjects with Bipolar I Disorder to Evaluate the

Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs. Placebo Plus a Mood

Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment with Both Agents

(A1281137)

Federal Funding

National Institutes of Mental Health

July 1, 2006 – June 30, 2012

NIMH # 5R01MH74928-3 – Bipolar II Depression: Randomized, Double-Blind Study of Lithium, SSRI, or the

Combination for Treatment of Depression.


Foundation Funding


March 1, 2005 – February 28, 2008

A Preliminary Study of the Effectiveness and Tolerability of 4-Aminopyridine in Bipolar Depression (Estevez,

M.D., Ph.D., PI)

Industry Funding

Wyeth Research Division of Wyeth Pharmaceuticals Inc.

August 2005 – April 2007

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Bifeprunox in the

Treatment of Depression in Outpatients with Bipolar Disorder

Novartis

January 2005 – November 2007

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and

Tolerability of Licarbazepine 750-2500 mg/d Combined with Lithium or Valproate in the Treatment of Manic

Episodes of Bipolar I Disorder over 6 weeks.

Novartis

January 2005 – November 2007

A 52-Week, Open-Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750/2000

mg/d Combined with Lithium or Valproate in the Treatment of Manic Episodes of Bipolar I Disorder Over 6

Weeks


Foundation Funding


April 2004 – July 2007

Changes in Cerebral Glucose Metabolism as Potential Predictor of Treatment Response to Medication

Treatment in Bipolar II Depression (C. Tamminga, M.D., PI)

Industry Funding

AstraZeneca

September 2004 – September 2007


Page 17 of 68

04.17.19

A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy and Safety of

Quetiapine Fumarate (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct

to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult

Patients

Janssen Pharmaceuticals

October 2004 – October 2005

A Randomized, Double-blind, Placebo-controlled Study of Risperidone Monotherapy in Ambulatory Bipolar

Disorder with Current at least Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder




August 2003 – August 2006

R-21 - Acute Treatment of Bipolar II Depression

Foundation Funding


January 2003 – January 2006

BPN Data Collection at Dallas serves as a permanent repository for data collected at the Dallas site of patient

demographic information and study-related data. Funding is used to interface with the database center at UCLA

and to share this information with other Stanley-funded research institutes when explicit queries are made.



Modafinil (Provigil) in the Treatment of Bipolar Depression Inadequately Responsive to Current Therapy: A

Placebo-controlled Investigation



A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression


Foundation Funding


August 2002 – August 2005

A Two-site, Randomized Comparison of Lamotrigine and Lithium in 80 Patients with Bipolar Type II

Depression



Texas Department Mental Health and Mental Retardation (TDMHMR)


Texas Implementation of Medication Algorithms (TIMA)

R03 - NIMH (National Institute of Mental Health)

February 2001 – February 2004

Adjunctive Acupuncture as a Treatment for Bipolar Depression, National Institute of Mental Health


Page 18 of 68

04.17.19

Foundation Funding


July 2002 – July 2004

Low-dose Testosterone Augmentation Therapy in Depressed Patients with Bipolar Disorder

Stanley Foundation Bipolar Network

January 2001 – December 2001

Long Term Follow-up of Patients with Bipolar Disorders

Industry Funding

Novartis

April 2001 – January 2003

An Open Add-On Study of Trileptal vs. Depakote for Hypomania in Patients with Bipolar Disorder

Glaxo Wellcome, Inc.


A Multicenter, Double-blind, Placebo-controlled, Fixed-dose Evaluation of the Safety, Efficacy and Tolerability

of Lamictal (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Type I Bipolar

Disorder

AstraZeneca Pharmaceuticals

January 2001 – August 2001

Evaluating the Effects of Add-On Seroquel for Patients with Bipolar Disorder



NIMH (National Institute of Mental Health)

October 2000 – October 2002

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) (N01-MH60006)

Foundation Funding


August 2000 – March 2005

A Pilot Safety and Efficacy Study of Vagus Nerve Stimulation in Patients with Rapid Cycling Bipolar Disorder

Forrest C. Lattner Foundation, Inc.


Complementary Therapies for Treatment of Bipolar Disorder

Industry Funding

AstraZeneca Pharmaceuticals LP

September 2000 – November 2001

A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Safety and Efficacy of Seroquel, as

Add On therapy with Lithium and Divalproex in Treatment of Acute Mania (5077IL-0099)


Page 19 of 68

04.17.19

Bristol-Myers Squibb

June 2000 – May 2002

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Aripiprazole in the Maintenance

Treatment of Patients with Bipolar Disorder (CN138-010)

Bristol-Myers Squibb

June 2000 – May 2002

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Flexible Doses of Aripiprazole in the

Treatment of Patients with Acute Mania (CN138-009)

Janssen Pharmaceutica Products

March 2000 – March 2001

Development of a Pilot Tool for Diagnosis of Bipolar Disorder


Foundation Funding

Timberlawn Psychiatric Research Foundation, Inc.

September 1999 – April 2002

Usefulness of Psychoeducational Group Therapy for Patients with Bipolar Disorder

Stanley Foundation Bipolar Network,

August 1999 – March 2004

Acupuncture to Treat Mood Lability in Bipolar Disorder

Industry Funding

Eli Lilly

May 1999 – November 1999

Olanzapine vs. Divalproex in the Treatment of Acute Mania (F1D-US-HGHQ)

Abbott Laboratories

March 1999 – March 2000

Divalproex vs. Placebo for the Treatment of Bipolar Disorder (M96-493)


Industry Funding

Eli Lilly

April 1998 – August 1999

Olanzapine Adjunctive Treatment in Patients with Nonpsychotic Bipolar Disorder (F1D-MC-X099)



Dallas County Mental Health Mental Retardation (Mental Health Connections),


Bipolar Disorder - Comprehensive Treatment Algorithm Project

Industry Funding

Eli Lilly



Page 20 of 68

04.17.19

Olanzapine Added to Mood Stabilizers in the Treatment of Bipolar Disorder (F1D-MC-HGFU)

Glaxo Wellcome


A Multicenter, Double-blind, Placebo-controlled, Fixed-dose Evaluation of the Safety and Efficacy of

LAMICTAL (Lamotrigine) in the Long Term Prevention of Mood Episodes in Patients with Bipolar Disorder

with Rapid Cycling: Incorporating Participation in Genotype Research - Optional for Both Patients and Sites

(Incorporating Amendment #1) Protocol 105-614 (SCAA2012)

Abbott Laboratories


An Open-Label Assessment of the Long Term Safety of Sertindole in the Treatment of Patients with

Schizophrenia and Other Psychotic Disorders, Protocol M94-222-Extension Amendment



Dallas County Mental Health Mental Retardation (Mental Health Connections)


Comprehensive Treatment Algorithm Project

Industry Funding

Glaxo Wellcome

July 1996 – June 1997

LAMICTAL (Lamotrigine) Bipolar Disorder Continuation Study (Protocol 105-604)

Glaxo Wellcome

May 1996 – June 1997

A Multicenter, Double-blind, Placebo-controlled, Fixed-dose Evaluation of the Safety and Efficacy of

LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients Suffering From Bipolar

Disorder (Protocol 105-602)

Parke-Davis Pharmaceuticals

March 1996 – September 1997

Gabapentin Adjunctive Treatment in Patients with Bipolar Disorder (Protocol 945-209)


Foundation Funding

National Alliance for Research on Schizophrenia and Depression (NARSAD)

July 1995 – June 1997

Long Term Efficacy of Clozapine and the Use of a Treatment Algorithm in Affectively III Patients

Foundation Funding



Long Term Follow-up of Patients with Bipolar Disorders


Page 21 of 68

04.17.19

Industry Funding

Abbott Laboratories



Schizophrenia and Other Psychotic Disorders, Protocol M94-222





K Award - Treatment of Bipolar I Disorder, Depressed Phase (MH01221)

Foundation Funding

Forrest C. Lattner Foundation, Inc.


Direct Cost: $66,000

Treatment Optimization for Patients with Schizophrenia and Bipolar Disorder

Forrest C. Lattner Foundation, Inc. Award


Treatment Optimization for Patients with Schizophrenia and Bipolar Disorder

Industry Funding

SmithKline-Beecham Pharmaceuticals

January 1994 – April 1995

A Double-blind, Placebo-controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar

Depression, Protocol 29060/352

Abbott Laboratories

January 1994 – February 1995


Schizophrenia and Other Psychotic Disorders, Protocol M93-061



National Alliance for Research on Schizophrenia and Depression (NARSAD) – K Award

July 1993 – June 1995

Clozapine Treatment of Schizoaffective and Bipolar Disorder Patients



Dallas County Mental Health Mental Retardation


Clozapine in Schizoaffective and Treatment-Resistant Bipolar Disorder Patients


Page 22 of 68

04.17.19

Past Research Support (Co-investigator/Other)



National Institutes of Health

Fall 2008

Key Note Speaker (C. Bowden, MD, PI)

R13 - The Bipolar Statistical Summit: Methodologies to Advance Long Term Intervention Trials.

NARSAD

July 2008 – June 2010

Mentor (R. Gonzalez, MD, PI)

A Study Examining the Association between the Gene Clock and Clinical Chronotypic Parameters in Bipolar I

Disorder.

Year Initiated - 2004

Industry Funding

AstraZeneca

April 2004 – July 2009

A Double-blind, Placebo-controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II

Patients. Investigator-initiated, primary site of two-site study.



University of Connecticut Health Center

July 1, 2003 – July 1, 2008

Consultant (R. Trestman, M.D., Ph.D., PI)

1R24 - Mental Health Research Infrastructure in Corrections.


July 2003 – June 2008

Senior Investigator/ Training Mentor (A. John Rush, M.D., PI)

T32 – Mood Disorders Clinical Intervention Training Program.


August 2003 – April 2008

(A. John Rush, M.D., PI)

R25 – Psychiatric Research Education Program (PREP) (Director of Clinical Research Unit).


Foundation Funding

The Robert Wood Johnson Foundation

September 1, 2000 – August 31, 2002

Co-Investigator (A.J. Rush, M.D., PI)

Analysis of the Texas Medication Algorithm Project (TMAP) Dataset.


Page 23 of 68

04.17.19


National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD)

July 2000 – June 2002

Mentor (E.B. Dennehy, Ph.D., PI)

The Measurement of Physician Adherence to a Guideline for Treatment of Bipolar Disorder, Young

Investigator Award.


December 1, 2000 – June 2003

(R. Scheffer, M.D., PI)

Pediatric Bipolar Collaborative Mood Stabilizer Trial.



National Alliance for the Mentally III (NAMI)

Stanley Foundation Research Award Program


Co-Investigator (M. Fulton, PI)

Quantitative Sleep EEG Abnormalities in Bipolar Disorders (Co-Investigator).

Foundation Funding

The Robert Wood Johnson Foundation

September 1, 1997 - August 31, 2000,

Co-Investigator (A.J. Rush, PI)

The Texas Medication Algorithm Project (TMAP): Phase 3. An Evaluation of the Clinical and Economic

Impact of Medication Algorithms in Public Sector Patients with Severe and Persistent Mental Illness.

National Alliance for the Mentally III (NAMI)

Stanley Foundation Research Award Program

August 1997 - July 1998

Co-investigator (A.J. Rush, PI)

Medication Treatment Algorithms for Bipolar, Schizophrenic, and Severe Major Depressive Disorders.

Industry Funding

Organon

April 1997 - September 1998

Co-Investigator (H.K. Manji, PI)

Efficacy of Mirtazapine (Remeron) in the Treatment of Bipolar Depression.



National Institute of Mental Health Research Fellowship Award

December 1996 - November 1998

Sponsor (E.S. Brown, PI)

Do Corticosteroids Provide a Model for Bipolar Disorder?

National Alliance for Research on Schizophrenia and Depression

July 1996 - June 1998


Page 24 of 68

04.17.19

Sponsor (E.S. Brown, PI)

Do Exogenously Given Corticosteroids Provide a Model for Bipolar Disorder in Humans?

Foundation Funding

Stanley Foundation

August 1996 - September 1998

(R. Kowatch, PI)

Development of a Treatment Algorithm for Child and Adolescent Bipolar Disorders

PUBLISHED SCIENTIFIC REPORTS

Journal Peer-Reviewed

1983

Kriegstein AR, Suppes T, Prince DA. Cholinergic enhancement of penicillin-induced epileptiform discharges

in guinea pig hippocampus are enhanced by application of acetylcholine. Brain Research, 1983; 266:

137-142.

1984

Suppes T. A late slow depolarization unmasked in the presence of tetraethylammonium in rat sympathetic

neurons in vitro. Brain Research, 1984; 293: 269-278.

1985

Suppes T, Kriegstein AR, Prince DA. The influence of dopamine on epileptiform burst activity in hippocampal

pyramidal neurons. Brain Research, 1985; 326: 273-280.

1987

Suppes T., Pinnock RD. Sensitivity of neuronal dopamine response in the substantia nigra and ventral

tementum to clozapine, metoclopramide and SCH 23390. Neuropharmacology, 1987; 26(4): 331-337.

Kriegstein AR, Suppes T, Prince DA. Cellular and synaptic physiology and epileptogenesis of developing rat

neocortical neurons in vitro. Developmental Brain Research, 1987; 34: 161-171.

Castiglione C, Suppes T, Macaulay W. Intraluminal Duodenal Diverticulum. Contemporary Surgery, 1987; 32:

83-90.

1991

Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium

treatment in bipolar disorder. Archives General Psychiatry, 1991; 48: 1082-1088.

1992

Suppes T, McElroy S, Gilbert J, Dessain E, Cole J. Clozapine in the treatment of dysphoric mania. Biological

Psychiatry, 1992; 32: 270-280.

1993

Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs. gradual discontinuation of

lithium treatment in bipolar disorders. Archives of General Psychiatry, 1993; 50: 448-455.

Frankenburg FR, Suppes T, McLean PE. Combined clozapine and electroconvulsive therapy. Convulsive

Therapy, 1993; 9(3): 176-180.


Page 25 of 68

04.17.19

Jackson PS, Suppes T, Harris KM. Stereotypical changes in the pattern and duration of long-term potentiation

expressed at postnatal days 11 and 15 in the rat hippocampus. Journal of Neurophysiology, 1993; 70(4):

1412-1419.

Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation of maintenance treatment in

bipolar disorder: Risks and implications. Harvard Review of Psychiatry, 1993; 1(3): 131-144.

1994

Suppes T, Phillips K, Judd C. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: A report of

three cases. Biological Psychiatry, 1994; 36(5): 338-340.

Stoll AL, Banov M, Kolbrener BA, Mayer PV, Tohen M, Strakowski SM, Castillo J, Suppes T, Cohen B.

Neurological factors predict a favorable valproate response in bipolar and schizoaffective disorder.

Journal of Clinical Psychopharmacology, 1994; 14: 311-313.

1995

Kowatch RA, Suppes T, Gilfillan SK, Fuentes RM. Clozapine treatment of children and adolescents with

bipolar disorder and schizophrenia: A clinical case series. Journal of Child and Adolescent

Psychopharmacology, 1995; 5(4): 241-253.

Suppes T, Calabrese JR, Mitchell PB, Pazzaglia PJ, Potter WZ, Zarin DA. Algorithms for the treatment of

bipolar, manic-depressive illness. Psychopharmacology Bulletin, 1995; 31(3): 469-474, 491-500.

Faedda GL, Baldessarini RJ, Suppes T, Tondo L, Becker I, Lipschitz DS. Pediatric-onset bipolar disorder: A

neglected clinical and public health problem. Harvard Review of Psychiatry, 1995; 3(4): 171-195.

Suppes T. New horizons in management and treatment of bipolar disease. Journal of the California Alliance for

the Mentally Ill, 1995; 6(2): 14-17

1996

Baldessarini RJ, Tondo L, Faedda GL, Suppes T, Floris G, Rudas N. Effects of the rate of discontinuing lithium

maintenance treatment in bipolar disorders. Journal of Clinical Psychiatry, 1996; 57(10): 441-448.

Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: Implications for clinical practice

and experimental therapeutics research. American Journal of Therapeutics, 1996; 3(7): 492-496.

Suppes T, Webb A, Carmody T, Gordon E, Gutierrez-Esteinou R, Hudson JI, Pope HG Jr. Is postictal electrical

silence a predictor of response to electroconvulsive therapy? Journal of Affective Disorders, 1996;

41(1): 55-58.

Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: Implications for clinical practice

and experimental therapeutics research. American Journal of Therapeutics, 1996; 3(7): 492-496.

1997

Lee AM, Knoll J, Suppes T. The atypical antipsychotic sertindole: A case series. Journal of Clinical

Psychiatry, 1997; 58(9): 410-416.

Suppes T, Baldessarini RJ, Motohashi N, Tondo L, Viguera AC. Special treatment issues: Maintaining and

discontinuing psychotropic medications. Modern Problems in Pharmacopsychiatry, 1997; 25: 235-254.

Suppes T. Management of treatment-resistant bipolar and schizoaffective disorder. Essential

Psychopharmacology, 1997; 2(1):53-70.

Bennett J, Goldman WT, Suppes T. Gabapentin for Treatment of Bipolar and Schizoaffective Disorders.

Journal of Clinical Psychopharmacology, 1997, 17(2):141-142.

1998

Brown ES, Suppes T. Mood symptoms during corticosteroid therapy: A review. Harvard Review of Psychiatry,

1998; 5(5): 239-46


Page 26 of 68

04.17.19

Sherwood Brown E, Shellhorn E, Suppes T. Gastrointestinal side effects after switch to generic valproic acid.

Pharmacopsychiatry, 1998; 31: 114.

Knoll J, Stegman K, Suppes T. Clinical experience using gabapentin adjunctively in patients with a history of

mania or hypomania. Journal of Affective Disorders, 1998; 49(3): 229-233.

Pearsall R, Glick ID, Pickar D, Suppes T, Tauscher J, Jobson KO. A new algorithm for treating schizophrenia.

Psychopharmacology Bulletin, 1998; 34(3): 349-353.

Suppes T, Rush AJ, Kraemer H, Webb A. Treatment algorithm use to optimize management of symptomatic

patients with a history of mania. Journal of Clinical Psychiatry, 1998; 59(2): 89-96.

McElroy SL, Frye MA, Denicoff KD, Altshuler LL, Nolen WA, Kupka R, Suppes T, Keck PE, Leverich GS,

Kmetz GF, Post RM. Olanzapine in treatment-resistant bipolar disorder. Journal of Affective Disorders,

1998; 49(2): 119-122.

1999

Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi MH, Swann AC, Biggs

MM, Shores-Wilson K, Kashner TM, Pigott T, Chiles JA, Gilbert DA, Altshuler KZ. Medication

treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project.

Journal of Clinical Psychiatry, 1999; 60(5): 284-291.

Rush AJ, Crismon ML, Toprac MG, Shon SP, Rago WV, Miller AL, Suppes T, Trivedi MH, Biggs MM,

Shores-Wilson K, Kashner TM, Altshuler KZ. Implementing guidelines and systems of care:

Experiences with the Texas Medication Algorithm Project TMAP. Journal of Practical Psychiatry &

Behavioral Health, 1999; 5(2): 75-86.

Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized one-year trial

of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.

American Journal of Psychiatry, 1999; 156(8): 1164-1169.

Altshuler LL, Keck PE, McElroy SL, Suppes T, Brown ES, Denicoff K, Frye M, Gitlin M, Hwang S, Goodman

R, Leverich G, Nolen W, Kupka R, Post R. Gabapentin in the acute treatment of refractory bipolar

disorder. Bipolar Disorders, 1999; 1: 61-65.

Kashner TM, Suppes T, Rush AJ, Altshuler KZ. Measuring use of outpatient care among mentally ill

individuals: A comparison of self reports and provider records. Evaluation and Program Planning,

1999; 22(1): 31-39.

Leibenluft E, Suppes T. Treating bipolar illness: Focus on treatment algorithms and management of the sleep-

wake cycle. American Journal of Psychiatry, 1999; 156(12): 1976-1979.

Suppes T, Brown ES, McElroy, Keck PE, Nolen W, Kupka R, Denicoff KD, Altshuler L, Leverich GS, Post R.

Lamotrigine for the treatment of bipolar disorders: A clinical case series. Journal of Affective Disorders,

1999; 53(1): 95-98.

Shon SP, Crismon ML, Toprac MG, Trivedi M, Miller AL, Suppes T, Rush AJ. Mental health care from the

public perspective: The Texas Medication Algorithm Project. Journal of Clinical Psychiatry, 1999,

60(suppl 3): 16-21.

Bowden CL, Mitchell P, Suppes T. Lamotrigine in the treatment of bipolar depression. European

Neuropsychopharmacology, 1999; 9(suppl 4): S113-S117.

Dennehy E, Suppes T. Medication algorithms for bipolar disorder. Journal of Practical Psychiatry and

Behavioral Health, 1999; 5(3): 142-152.

Vangala VR, Brown ES, Suppes T. Clozapine associated with decreased suicidality in bipolar disorder: A case

report. Bipolar Disorders, 1999; 1(2): 123-4.

2000

Suppes T. Rapid cycling bipolar disorder: A new treatment option. Current Psychiatry Reports, 2000; 2(4):

283-285.


Page 27 of 68

04.17.19

Bogan AM, Shellhorn E, Brown ES, McDanald C, Suppes T. Switching outpatients between atypical

antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2000; 24(2): 351-

355.

Tohen M, Hennen J, Zarate C, Baldessarini R, Strakowski S, Stoll A, Faedda G, Suppes T, Gebre-Medhin P,

Cohen B. Two-year syndromal and functional recovery in 219 cases of first-episode major affective

disorder with psychotic features. American Journal of Psychiatry, 2000; 157(2): 220-228.

McElroy SL, Suppes T, Keck PE, Frye M, Denicoff K, Altshuler L, Brown ES, Nolen WA, Kupka R,

Rochussen J, Leverich GS, Post RM. Open-label adjunctive topiramate in the treatment of bipolar

disorders. Biological Psychiatry, 2000; 47(12): 1025-1033.

Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, Emslie GJ, Weinberg WA, Rush AJ.

Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar

disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2000; 39(6): 713-720.

Brown ES, Bauer MS, Suppes T, Khan DA, Carmody T. Comparison of the Internal State Scale to clinician-

administered scales in asthma patients receiving corticosteroid therapy. General Hospital Psychiatry,

2000; 22(3): 180-183.

Tohen M, Strakowski SM, Zarate C Jr., Hennen J, Stoll AL, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin

P, Baldessarini RJ. The McLean-Harvard First-Episode Project: 6-month symptomatic and functional

outcome in affective and nonaffective psychosis. Biological Psychiatry, 2000; 48(6): 467-476.

Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL,

Greene PL, Monaghan ET. A double blind, placebo-controlled, prophylaxis study of lamotrigine in

rapid-cycling bipolar disorder. Journal of Clinical Psychiatry, 2000; 61(11): 841-850.

Bogan A, Brown ES, Suppes T. Efficacy of divalproex therapy for schizoaffective disorders. Journal of

Clinical Psychopharmacology, 2000; 20(5): 520-522.

Keck PE, Mendlwicz J, Calabrese J, Fawcett J, Suppes T, Vestergaard P, Carbonell C. A review of randomized

controlled clinical trails in acute mania. Journal of Affective Disorders, 2000; 59(suppl 1): S31-S37.

Suppes T, Dennehy EB, Gibbons EW. The longitudinal course of bipolar disorder. Journal of Clinical

Psychiatry, 2000; 61(suppl 9): 23-30.

Denicoff KD, Leverich GS, Nolen W, Rush AJ, McElroy SL, Keck PE, Suppes T, Altshuler LL, Kupka R, Frye

MA, Hatef J, Brotman MA, Post RM. Validation of the prospective NIMH-Life-Chart Method (NIMH-

LCM-super(TM)-p) for longitudinal assessment of bipolar illness. Psychological Medicine ,2000; 30(6):

1391-1397.

Rush AJ, Post RM, Nolen WA, Keck PE, Suppes T, Altshuler L, McElroy SL. Methodological issues in

developing new acute treatments for patients with bipolar illness. Biological Psychiatry, 2000; 48(6):

615-624.

2001

Leverich GS, Nolen W, Rush AJ, McElroy S, Keck PE, Denicoff KD, Suppes T, Altshuler L, Kupka R,

Kramlinger K, Post RM. The Stanley Foundation Bipolar Treatment Outcome Network: 1.

Longitudinal methodology. Journal of Affective Disorders, 2001; 67(1-3): 33-44.

Suppes T, Leverich GS, Keck PE Jr, Nolen W, Denicoff KD, Altshuler LL, McElroy SL, Rush AJ, Kupka R,

Frye MA, Bickel M, Post RM. The Stanley Foundation Bipolar Network. II. Demographics and illness

characteristics of the first 261 patients with bipolar disorder. Journal of Affective Disorders, 2001;

67(1-3): 45-59.

Post R, Altshuler L, Frye M, Suppes T, Rush AJ, Keck PE, McElroy S, Denicoff K, Leverich G, Kupka R,

Nolen A. Rate of switch in bipolar patients prospectively treated with second generation

antidepressants as augmentation to mood stabilizers. Bipolar Disorders, 2001; 3: 259-265.


Page 28 of 68

04.17.19

McElroy S, Altshuler L, Suppes T, Keck PE, Frye M, Denicoff K, Nolen W, Kupka R, Leverich G, Rochussen

J, Rush AJ, Post R. Axis I psychiatric comorbidity and its relationship to historical illness variables in

288 patients with bipolar disorder. American Journal of Psychiatry, 2001; 158(3): 420-426.

Glick ID, Suppes T, DeBattista C, Hu RJ, Marder S. Psychopharmacologic treatment strategies for depression,

bipolar disorder and schizophrenia. Annals of Internal Medicine, 2001; 134: 47-60.

Brown ES, Suppes T, Adinoff B, Thomas NR. Drug abuse and bipolar disorder: Comorbidity or misdiagnosis?

Journal of Affective Disorders, 2001; 65(2): 105-115.

Suppes T, Swann A, Dennehy EB, Habermacher E, Mason M, Crismon L, Toprac M, Rush AJ, Shon S,

Altshuler KZ. Texas Medication Algorithm Project: Development and feasibility testing of a treatment

algorithm for patients with bipolar disorder. Journal of Clinical Psychiatry, 2001; 62(6): 439-447.

Montgomery S, Van Zwieten-Boot B, Angst J, Bowden CL, Calabrese JR, Chengappa R, Goodwin G,

Lecrubier Y, Licht R, Nolen WA, Sachs G, Saint Raymond A, Storosum J, Suppes P, Van Ree JM.

ECNP Consensus Meeting March 2000 Nice Guidelines for investigating efficacy in bipolar disorder.

European Neuro-Psychopharmacology, 2001; 11: 79-88.

Calabrese JR, Shelton MD, Bowden CL, Rapport DJ, Suppes T, Shirley ER, Kimmel SE, Caban SJ. Bipolar

rapid cycling: Focus on depression as its hallmark. Journal of Clinical Psychiatry, 2001; 62(suppl 14):

34-41.

Post RM, Nolen WA, Kupka RW, Denicoff KD, Leverich GS, Keck PE Jr, McElroy SL, Rush AJ, Suppes T,

Altshuler LL, Frye MA, Grunze H, Walden J. The Stanley Foundation Bipolar Network. 1. Rationale

and methods. British Journal Psychiatry, 2001; 41: s169-76.

Kupka R, Nolen W, Altshuler L, Denicoff K, Frye M, Leverich G, Keck PE, McElroy S, Rush AJ, Suppes T,

Post R. The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of

illness and response to novel treatments. British Journal of Psychiatry, 2001; 41: s177-83.

2002

Post RM, Leverich GS, Denicoff KD, Altshuler LL, Frye MA, Rush J, Suppes T, Kramlinger K, Keck PEJr,

McElroy SL, Nolen WA, Kupka R, Walden J, Grunze H. The Stanley Foundation Bipolar Network. Pt

1: New findings on suicide attempts, substance abuse, obesity, and more. Current Psychiatry, 2002; 1:

26-32.

Post RM, Leverich GS, Denicoff KD, Altshuler LL, Frye MA, Rush J, Suppes T, Kramlinger K, Keck PEJr,

McElroy SL, Nolen WA, Kupka R, Walden J, Grunze H. The Stanley Foundation Bipolar Network. Pt.

2: Efficacy of adjunctive therapies for treatment-resistant patients. Current Psychiatry, 2002; 1: 36-44.

Calabrese JR, Sullivan J, Bowden CL, Suppes T, Sachs G, Goldberg J, Shelton M, Kusumakar V. Rash in

multicenter trials of lamotrigine mood disorder: Clinical relevance and management. Journal of Clinical

Psychiatry, 2002; 63(11): 1012-1019.

Suppes T, Chisholm KA, Dhavale D, Frye MA, Altshuler LL, McElroy S, Keck PE, Nolen WA, Kupka R,

Denicoff K, Leverich G, Rush AJ, Post R. Tiagabine in treatment refractory bipolar disorder: A clinical

case series. Bipolar Disorders, 2002; 4(5): 283.

Tohen M, Baker RW, Altshuler L, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier

A, Tollefson GA. Olanzapine versus divalproex in the treatment of acute mania. American Journal of

Psychiatry, 2002; 159(6): 1011-1017.

Tohen M, Chengappa R, Suppes T, Zarate C, Calabrese J, Bowden C, Sachs G, Kupfer D, Baker R, Risser R,

Keeter E, Feldman P, Tollefson G, Breier A. Efficacy of olanzapine in combination with valproate or

lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium

monotherapy. Archives of General Psychiatry, 2002; 59(1):62-69.

Dennehy EB, Webb A, Suppes T. Assessment of beliefs in the effectiveness of acupuncture for treatment of

psychiatric symptoms. Journal of Alternative and Complementary Medicine, 2002; 8:421-426.


Page 29 of 68

04.17.19

Suppes T, Dennehy EB. Evidence-based long-term treatment of bipolar II disorder. Journal of Clinical

Psychiatry, 2002; 63(suppl 10): 29-333.

McElroy S, Frye M, Suppes T, Dhavale D, Keck PE, Leverich G, Altshuler L, Denicoff K, Nolen W, Kupka R,

Grunze H, Walden J, Post R. Correlates of overweight and obesity in 644 patients with bipolar disorder.


Tamminga C, Nemeroff C, Blakely R, Brady L, Carter C, Davis K, Dingledine R, Gorman J, Griforiadis D,

Henderson D, Innis R, Killen J, Langhren T, McDonald W, Murphy G, Paul S, Rudorfer M, Sausville E,

Schatzberg, Scolnick E, Suppes T. Developing novel treatments for mood disorders: Accelerating

discovery. Biological Psychiatry, 2002; 52(6): 589-609.

Brown ES, Suppes T, Khan DA, Carmody TJ. Mood changes during prednisone bursts in outpatients with

asthma. Journal of Clinical Psychopharmacology, 2002; 22(1): 55-61.

Leverich G, McElroy S, Suppes T, Keck PE, Denicoff K, Nolen W, Altshuler L, Rush AJ, Kupka R, Frye M,

Autio K, Post R. Early physical and sexual abuse associated with an adverse course of bipolar illness.

Biological Psychiatry, 2002; 51(4): 273-346.

Suppes T, Dennehy EB, Swann AC, Bowden C, Calabrese J, Hirschfeld R, Keck PE, Sachs G, Shon SP. Report

of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder 2000. Journal

of Clinical Psychiatry, 2002; 63(4): 288-298.

Bowden C, Goodwin F, Keck PE, Calabrese J, Suppes T. Long-term use of mood stabilizers in bipolar

disorder. Journal of Clinical Psychiatry, 2002; 5(suppl 6): audiograph.

Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE Jr, Leverich

GS, Rush AJ, Suppes T, Pollio C, Drexhage HA. High rate of autoimmune thyroiditis in bipolar

disorder: Lack of association with lithium exposure. Biological Psychiatry, 2002; 51(4): 305-311.

Suppes T. Review of the use of topiramate for treatment of bipolar disorder. Journal of Clinical


American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder

(revision). American Journal of Psychiatry, 2002, 159, 1-50.

2003

Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush JA. Clinical outcome in a randomized 1-year trial of

clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.

Focus. The Journal of Lifelong Learning in Psychiatry, 2003; 1(1): 37-43.

Brown SE, Rush JA, Biggs MM, Shores-Wilson K, Carmody TJ, Suppes T. Clinician ratings versus global

ratings of symptom severity: A comparison of symptom measures in the bipolar disorder module, Phase

II, Texas Medication Algorithm Project. Psychiatry Research, 2003; 117: 167-175.

Altshuler L, Suppes T, Black D, Nolen WA, Keck PE Jr, Frye MA, McElroy S, Kupka R, Grunze H, Walden J,

Leverich G, Denicoff K, Luckenbaugh D, Post R. Impact of antidepressant discontinuation after acute

remission from bipolar depression on rates of depressive relapse at one-year follow-up. American

Journal of Psychiatry, 2003; 160(7): 1252-1262.

Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE Jr, McElroy SL,

Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1

year with daily prospective ratings on the NIMH life chart method. Journal of Clinical Psychiatry, 2003;

64(6): 680-690.

Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE, McElroy SL, Denicoff KD, Obrocea B, Nolen WA,

Kupka R, Walden J, Grunze H, Perez S, Luckenbaugh DA, Post RM. Factors associated with suicide

attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. Journal of

Clinical Psychiatry, 2003; 64(5): 506-515.


Page 30 of 68

04.17.19

Frye MA, Altshuler LL, McElroy SL, Suppes T, Keck PE, Denicoff K, Nolen WA, Kupka R, Leverich GS,

Pollio C, Grunze H, Walden J, Post RM. Gender differences in prevalence, risk, and clinical correlates

of alcoholism comorbidity in bipolar disorder. American Journal Psychiatry, 2003; 160(5): 883-889.

Tohen M, Ketter TA., Zarate CA., Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E,

Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of

remission: A 47-week study. American Journal of Psychiatry, 2003; 160: 1263-1271

Dennehy E, Doyle K, Suppes T. The efficacy of olanzapine monotherapy for acute hypomania or mania in an

outpatient setting. International Clinical Psychopharmacology, 2003; 18(3): 143-145.

Rush JA, Crismon LM, Kashner MT, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM,

Shores-Wilson K, Witte BP, Shon SP. Texas Medication Algorithm Project, Phase 3 (TMAP-3):

Rationale and study design. Journal of Clinical Psychiatry, 2003; 64(4): 357-369.

Suppes T, Rush JA, Dennehy EB, Crismon LM, Kashner MT, Toprac MG, Carmody TJ, Brown SE, Biggs

MM, Shores-Wilson K, Witte B, Trivedi M, Miller AL, Altshuler KZ, Shon SP. Texas Medication

Algorithm Project, phase 3 (TMAP-3): Clinical results for patients with a history of mania. Journal of

Clinical Psychiatry, 2003; 64(4): 370-382.

Breunis NN, Kupka RW, Nolen WA., Suppes T, Denicoff KD., Leverich GS., Post RM., Drexhage HA. High

numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder.

Biological Psychiatry, 2003; 53(2): 157-165.

Keck PE Jr, McElroy SL, Havens JR, Altshuler LL, Nolen WA, Frye MA, Suppes T, Denicoff KD, Kupka R,

Leverich GS, Rush AJ, Post RM. Psychosis in bipolar disorder: Phenomenology and impact on

morbidity and course of illness. Comprehensive Psychiatry, 2003; 44(4): 263-269.

Kashner TM, Carmody TJ, Suppes T, Rush AJ, Crismon ML, Miller AL, Toprac M, Trivedi M. Catching up on

health outcomes: The Texas Medication Algorithm Project. Health Services Research, 2003; 38(1 pt 1):

331-331. PMCID: PMC1360886.

Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Kupka R, Nolen WA,

Grunze H, Walden J. An overview of recent findings of the Stanley Foundation Bipolar Network (Part

I). Bipolar Disorders, 2003; 5: 310-319.

Post R, Leverich G, Nolen W, Kupka R, Altshuler L, Frye M, Suppes T, McElroy S, Keck PE, Grunze H,

Walden J. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: Data

from the Stanley Foundation Bipolar Network. Bipolar Disorders, 2003; 5: 396-406.

2004

Shivakumar G, Suppes T. Bipolar update: Evidence is driving change in mania, depression algorithms. Current

Psychiatry, 2004; 3(2): 22-23, 35-36, 39.

Trivedi M, Rush A, Ibrahim H, Carmody T, Biggs M, Suppes T, Crismon M, Shores-Wilson K, Toprac M,

Dennehy E, Witte B, Kashner T. Inventory of Depressive Symptomatology, Clinician Rating (IDS-C)

and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating

(QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric

evaluation. Psychological Medicine, 2004; 34: 73-82.

McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J. A 52-week, open-label

continuation study of lamotrigine in the treatment of bipolar depression. Journal of Clinical Psychiatry,

2004; 65: 204-210.

Yonkers K, Wisner K, Stowe Z, Leibenluft E, Cohen L, Miller L, Manber R, Viguera A, Suppes T, Altshuler L.

Management of bipolar disorder during pregnancy and the postpartum period. American Journal of

Psychiatry, 2004; 161: 608-620.

Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN,

Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month


Page 31 of 68

04.17.19

comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. British Journal of Psychiatry,

2004; 184: 337-345.

Dennehy E, Suppes T, Rush J, Crismon L, Witte B, Webster J. Development of a computerized assessment of

clinician adherence to a treatment guideline for patients with bipolar disorder. Journal of Psychiatric

Research, 2004; 38: 285-294.

Sachs G, Chengappa R, Suppes T, Mullen J, Brecher M, Devine N, Sweitzer D. Quetiapine with lithium or

divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study.

Bipolar Disorders, 2004; 6: 213-223.

Suppes T, McElroy S, Keck PE, Altshuler L, Frye M, Grunze H, Leverich G, Nolen W, Chisholm K, Dennehy

E, Post R. Use of quetiapine in bipolar disorder: A case series with prospective evaluation. International

Clinical Psychopharmacology, 2004; 19(3): 173-174.

Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson

K, Witte B, Suppes T, Miller AL, Altshuler KZ, and Shon SP. Clinical results for patients with major

depressive disorder in the Texas Medication Algorithm Project (TMAP). Archives of General

Psychiatry, 2004; 61(7): 669-680.

Dennehy EB, Suppes T, Crismon ML, Toprac M, Carmody TJ, Rush AJ. Development of the Brief Bipolar

Disorder Symptom Scale (BDSS) for patients with bipolar disorder. Psychiatry Research, 2004; 127:

137-145.

Suppes T, Ozcan E, Carmody T. Response to clozapine of rapid cycling vs. noncycling patients with a history

of mania. Bipolar Disorders, 2004; 6(4): 329-332.

Post RM, Chang KD, Suppes T. Treatment of rapid-cycling bipolar disorder. CNS Spectrum, 2004; 9(2): 1-11.

Nolen WA, Luckenbaugh DA, Altshuler LL, Suppes T, McElroy SL, Frye MA, Kupka RW, Keck PE, Jr.,

Leverich GS, Post RM. Correlates of 1-year prospective outcome in bipolar disorder: Results from the

Stanley Foundation Bipolar Network. American Journal of Psychiatry, 2004; 161(8): 1447-1454.

Carlson P, Merlock M, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: Treatment of

residual depression and sedation. Bipolar Disorders, 2004; 6(5): 416-420.

Armitage R, Cole D, Suppes T, Ozcan E. Effects of clozapine on sleep in bipolar and schizoaffective disorders.

Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2004; 28: 1065-1070.

Miller A, Crismon L, Rush J, Chiles J, Kashner M, Toprac M, Carmody T, Biggs M, Shores-Wilson K, Chiles

J, Witte B, Bow-Thomas C, Velligan D, Trivedi M, Suppes T, Shon S. The Texas Medication

Algorithm Project: Clinical results for schizophrenia. Schizophrenia Bulletin, 2004; 30(3): 627-647.

Wang PW, Suppes T, Ketter TA. Pharmacotherapy in bipolar depression. Depression: Mind and Body, 2004;

1(3): 89-97.

Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Review of

Neurotherapeutics, 2004, 4(6 Suppl 2): S17-S25.

2005

Post RM, Altshuler LL, Frye MS, Suppes T, Keck PEJr, McElroy SL, Leverich GS, Nolen WA, Kupka R,

Walden J, Grunze H. An overview of recent findings of the Stanley Foundation Bipolar Network

(SFBN) (Part II): Focus on anticonvulsants. Aspects of Affect, 2005; 1(1): 8-17.

Leverich GS, McElroy SL, Altshuler LL, Frye MA, Grunze H, Keck Jr. PE, Kupka RW, Nolen WA, Suppes T,

Walden J, Post RM. The anticonvulsant zonisamide in bipolar illness: clinical response and weight loss.

Aspects of Affect, 2005; 1(1): 53-56.

Post RM, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Leverich GS, Kupka R, Nolen WA,

Luckenbaugh DA, Walden J, Grunze H. Preliminary observations on the effectiveness of levetiracetam

in the open adjunctive treatment of refractory bipolar disorder. Journal of Clinical Psychiatry, 2005;

66(3): 370-374.


Page 32 of 68

04.17.19

Fehr BS, Ozcan ME, Suppes T. Low doses of clozapine may stabilize treatment-resistant bipolar patients.

European Archives of Psychiatry and Clinical Neuroscience, 2005; 255(1): 10-14.

Golden R, Gaynes B, Ekstrom D, Hamer R, Jacobsen F, Nemeroff C, Suppes T, Wisner K, Nemeroff CB. The

efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis of the evidence.

American Journal of Psychiatry, 2005; 162(4): 656-662.

McElroy SL, Suppes T, Keck PE, Black D, Frye MA, Altshuler LL, Nolen WA, Kupka RW, Leverich GS,

Walden J, Grunze H, Post RM. Open-label adjunctive zonisamide in the treatment of bipolar disorders:

A prospective trial. Journal of Clinical Psychiatry, 2005; 65(5):617-624.

Rasgon NL, Altshuler LL, Fairbanks L, Elman S, Bitran J, Labarca R, Saad M, Kupka R, Nolen WA, Frye MA,

Suppes T, McElroy SL, Keck PE Jr., Leverich G, Grunze H, Walden J, Post R, Mintz J. Reproductive

function and risk for PCOS in women treated for bipolar disorder. Bipolar Disorders, 2005; 7(3): 246-

259.

Velligan D, Prihoda T, Dennehy E, Biggs M, Shores-Wilson K, Crismon ML, Rush AJ, Miller A, Suppes T,

Trivedi M, Kashner TM, Witte B, Toprac M, Carmody T, Chiles J, Shon S. Brief Psychiatric Rating

Scale Expanded Version: How do new items affect factor structure? Psychiatry Research, 2005; 135(3):

217-228.

Kupka RW, Luckenbaugh DA, Post RM, Suppes T, Altshuler LL, Keck PE Jr., Frye MA, Denicoff KD, Grunze

H, Leverich GS, McElroy SL, Walden J, Nolen WA. Comparison of rapid and non-rapid-cycling bipolar

disorder based on prospective mood ratings in 539 outpatients. American Journal of Psychiatry, 2005;

162(7): 1273-1280.

Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA,

Sachs G, Swann AC for the Texas Consensus Conference Panel on Medication Treatment of Bipolar

Disorder. The Texas Implementation of Medication Algorithms: Update to the algorithms for treatment

of bipolar I disorder. Journal of Clinical Psychiatry, 2005; 66(7): 870-886.

Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. Journal of Clinical

Psychiatry, 2005; 66(suppl 5):11-16.

Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR. Atypical

antipsychotics in bipolar depression: potential mechanisms of action. Journal of Clinical Psychiatry,

2005; 66(suppl 5): 40-48.

Duffy FF, Narrow W, West JC, Fochtmann LJ, Kahn DA, Suppes T, Oldham JM, McIntyre JS, Manderscheid

RW, Sirovatka P, Regier D. Quality of care measures for the treatment of bipolar disorder. The

Psychiatric Quarterly, 2005; 76(3): 213-230.

Dennehy EB, Suppes T, Rush AJ, Miller AL, Trivedi MH, Crismon ML, Carmody TJ, Kashner TM. Does

provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder?

Results from the Texas Medication Algorithm Project. Psychological Medicine, 2005, 35(12), 1695-

1706.

Suppes T, Mintz J, McElroy SL, Altshuler LL, Kupka RW, Frye MA, Keck PE, Nolen WA, Leverich GS,

Grunze H, Rush AJ, Post RM. Mixed hypomania in 908 patients with bipolar disorder evaluated

prospectively in the Stanley Bipolar Treatment Network: A sex-specific phenomenon. Archives of

General Psychiatry, 2005, 62(10), 1089-1096.

Suppes T, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of

response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: Post hoc

analyses of 47-week data. Journal of Affective Disorders, 2005, 89(1-3), 69-77.

2006


Page 33 of 68

04.17.19

Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Hwang CH, Hall JE, Sachs GS.

Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar

disorder. Biological Psychiatry, 2006; 59(11): 1078-86. Epub: Jan 31, 2006; doi:10.1016/j.biopsych.

2005.10.017.

Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Kupka RW, Denicoff KD, Nolen

WA, Grunze H, Martinez MI, Post RM. Risk of switch in mood polarity to hypomania or mania in

patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and

bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry, 2006; 163(2): 232-9. doi:

10.1176/appi.ajp.163.2.232.

Altshuler LL, Suppes T, Black DO, Nolen WA, Leverich G, Keck PE Jr, Frye MA, Kupka R, McElroy SL,

Grunze H, Kitchen CM, Post R. Lower switch rate in depressed patients with bipolar II than bipolar I

disorder treated adjunctively with second-generation antidepressants. American Journal of Psychiatry,

2006; 163(2): 313-5. doi: 10.1176/appi.ajp.163.2.313.

Ketter TA, Suppes T, Morrell MJ, Rasgon N, Cohen LS, Viguera AC. Reproductive health and bipolar

disorder. CNS Spectrums, 2006; 11(5 Suppl 5): 1-16.

Kashner TM, Rush AJ, Crismon ML, Toprac M, Carmody TJ, Miller AL, Trivedi MH, Wicker A, Suppes T.

An empirical analysis of cost outcomes of the Texas Medication Algorithm Project. Psychiatric

Services, 2006; May 57(5): 648-59. doi: 10.1176/appi.ps.57.5.648.

Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M, White R, DeVeaugh-Geiss A, Thompson TR.

Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance

studies. Biological Psychiatry, 2006; 59(11): 1061-4. Epub: June 10, 2006; doi:

10.1016/j.biopsych.2006.02.034.

Keck PE, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA,

Leverich GS, Denicoff KD, Grunze H, Walden J, Duan N, Post RM. Double-blind, randomized,

placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid

cycling bipolar disorder. Biological Psychiatry, 2006; 60(9): 1020-1022. Epub: Jun 30, 2006; doi: 10.

1016/j.biopsych.2006.03.056.

Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE,

Denicoff KD, Grunze H, Walden J, Kitchen CMR, Mintz J. Mood switch in bipolar depression:

comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry, 2006;

189(2): 124-131. doi :10.1192/bjp.bp.105.013045. Erratum in: Br J Psychiatry, 2006; 189: 569.

Marangell LB, Suppes T, Ketter TA, Dennehy EB, Zboyan H, Kertz B, Nierenberg A, Calabrese J, Wisniewski

SR, Sachs G. Omega-3 fatty acids in bipolar disorder: clinical and research considerations.

Prostaglandins Leukotrienes and Essential Fatty Acids, 2006; 75: 315–321. Epub: Aug 22, 2006; doi:

10.1016/j.plefa.2006.07.008.

Ozcan ME, Shivakumar G, Suppes T. Treating rapid cycling bipolar disorder with novel medications. Current

Psychiatry Reviews, 2006; 2(3): 361-369.

Joffe H, Cohen LS, Suppes T, Hwang CH, Molay F, Adams JM, Sachs GS, Hall JE. Longitudinal follow-up of

reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: A

preliminary report. Biological Psychiatry, 2006; 60(12): 1378-81. Epub: Sept 1, 2006; doi:

10.1016/j.biopsych.2006.05.027.

Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, Suppes T, Rush AJ.

Implementation of the Texas Medication Algorithm Project Patient and Family Education Program.


Altshuler LL, Post RM, Black DO, Keck PE, Nolen WA, Frye MA, Suppes T, Grunze H, Kupka RW, Leverich

GS, McElroy SL, Walden J, Mintz J: Subsyndromal depressive symptoms are associated with functional

impairment in patients with bipolar disorder. Journal of Clinical Psychiatry, 2006; 67(10): 1551-1560.


Page 34 of 68

04.17.19

Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR. Incidence

and time course of subsyndromal symptoms in patients with bipolar I disorder: An evaluation of two

placebo-controlled maintenance trials. Journal of Clinical Psychiatry, 2006; 67(11): 1721-8.

Post RM, Altshuler LL, Frye MA, Suppes T, McElroy S, Keck PE Jr, Leverich GS, Kupka R, Nolen WA,

Grunze H. New Findings from the Bipolar Collaborative Network: Clinical implications for

therapeutics. Current Psychiatry Reports, 2006; 8(6): 489-97.

2007

Levander E, Frye MA, McElroy S, Suppes T, Grunze H, Nolen WA, Kupka R, Keck PE Jr, Leverich GS,

Altshuler LL, Hwuang S, Mintz J, and Post RM. Alcoholism and anxiety in bipolar illness: Differential

lifetime anxiety comorbidity in bipolar I women with and without alcoholism. Journal of Affective

Disorders, 2007; 101(1-3): 211-7. Epub: Jan 23, 2007; doi: 10.1016/j.jad.2006.11.023.

McElroy SL, Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck PE Jr.

Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial. Journal of

Affective Disorders, 2007; 101(1-3): 275-281. Epub: Jan 16, 2007; doi: 10.1016/j.jad.2006.11.025.

McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, Mintz J, Kupka R, Nolen W, Leverich

GS, Denicoff KD, Post RM, Keck PE Jr. A 24-week, randomized, controlled trial of adjunctive

sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with

bipolar disorders. Bipolar Disorders, 2007; 9(4): 426-434. doi: 10.1111/j.1399-5618.2007.00488.x.

Nolen WA, Kupka RW, Hellemann G, Frye MA, Altshuler LL, Leverich GS, Suppes T, Keck PE Jr, McElroy

S, Grunze H, Mintz J, Post RM. Tranylcypromine versus lamotrigine in the treatment of refractory

bipolar depression: a failed but clinically useful study. Acta Psychiatrica Scandinavica, 2007; 115(5):

360-5. doi: 10.1111/j.1600-0447.2007.00993.x.

Suppes T, Kelly DI, Hynan LS, Snow DE, Sureddi S, Foster B, Curley E. Comparison of two anticonvulsants

in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder.

Australian and New Zealand Journal of Psychiatry, 2007; 41(5): 397-402. Epub: May 1, 2007; doi:

10.1080/00048670701261186.

Leverich GS, Post RM, Keck PE Jr, Altshuler LL, Frye MA, Kupka RW, Nolen WA, Suppes T, McElroy SL,

Grunze H, Denicoff K, Moravec MK, Luckenbaugh D. The poor prognosis of childhood-onset bipolar

Disorder. Journal of Pediatrics, 2007; 150(5): 485-90. Epub: April 21, 2007; doi:

10.1016/j.jpeds.2006.10.070.

Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of

pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists.

Psychopharmacology Bulletin, 2007; 40(2): 22-37.

Allardyce J, Suppes T, Van OS J. Dimensions and the Psychosis Phenotype. International Journal of Methods

in Psychiatric Research, 2007, 16(S1): S34-S40. doi: 10.1002/mpr.214.

Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE Jr., Walden J, Leverich GS, Altshuler LL, Nakelsky S,

Hwuang S, Mintz J, Post RM. A Placebo-Controlled Evaluation of Adjunctive Modafinil in the

Treatment of Bipolar Depression. American Journal of Psychiatry, 2007; 164(8): 1242-1249. doi:

10.1176/appi.ajp.2007.06060981.

Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, Frye MA, Keck Jr. PE,

McElroy SL, Grunze H, Post RM. Three times more days depressed than manic or hypomanic in both

bipolar I and bipolar II disorder. Bipolar Disorders, 2007; 9: 531-535. doi: 10.1111/j.1399-

5618.2007.00467.x.

Suppes T, Keck PE Jr., McElroy SL, Altshuler LL, Frye MA, Nolen WA, Kupka RW, Grunze H, Leverich GS,

Mintz J, Luckenbaugh DA, Kelly DI, Post RM. Quetiapine for the continuation treatment of bipolar

depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network.


Page 35 of 68

04.17.19

International Clinical Psychopharmacology, 2007 Nov; 22(6):376-81. doi:

10.1097/YIC.0b013e3281c55f63.

Byerly M, Suppes T, Pikalov AA III, Baker RA. Clinical implications of antipsychotic-induced

hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent

developments and current perspectives. Journal of Clinical Psychopharmacology, 2007; 27(6):639-61.

doi: 10.1097/jcp.0b013e31815ac4e5.

2008

Suppes T, Hirschfeld R, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression:

analysis of data from two randomized, double-blind, placebo-controlled studies. World Journal of

Biological Psychiatry, 2008; 9(3): 198-211. doi: 10.1080/15622970701317265.

Bauer M, Lecrubier Y, Suppes T. Awareness of metabolic concerns in patients with bipolar disorder: a survey

of European psychiatrists. European Psychiatry, 2008 Apr; 23(3):169-77. Epub: Dec 21, 2007; doi:

10.1016/j.eurpsy.2007.10.007.

Marangell LB, Suppes T, Zboyan H, Prashad SJ, Fischer EG, Snow D, Sureddi S, Allen JC Jr. A 1-year pilot

study of vagus nerve stimulation in treatment-resistant rapid cycling bipolar disorder. Journal Clinical

Psychiatry, 2008 Feb; 69(2); 183-89. Epub: Jan, 16 2008.

Goldberg JF, Bowden CL, Calabrese JR, Ketter TA, Dann RS, Frye MA, Suppes T, Post RM. Six-month

prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid

cycling bipolar disorder. Biological Psychiatry, 2008 Jan; 63:125-130. Epub: June 1, 2007; doi:

10.1016/j.biopsych.2006.12.031.

Suppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B. Efficacy and safety of aripiprazole in

subpopulations with acute manic or mixed episodes of bipolar I disorder. Journal of Affective Disorders,

2008 Apr; 107(1-3): 145-154. Epub: Sept 27, 2007; doi: 10.1016/j.jad.2007.08.015.

Post RM, Luckenbaugh DA, Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Nolen

WA, Kupka R, Grunze H, Walden J. Incidence of childhood-onset bipolar illness in the USA and

Europe. British Journal of Psychiatry, 2008 Feb; 192:150-1. doi: 10.1192/bjp.bp.107.037820.

Shivakumar G, Bernstein IH, Suppes T, Stanley Foundation Bipolar Network. Are bipolar mood symptoms

affected by the phase of the menstrual cycle? Journal of Women’s Health, 2008 Apr; 17(3): 473-8.

Epub: Mar 8, 2008; doi: 10.1089/jwh.2007.0466.

Ghaemi SN, Bauer M, Cassidy F, Malhi GS, Mitchell P, Phelps J, Vieta E, Youngstrom E; ISBD Diagnostic

Guidelines Task Force. Diagnostic guidelines for bipolar disorder: a summary of the International

Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. Bipolar Disorders, 2008 Feb;

10(1 Pt 2):117-28. doi: 10.1111/j.1399-5618.2007.00556.x. (Collaborator).

Vieta E, Suppes T. Bipolar II disorder: Arguments for and against a distinct diagnostic entity. Bipolar

Disorders, 2008 Feb; 10(1 Pt 2): 163-78. doi: 10.1111/j.1399-5618.2007.00561.x.

Suppes T, Marangell LB, Bernstein IH, Kelly DI, Fischer EG, Zboyan HA, Snow DE, Martinez M, Al Jurdi, R,

Sureddi S, Gonzalez R. A single blind comparison of lithium and lamotrigine for the treatment of

bipolar II depression. Journal of Affective Disorders, 2008 Dec; 111(2-3): 334-43. Epub: Mar 20, 2008;

doi: 10.1016/j.jad.2008.02.004. PMCID: PMC2646842.

Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M, on behalf of the Trial 126 Study Investigators.

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients

with bipolar I disorder (International Trial 126). Journal of Affective Disorders, 2008 Aug; 109 (3): 251-

63. Epub: Jun 24, 2008; doi: 10.1016/j.jad.2008.06.001.

Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, Suppes T. Efficacy of quetiapine

monotherapy for the treatment of depressive episodes in bipolar I disorder: combined results from two

double-blind, randomized, placebo-controlled studies. Journal of Clinical Psychiatry, 2008 May; 69 (5):

769-82. Epub: April 29, 2008.

http://dx.doi.org.laneproxy.stanford.edu/10.1016/j.jad.2008.06.001


Page 36 of 68

04.17.19

Gonzales R, Suppes T. Stimulants for Adult Bipolar Disorder? Current Psychiatry, 2008, 7(11): 33-46.

2009

Frye MA, Helleman G, McElroy S, Black D, Altshuler LL, Keck PE Jr., Nolan W, Kupka R, Leverich GS,

Grunze H, Mintz J, Post RM, Suppes T. Correlates of treatment-emergent mania associated with

antidepressant treatment in bipolar depression. American Journal of Psychiatry, 2009 Feb; 166: 164-

172. Epub: November 17, 2008; doi: 10.1176/appi.ajp.2008.08030322.

Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE Jr., Janavs J, Rogers J, Gonzalez R, Shivakumar G,

Suppes T. Randomized, Placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.

Journal of Affective Disorders, 2009 Jun; 115(3): 376-85. Epub: November 29, 2008; doi:

10.1016/j.jad.2008.10.005.

Frye MA, Yatham L, Ketter TA, Goldberg J, Suppes T, Calabrese JR, Bowden CL, Bourne E, Bahn R, Adam

B. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating

hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatrica

Scandinavica, 2009 Jul; 120(1): 10-3. Epub: Jan 31, 2009; doi: 10.1111/j.1600-0447.2008.01343.x.

Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance Treatment for Patients with Bipolar I Disorder:

Results from a North American study of quetiapine in combination with lithium or divalproex (Trial

127). American Journal of Psychiatry, 2009 Apr; 166(4): 476-88. Epub: Mar 16, 2009; doi:

10.1176/appi.ajp.2008.08020189.

Altshuler L, Post RM, Hellemann G, Leverich GS, Nolen W, Frye M, Keck PE Jr, Kupka R, Grunze H, Elroy

SL, Sugar C, Suppes T. Impact of antidepressant continuation after acute positive or partial treatment

response for bipolar depression: A blinded, randomized study. Journal of Clinical Psychiatry, 2009 Apr;

70(4): 450-7. Epub: April 7, 2009; doi: 10.4088/JCP.08m04191.

Dennehy EB, Schnyer R, Bernstein IH, Gonzalez R, Shivakumar G, Kelly DI, Snow DE, Sureddi S, Suppes T.

The safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for bipolar

disorder. Journal of Clinical Psychiatry, 2009 Jun; 70(6): 897-905. Epub: May 5, 2009;

doi:10.4088/JCP.08m04208.

Bernstein IH, Rush AJ, Suppes T, Trivedi MH, Woo A, Yasushi K, Crismon ML, Dennehy E, Carmody TJ. A

psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-

C16) in bipolar patients. International Journal of Methods in Psychiatric Research, 2009 Jun; 18(2): 138-

146. Epub: Nov 29, 2008; doi: 10.1002/mpr.285.

Tohen M, Frank E, Bowden CL, Colom F, Ghaemi NS, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta

E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KNR, Grunze H, Mitchell PB,

Kanba S, Berk M. The International Society of Bipolar Disorders (ISBD) Task Force on the

nomenclature of course and outcome in bipolar disorders. Bipolar Disorders, 2009 Aug; 11(5): 453-473.

doi: 10.1111/j.1399-5618.2009.00726.x.

Goldberg JF, Calabrese JR, Saville BR, Frye MA, Ketter TA, Suppes T, Post RM, Goodwin FK. Mood

stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder

with lamotrigine or placebo. Journal of Clinical Psychiatry, 2009 Sep; 70(9):1273-80. Epub: August 11,

2009; doi: 10.4088/JCP.08m04381.

2010

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended-release

formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (Trial

D144CC00002), Journal of Affective Disorders, 2010 Feb; 121(1-2): 106-115. Epub: November 8,

2009; doi: 10.1016/j.jad.2009.10.007.

http://dx.doi.org/10.1016/j.jad.2009.10.007


Page 37 of 68

04.17.19

Ivleva, EI, Morris DW, Moates AF, Suppes T, Thaker GK, Tamminga CA. Genetics and intermediate

phenotypes of the schizophrenia-bipolar boundary. Neuroscience and Biobehavioral Reviews, 2010

May; 34(6): 897-921. Epub: November 30, 2009; doi: 10.1016/j.neubiorev.2009.11.022.

Altshuler LL, Kupka RW, Hellemann G, Frye MA, Sugar CA, McElroy SL, Nolen WA, Grunze H, Leverich

GS, Keck PE Jr, Zermeno M, Post RM, Suppes T. Gender and depressive symptoms in 711 patients

with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network.

American Journal of Psychiatry, 2010 Jun; 167(6): 708-15. Epub: March 15, 2010; doi:

10.1176/appi.ajp.2009.09010105.

Bernstein I, Rish J, Suppes T, Kyotoku Y, Warden D. The Quick Inventory of Depressive Symptomatology

(Clinician and Self-Report Versions) in patients with bipolar disorder. CNS Spectrums, 2010 Jun, 15(6):

136-73.

Post RM, Leverich GS, Kupka RW, Keck PE Jr, McElroy SL, Altshuler LL, Frye MA, Luckenbaugh DA, Rowe

M, Grunze H, Suppes T, Nolen WA. Early onset bipolar disorder and treatment delay are risk factors

for poor outcome in adulthood. Journal of Clinical Psychiatry, 2010 Jul, 71(7): 846-72.

Post RM, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Leverich GS, Luckenbaugh DA, Rowe

M, Pizzarello S, Kupka RW, Grunze H, Nolen WA. Complexity of pharmacologic treatment required

for sustained improvement in outpatients with bipolar disorder. Journal of Clinical Psychiatry, 2010

Sep, 71(9): 1176-86.

2011

McElroy SL, Frye MA, Hellemann G, Altshuler L, Leverich GS, Suppes T, Keck PE, Nolen WA, Kupka R,

Post RM. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. Journal of

Affective Disorders, 2011 Feb, 128(3): 191-8. Epub: July 29, 2010; doi: 10.1016/j.jad.2010.06.037.

Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE, McElroy SL, Nolen WA, Kupka R,

Grunze H, Walden J, Rowe M. Differential clinical characteristics, medication usage, and treatment

response of bipolar disorder in the US versus The Netherlands and Germany. International Clinical

Psychopharmacology, 2011 Mar, 26(2): 96-106.

Kupfer DJ, Angst J, Berk M, Dickerson F, Frangou S, Frank E, Goldstein BI, Harvey A, Laghrissi-Thode F,

Leboyer M, Ostacher MJ, Sibille E, Strakowski SM, Suppes T, Tohen M, Yolken RH, Young LT,

Zarate CA. Advances in bipolar disorder: selected sessions from the 2011 International Conference on

Bipolar Disorder. Annals of the New York Academy of Sciences. 2011 Dec, 1242(1): 1-25. Doi:

10.1111/j.1749-6632.2011.06336.x.

2012

Feldman N, Gwizdowski IS, Fischer EG, Yang H, Suppes T. Co-occurrence of serious or undiagnosed medical

conditions with bipolar disorder preventing clinical trial randomization: A case series. Journal of

Clinical Psychiatry, 2012 June; 73(6):874-7. Epub: March 20, 2012.

Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Nolen WA, Rowe M, Kupka R,

Grunze H, Goodwin FK. Relationship of prior antidepressant exposure to longterm prospective outcome

in bipolar I outpatients. Journal of Clinical Psychiatry, 2012 Aug; 73(7):924-30. Epub: March 20, 2012.

Vieta E, Suppes T, Ekholm B, Udd M, Gustafsson U. Long-term efficacy of quetiapine in combination with

lithium or divalproex on mixed symptoms in bipolar I disorder. Journal of Affective Disorders, 2012;

142(1-3): 36-44. Epub October 9, 2012. Doi: 10.1016/j.jad.2012.04.014.

2013

Seo JS, Jamieson K, Cosgrove V, Gwizdowski IS, Yang H, Sheehan DV, McElroy SL, Suppes T.

Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring

http://dx.doi.org.laneproxy.stanford.edu/10.1016/j.neubiorev.2009.11.022


Page 38 of 68

04.17.19

bipolar disorder and anxiety disorder, European Psychiatry, 2013; 28(3): 190-6. Epub: November 28,

2011. doi: 10.1016/j.eurpsy.2011.08.001.

Swann AC, Lafer B, Perugi G, Frye MA, Bauer M, Bahk WM, Scott J, Ha K, Suppes T. Bipolar mixed states:

An International Society for Bipolar Disorders Task Force Report of Symptom Structure, Course of

Illness, and Diagnosis. American Journal of Psychiatry, 2013; 170(1): 31-42. Epub: December 7, 2012.

Doi: 10.1176/appi.ajp.2012.12030301.

Swann AC, Suppes T, Ostacher MJ, Eudicone J, McQuade R, Forbes A, Carlson BX. Multivariate analysis of

bipolar mania: Retrospectively assessed structure of bipolar I manic episodes in randomized clinical trial

participants. Journal of Affective Disorders, 2013; 144(1-2): 59-64. Epub: August 1, 2012. Doi:

10.1016/j.jad.2012.05.061.

Post RM, Altshuler L, Leverich G, Frye MS, Suppes T, McElroy S, Keck P, Nolan W, Kupka R, Grunze H,

Rowe M. The role of childhood adversity in the development of medical co-morbidities associated with

bipolar disorder. Journal of Affective Disorders, 2013; 147(1-3): 288-94.. Epub: January 18, 2013. Doi:

10.1016/j.jad.2012.11.020.

Sheehan DV, Harnett-Sheehan K, Hidalgo RB, Janavs J, McElroy SL, Amado D, Suppes T. Randomized,

placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the

anxious bipolar patient. Journal of Affective Disorders, 2013; 145(1):83-94. Epub: August 21, 2012.

Doi: 10.1016/j.jad.2012.07.016.

Gonzalez R, Tohen M, Suppes T, Tamminga C. Comparison of objective and subjective assessments of sleep

time in subjects with bipolar disorder. Journal of Affective Disorders, 2013, 149(1-3):363-6. Epub:

March 11, 2013. doi: 10.1016/j.jad.2013.02.013.

Cosgrove VE, Suppes T. Informing DSM 5: biological boundaries between bipolar I disorder, schizoaffective

disorder, and schizophrenia. BMC Medicine, 2013; 11: 127. Epub: May 14, 2013. Doi: 10.1186/1741-

7015-11-127.

Suppes T, Vieta E, Gustafsson U, Udd M. Maintenance treatment with quetiapine when combined with either

lithium or divalproex in bipolar I disorder: analysis of 2 large placebo controlled trials. Depression and

Anxiety, Epub: June 12, 2013. Doi: 10.1002/da.2213.

Hernandez JM, Cordova MJ, Ruzek J, Reiser R, Gwizdowski IS, Suppes T, Ostacher MJ. Presentation and

Prevalence of PTSD in a Bipolar Disorder Population: A STEP-BD examination. Journal of Affective

Disorders, Epub: May 23, 2013. Doi: 10.1016/j.jad.2013.04.038.

Suppes T, Ketter TA, Gwizdowski IS, Dennehy EB, Hill SJ, Fischer EG, Snow DE, Gonzalez R, Sureddi S,

Shivakumar G, Cosgrove VE. First controlled treatment trial of bipolar II mixed hypomania: Quetiapine

versus placebo, Journal of Affective Disorders, 2013, Epub: March 19, 2013. doi:pii: S0165-

0327(13)00191-2. 10.1016/j.jad.2013.02.031.

Post RM, Leverich GS, Kupka R, Keck P, McElroy S, Altshuler L, Frye MA, Luckenbaugh DA, Rowe M,

Grunze H, Suppes T, NolenWA. Increased parental history of bipolar disorder in the U.S.: Association

with early age of onset. Acta Psychiatrica Scandinavica, 2012, Epub: October 19, 2013.

doi: 10.1111/acps.12208

Post RM, Leverich GS, Kupka R, Keck P, McElroy S, Altshuler L, Frye MA, Luckenbaugh DA, Rowe M,

Grunze H, Suppes T, NolenWA. More stressors prior to and during the course of bipolar illness in

patients from the United States compared with the Netherlands and Germany. Psychiatry Research,

2013. Epub: September 8, 2013. doi: 10.1016/j.psychres.2013.08.007

Young AH, Calabrese JR, Gustafsson U, Berk M, McElroy S, Thase ME, Suppes T, Earley W. Quetiapine

monotherapy in bipolar II depression: combined data from four large, randomized studies. July 2013.

doi: 10.1186/2194-7511-1-10

Post RM, Kupka RW, Nolen WA, Altshuler LA, Suppes T, Frye MA, McElroy SL, Keck PE Jr, Leverich GS,

Grunze H, Rowe M. Clinical correlates of sustained response to individual drugs used in naturalistic

treatment of patients with bipolar disorder. Depression and Anxiety, 2013.


Page 39 of 68

04.17.19

Gonzalez R, Tohen M, Suppes T, Tamminga C. The effects of manic and depressive symptoms on the

rhythmicity of activity levels in bipolar disorder. Journal of Clinical Psychiatry, 2013

2014

Hsin H, Suppes T. Psychopharmacology of bipolar II depression and bipolar depression with mixed features.

Focus. 2014 April; 136-145

Dell’Osso B, Dobrea C, Palazzo MC, Cremaschi L, Benatti B, Camuri G, Arici C, Suppes, T, and Altamura

AC. Neuroimaging procedures and related acquisitions in bipolar disorder. Depression and Anxiety, 2014

Jan-Feb;49(1):2-11

Post RM, Altshuler L, Kupka R, McElroy S, Frye M, Rowe M, Leverich G, Grunze H, Suppes T, Keck P,

Nolen W. Verbal abuse, like physical and sexual abuse, in childhood is associated with an earlier onset

and more difficult course of bipolar disorder. Bipolar Disorders, 2014: Oct 13. doi: 10.1111/bdi.12268.

Gonzalez R, Tamminga C, Tohen M, Suppes T. The relationship between affective state and the rhythmicity of

activity in bipolar disease. Journal of Clinical Psychiatry. 2014 Apr;75(4):e317-22. doi:

10.4088/JCP.13m08506.

Post RM, Altshuler L, Leverich GS, Frye MA, Suppes T, McElroy SL, Keck PE Jr. Nolen WA, Kupka RW,

Grunze H, Rowe M. Relationship of clinical course of illness variables to medical comorbidities in 300

adult outpatients with bipolar disorder. Compr Psychiartry, 2014 August; 56-59

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectivness of the extended release

formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of

Affect Disorder. 2014 Oct;168:485-93.

Post Rm, Alshuler L, Kupka R, McElroy S, Frye MA, Rowe M, Leverich GS, Grunze H, Suppes T, Keck PE

Jr, Nolen WA. More pernicious course of bipolar disorder in the United States thank in many European

countries: implications and policy and treatment. Journal of Affective Disorders, 2014 Feb; 160:27-33.

Suppes T, McElroy S, Sheehan D, Hidalgo R, Cosgrove V, Gwizdowski I, Feldman N. A randomized,

double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co occurring

lifetime panic or generalized anxiety disorder. Journal of Clinical Psychiatry. 2014 Jan;75(1):77-84.

doi: 10.4088/JCP.12m08297.

2015

Post Rm, Alshuler L, Leverich GS, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Nolen WA, Kupka RW,

Grunze H, Rowe M. Relationship of clinical course of illness variables to medical comorbidities in 900

adult outpatients with bipolar disorder. Journal of Compr Psychiatry. 2015 January; 56:21-8

Ostacher M, Suppes T, Swann A, Eudicone J, Landsberg W, Baker R, Carlson B. Patterns of response to

aripiprazole, lithium, haloperidol and placebo across factor scores of mania. International Journal of

Biopolar Disorders 2015 May;3:11

Post RM, Leverich GS, Kupka R, Keck PE, McElroy SL, Altshuler LL, Frye MA, Rower M, Grunze H, Suppes

T, Nolen WA. Increases in multiple psychiatric disorders in parents and grandparents of patients with

bipolar disorder from the USA compared with The Netherlands and Germany. Journal of Psychiatry

Genetics. 2015 October; 194–200

Post RM, Altshuler L, Kupka R. McElroy SL, Frye MA, Rowe, M, Grunze H, Suppes T, Keck PE Jr, Leverich

GS, Nolen WA. Verbal Abuse, like physical and sexual abuse, in childhood is associated with an earlier

noset and more difficult course of bipolar disorder. Bipolar Disorders. 2015 May;17(3):323-30

Post RM, Altshuler L, Kupka R. McElroy SL, Frye MA, Rowe, M, Grunze H, Suppes T, Keck PE Jr, Leverich

GS, Nolen WA. Multigenerational Positive Family History of Psychiatric Disorders Is Associated with a

Poor Prognosis in Bipolar Disorder. Journal of Neuropsychiatry 2015 Oct; 194–200

Colom F., Vieta E., Suppes T. Predominant polarity in bipolar disorders: refining or re-defining diagnosis?


Page 40 of 68

04.17.19

(Sepetember 2015) Acta Psychiatrica Scandinavica Sept 2015: 132: 324-326

Ostacher M, Tandon R, Suppes T. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults

with Bipolar Disorder. Journal of Clinical Psychiatry. J Clin Psychiatry. 2015 Jul;77(7):920-6

2016

Suppes T. A brief commentary on the Bipolar CHOICE study. J Clin Psychiatry. Jan 2016: 77(1): e43-4

Cosgrove VE, Kelsoe JR, Suppes T. Toward a Valid Animal Model of Bipolar Disorder: How the Research

Domain Criteria Help Bridge the Clinical-Basic Science Divide. Biol Psychiatry Jan 2016; 79 (1): 62-70

Post RM, Altshuler LL, Jupka R, McElroy SL, Frye MA, Rowe M, Grunze H, Suppes T, Keck PE, Leverich

GS, Nolen WA. More illness in offspring of bipolar patients from the US compared to Europe. J Affect

Disorders. February 2016; 191: 180-6

Miller S, Dennehy EB, Suppes T. The Prevalence and Diagnostic Validity of Short-Duration Hypomanic

Episodes and Major Depressive Episodes. Curr Psychiatry Rep. March 2016; 18(3):27

Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar

depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J

Psychiatry Res. March 2016;78:86-93

Suppes T, Silva R, Cucchiaro J, Mao Y, targum S, Streicher C, Pikalov A, Loebel A. Lurasidone for the

Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-

Controlled Study. Am J Psychiatry. April 2016;173(4):400-7

Miller S, Suppes T, Mintz J, Hellemann G, Frye MA, McElroy SL, Nolen WA, Kupka R, Leverich GS, Grunze

H, Alshuler LL, Keck PE Jr, Post RM. Mixed Depression in Bipolar Disorder: Prevalence Rate and

Clinical Correlates During Naturalistic Follow-Up in the Stanley Bipolar Network. Am J Psychiatry.

October 2016. 173 (10):1015-1023.

Post RM, Leverich GS, Kupka R, Keck PE Jr, McElroy SL, Altshuler LL, Frye MA, Rowe M, Grunze H,

Suppes T, Nolen WA. Clinical correlates of sustained response to individual drugs used in naturalistic

treatment of patients with bipolar disorder. Compr Psychiatry. April 2016; 66: 146-56

Targum SD, Suppes T, Pendergrass JC, Lee S, Silva R, Cucchiaro J, Loebel A. Major depressive disorder with

subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional,

placebo-control study. Prog Neuropsychopharmacol Biol Psychiatry. July 2016;68-9:9-14

Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M, Grunze H, Suppes T, leverich GS, Nolen

WA. Age of onset of bipolar disorder: Combined effect of childhood adversity and familial loading of

psychiatric disorders. J Psychiatry Res. June 2016; 81: 63-70

Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M, Grunze H, Suppes T, leverich GS, Nolen

WA. Furthur Evidence of a Cohort Effect in Bipolar Disorder: More Early Onsets and Family History of

Psychiatric Illness in More Recent Epochs. J Clin Psychiatry Jul 2016. (epub ahead of print)

Carter JM, Arentsen TJ, Cordova MJ, Ruzek J, Reiser R, Suppes T, Ostacher MJ. Increased Suicidal Ideation in

Patients with Co-Occurring Bipolar Disorder and Posttraumatic Stress Disorder. Arch Suicide Res June

2016 (epub ahead of print)

Williams LM, Goldstein –Piekarski An, Chowdhry N, Grisanzio KA, Haug NA, Samara Z, Etkin A, O’Hara R,

Schatzberg AF, Suppes T, Yesavage J. Developing a clinical translational neuroscience taxonomy for

anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and

Depression (“RAD”) project. BMC Psychiatry. March 2016; 16:68

Goldstein-Piekarski A, Korgaonkar M, Green E , Suppes T, Schatzberg A , Hastie T ,Nemeroff C, Williams L.

Human Amygdala Engagement moderated by Early Life Stress Exposure is a Biobehavioral Target for

Predicting Recovery on Antidepressants. PNAS 113(42)11955-11960.

Machado-Vieira, Luckenbaugh DA, Ballard ED, Henter ID, Tohen M, Suppes T, Zarate C. Increased activity

or Energy as a Primay Criterion for the Diagnonsis of Bipolar Mania in DSM-5: Findings From the

STEP-BD Study. AJP August 2016; doi: 10.1176/appi.ajp.2016.15091132

http://www.ncbi.nlm.nih.gov/pubmed/26580001


Page 41 of 68

04.17.19

2017

Buoli M, Dell-Osso B, Caldiroli A, Carnevali G, Serati M, Suppes T, Ketter T, Altamura A. Obesity and

obstetric complications are associated with rapid-cycling in Italian patients with bipolar disorder.

Journal of Affective Disorders. January 2017; doi: 10.1016/j.jad.2016.10.010.

Bartoli F, Dell’Osso B, Crocamo C, Fiorillo A, Ketter TA, Suppes T, Clerici M, Carra G. Benefits and harms

of low an dhigh second-generation antipsychotics doses for bipolar depression: A meta-analysis. Jounral

of Psychiatric Research. January 2017; ;88:38-46. doi: 10.1016/j.jpsychires.2016.12.021.

Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M, Grunze H, Suppes T, Keck PE Jr, Nolen

WA. Illnesses in siblings of US patients with bipolar disorder relate to multimgenerational family

history and patients serverity of illness. Journal of Affective Disorders. 2017 Jan 1;207:313-319. doi:

10.1016/j.jad.2016.09.042

Post RM, Altshuler L, Kupka R, McElroy S, Frye M, Rowe M, Grunze H, Suppes T, Keck PE Jr, Leverich G,

Nolen WA. More childhood onset bipolar disorder in the United Staes than Canada or Europe:

Implications for treatment and prevention. Neuroscience and Biobehavioral Reviews. 74 (204-213)

January 2017.

Altshuler L, Sugar C, McElroy S, Calimlim B, Gitlin M, Keck P, Aquino-Elias A, Martens B, Fischer E,

English T, Roach J, Suppes T. Switch rates during acute treatment for bipolar II depression with

lithium, sertraline or the combination for bipolar II depression: a randomized, double-blind comparison.

Am J Psychiatry. January 2017 174:3, 266-276

Riemann G, Weisscher N, Post RM, Altshuler L, McElroy S, Frye MA, Keck PE, Leverich GS, Suppes T,

Grunze H, Nolen WA, Kupka RW. The relationship between self-reported borderline personality

features and prospective illness course in bipolar disorder. Int J Bipolar Disord. 2017 Sep 25;5(1):31.

Dodd S, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, Williams L, Suppes T, Lopez Jaramillo

C, Trivedi MH, Fava M, Rush AJ, McIntyre RS, Thase ME, Lam RW, Severus E, Kasper S, Berk M.

Monitoring for antidepressant-associated adverse events in the treatment of patients with major

depressive disorder: An international consensus statement. World J Biol Psychiatry. 2017 Oct 06:1-19.

McIntyre R, Tandon R, Ostacher M, Suppes T. Florida Best Practice Psychotherapeutic Medication Guidelines

for Adults with Major Depressive Disorder. Journal of Clinical Psychiatry. October 2016;77(7):920–

926

Suppes, T., Ostacher M. Mixed Features in Major Depressive Disorder: Diagnoses and Treatments. CNS

Spectrums and The Canadian Journal of Neurological Sciences. April 2017

Suppes, T., Eberhard J, Lemming O, Young AH, McIntyre RS. Anxiety, irritability, and agitation as indicators

of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. Int J Bipolar

Disord. 6 November 2017; 5(1):36

Carter JM, Arentsen TJ, Cordova MJ, Ruzek J, Reiser R, Suppes T, Ostacher MJ. Increased suicidal ideation

in patients with co-occurring bipolar disorder and post-traumatic stress disorder. Archives of suicide

research. Volume 21, 2017 – issue 4. doi.org/10.1080/13811118.2016.1199986

Lauder S, Cosgrove V, Gliddon E, Grimm D, Dodd S, Berk L, Castle D, Suppes T, Berk M. Progressing

Moodswings. The upgrade and evaluations of Moodswings 2.0: An online intervention for Bipolar

Disorder. Contemporary Clinical Trials. 2017; 56:18-24.

http://sfx.stanford.edu/local?sid=stanford:laneweb-search-pubmed&id=pmid:28944443





Page 42 of 68

04.17.19

Cosgrove V, Gliddon E, Berk L, Grimm D, Lauder S, Dodd S, Berk M, Suppes T. Online ethics: where will

the interface of mental health and the internet lead us? Int J Bipolar Disord. 2017 Dec; 5(1):26.

2018

Vieta E, Salagre E, Grande I, Carvalho AF, Fernandes BS, Berk M, Birmaher B, Tohen M, Suppes T. Early

Intervention in Bipolar Disorder. Am J Psychiatry. 2018 Jan 24: appiajp201717090972.

Post RM, Leverich GS, McElroy S, Kupka R, Suppes T, Altshuler L, Nolen W, Frye M, Kech P, Grunza H,

Hellemann G. Prevalence of Axis II Comorbidities in Bipolar Disorder: Relationship to Mood State.

Bipolar disorders. 25 Jan 2018; Epub doi: 10.1111/bdi.12596

Williams LM, Pines A, Goldstein-Piekarski AN, Rosas LG, Kullar M, Sacchet MD, Gevaert O, Bailenson J,

Lavori PW, Dagum P, Wandell B, Correa C, Greenleaf W, Suppes T, Perry LM, Smyth JM, Lewis MA,

Venditti EM, Snowden M, Simmons JM, Ma J. The ENGAGE study: Integrating neuroimaging, virtual

reality and smartphone sensing to understand self-regulation for managing depression and obesity in a

precision medicine model. Behav Res Ther. 2018 Feb; 101:58-70.

Gonzalez R, Suppes T, Zeitzer J, McClung C, Tamminga C, Tohen M, Forero A, Dwivedi A, Alvarado A.

The association between mood state and chronobiological characteristics in bipolar I disorder: A

naturalistic, variable cluster analysis-based study. International Journal of Bipolar Disorders. 19

February 2018; 6:5

Yatham L, Kennedy S, Parikh S, Schaffer A, Bond D, Frey B, Sharma V, Goldstein B, Rej S, Beaulieu S, Alda M,

MacQueen G, Milev R, Ravindran A, O’Donovan C, McIntosh D, Lam R, Vazquez G, Kapczinski F,

McIntyre R, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese J, Vieta E, Malhi G, Post R, Berk M.

Canadian Network for Mood and Anxiety Treatments (CANMAT)/International Society for Bipolar

Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar

Disorders. 13 March 2018; DOI: 10.1111/bdi.12609

Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, Gao K, Miskowiak KW, Grande I.

Bipolar Disorder. Nature Reviews Disease Primers, 8 March 2018; doi:10.1038/nrdp.2018.8

Post R, Leverich G, McElroy S, Kupka R, Suppes T, Altshuler L, Nolen W, Frye M, Keck P,

Grunze H, Hellemann G. Prevalence of axis II comorbidities in bipolar disorder:

relationship to mood state. Bipolar Disorders. 10 June 2018; 20(4):303-312; doi.org/10.1111/bdi.12596

Post R, Altshuler L, Kupka R, McElroy S, Frye M, Rowe M, Grunze H, Suppes T, Keck Jr P, Leverich G,

Nolen W. Multigenerational Transmission of Liability To Psychiatric Illness In Offspring Of Parents

With Bipolar Disorder. Bipolar Disorders. 21 June 2018; 10.1111/bdi.12668

Gliddon E, Cosgrove V, Berk L, Lauder S, Mohebbi M, Grimm D, Dodd S, Coulson C, Raju K, Suppes T,

Berk M. A Randomized Controlled Trial of MoodSwings 2.0: An Internet-Based Self-Management

Program for Bipolar Disorder. Bipolar Disorders. 21 June 2018

Findling R, Earley W, Suppes T, Patel M, Wu X, Chang C, McIntyre R. Post hoc analyses of asenapine

treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage

of illness, and body weight. Neuropsychiatric Disease and Treatment. 2 August 2018








https://doi.org/10.1111/bdi.12596


Page 43 of 68

04.17.19

Post R, Altshuler L, Kupka R, McElroy S, Frye M, Rowe M, Grunze H, Suppes T, Keck P, Nolen W. More

Assortative Mating in Parents and Spouses of US Compared to European Patients with Bipolar Disorder:

Implications for psychiatric illness in the offspring. European Archives of Psychiatry and Clinical

Neuroscience. 11 August 2018

Van der Markt A, Klumpers UMH, Draisma S, Dols A, Nolen WA, Post RM, Altshuler LL, Frye MA, Grunze

H, Keck PE, McElroy SL, Suppes T, Beekman ATF, Kupka RW. Testing a Clinical Staging Model for

Bipolar Disorder using Longitudinal Life Chart Data. Bipolar Disorders. 17 November 2018. DOI:

10.1111/bdi.12727

2019

Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Di Florio A, Dietch D, Geddes JR, Goodwin GM, Heinz

Grunze H, Joseph F. Hayes, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R,

Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young

AH, Stokes PRA. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression:

consensus definition. BJPsych. January 2019; 214, 27-35. 35. doi: 10.1192/bjp.2018.257

Kramer NE, Cosgrove VE, Dunlop K, Subramaniapillai M, McIntyre RS, Suppes T. A clinical model for

identifying an inflammatory phenotype in mood disorders. Journal of Psychiatric Research. 10

February 2019; 113: 148-158. doi: 10.1016/j.jpsychires.2019.02.005

Gonzalez R, Suzanne D. Gonzalez SD, Guptae J, Mallawaarachchic I, Suppes T. The relationship between

circadian gene single nucleotide polymorphisms and clinical and behavioral assessments of sleep and

rhythms and course of illness characteristics in subjects with bipolar type I disorder. Personalized

Medicine in Psychiatry. 12 February 2019; 13-14 (2019) 11-18.

https://doi.org/10.1016/j.pmip.2019.01.001

In Press

McIntyre R, Subramaniapillai M, Lee Y, Pan Z, Carmona N, Shekotikhina M, Rosenblat J, Brietzke E,

Soczynska J, Cosgrove V, Miller S, Fischer E, Kramer-Lange N, Dunlap K, Suppes T, Mansur R. A

Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Infliximab in the Treatment of

Adults with Bipolar I/II Depression: Efficacy in Persons Reporting Childhood Trauma. JAMA,

Psychiatry, 2019

In Submission

Bennett F, Hodgetts S, Altshuler L, Close A, Frye M, Grunze H, Keck P, Kupka R, Leverich G, McElroy S, Nolen

W, Post R, Schärer L, Suppes T, Sharma A. Predictors of Psychosocial Outcome of bipolar disorder:

Results from the Stanley Foundation Bipolar Network. Submitted February 2018

Earley W, Burgess MV, Khan B, Rekeda L, Suppes T, Mauricio Tohen M, Calabrese JR. Cariprazine

Treatment of Bipolar I Depression: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study.

Submitted December 2018

McIntyre RS, Suppes, Hankinson A, Calabrese J, Burgess M, Yatham L, Rekeda L. A Pooled Post Hoc

Analysis Evaluating the Safety of Cariprazine in Bipolar Depression. Submitted March 2019

https://doi.org/10.1016/j.pmip.2019.01.001


Page 44 of 68

04.17.19

Fredskild MU, Mintz J, Frye MA, MD, McElroy SL, Nolen WA, Kupka R, Grunze H, Keck PE, Post RM,

Kessing LV, Suppes T. Hypomania/Mania by DSM-5 Definition Evaluated in 907 Patients from the

Stanley Foundation Bipolar Treatment Network: Does adding Energy/Activity to Criterion (A) Matter?

Submitted March 2019

Letters

Costello LE, Suppes T. A clinically significant interaction between clozapine and valproate. Journal of Clinical


Brown ES, Thompson R, Suppes T. Capgras' and Fregoli's syndromes in one family. Journal of Clinical

Psychiatry, 1996; 57(3): 137-138.

Suppes T, Rush AJ. Medication optimization during clozapine treatment. Journal of Clinical Psychiatry, 1996;

57(7): 307-308.

Bennett J, Goldman WT, Suppes T. Gabapentin for treatment of bipolar and schizoaffective disorders. Journal

of Clinical Psychopharmacology, 1997; 17(2): 141-142.

Rush AJ, Suppes T. What are the new treatments for bipolar disorder? In: Grinspoon L ed. The Harvard Mental

Health Letter, 1998; 14(11): 8.

Brown ES, Shellhorn E, Suppes T. Gastrointestinal side-effects after switch to generic valproic acid.

Pharmacopsychiatry, 1998; 31: 114.

Brown ES, Khan DA, Suppes T. Treatment of corticosteroid-induced mood changes with olanzapine. American

Journal of Psychiatry, 1999; 156(6): 968.

Brown ES, Suppes T. What are the mental health complications of steroid therapy? Harvard Mental Health

Letter, 2000; 16(8): 8.

Ozcan ME, Shiekh M, Suppes T. How rare is bipolar disorder not otherwise specified? Bipolar Disorders,

2003; 5(3): 226-7. Doi: 10.1034/j.1399-5618.2003.00039.x.

Dennehy E, Gonzalez R, Suppes T. Self-reported participation in nonpharmacologic treatments for bipolar

disorder. Letter to the Editor, Journal of Clinical Psychiatry, 2004; 65(2): 278.

Altshuler L, Suppes T, Black D, Luckenbaugh D, Post R. Dr. Altshuler and colleagues reply. American Journal

of Psychiatry, 2004; 161(7): 1313.

Majeres KD, Suppes T. A cautionary note when using zonisamide in youths: a case report of association with

toxic epidermal necrolysis. Letter to the Editor, Journal of Clinical Psychiatry, 2004, 65(12): 1720.

Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE Jr., Walden J, Leverich GS, Altshuler LL, Nakelsky S,

Hwuang S, Mintz J, Post RM. Treatment emergent hypomania or mania with modafinil. Letter to the

Editor, American Journal of Psychiatry, 2008, 165(1): 35.

Gonzalez R, Bernstein IH, Suppes T. An investigation of water lithium concentrations and rates of violent acts

in 11 Texas counties: can an association be easily shown? Research Support Letter, Journal of Clinical

Psychiatry, 2008; 69(2): 325-6.

Suppes T, McElroy SL, Hirschfeld R. Glucose Testing in Patients Receiving Antipsychotic Pharmacotherapy:

Author Reply. Psychopharmacology Bulletin, 2008; 41(2): 7-8.

Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Andreasen NC, Brady KT, Brent

DA, Brzustowicz L, Carter CS, Eisenberg L, Goldman H, Javitt DC, Leibenluft E, Lieberman JA,

Milrod B, Oquendo MA, Rosenbaum JF, Rush AJ, Siever LJ, Suppes P, Weissman MM, Roy MD,

Scully JH Jr, Yager J. Conflict of interest—an issue for every psychiatrist. Commentary, American

Journal of Psychiatry, 2009; 166(3): 274.

Suppes T, Vieta E. Maintenance Treatment for Patients with Bipolar I Disorder: Results from a North

American study of quetiapine in combination with lithium or divalproex: Author Reply. American

Journal of Psychiatry, 2009; 166(10): 1186-7. doi: 10.1176/appi.ajp.2009.09060846.


Page 45 of 68

04.17.19

Suppes T, Frank E, DePaulo R, Davis L, Zarate C, Angst J, Fawcett J. Letter to the Editor of Bioploar Disorder

in response to 2012 article by Alan Frances: Author Reply. Bipolar Disorders, 2013.

Books

Macken E, Van den Heuvel R, Suppes P, Suppes T. Home Based Education: Needs and Technological

Opportunities - National Institute of Education, U.S. Department of H.E.W., April 1976. 220 pp.

Suppes P. The Effects of Tetraethylammonium on the Electrophysiological Properties of Sympathetic Neurons

Isolated from the Superior Cervical Ganglia of Neonatal Rats Grown in Cell Culture. Doctoral Thesis,

University of California, Los Angeles, 172 pp., filed 1980.

Suppes T, Keck PE. Bipolar Disorder: Treatment and Management. Compact Clinicals, 2005.

Suppes T, Dennehy E. Bipolar Disorder: The Latest Diagnostic and Treatment Strategy, Compact Clinicals,

2005.

Suppes T, Manning JS, Keck PE Jr. Decoding Bipolar Disorder, Compact Clinicals, 2006.

Suppes T, Dennehy E. Bipolar Disorder Assessment and Treatment, Second Edition, Jones and Bartlett, 2012.

Reiser R, Thompson L.

Reiser RP, Thompson LW, Johnson SL, Suppes T. Bipolar Disorder: Advances in Psychotherapy: Evidence-

Based Practice, Second Edition, Hogrefe Publishing Group, 2017

Swartz HA, Suppes T., eds. Bipolar II Disorder: Recognition, Understanding, and Treatment. APA

Publishing, In Press 2019

Book Chapters and Invited Articles

Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium

treatment in bipolar disorder. Excerpted in: Talbott JA, ed. The Yearbook of Psychiatry and Applied

Mental Health. St. Louis: Mosby; 1994.

Baldessarini RJ, Suppes T, Tondo L, Faedda G, Viguera A, Tohen M. Risks of interrupting maintenance

therapy with psychotropic drugs. In: Flach F, ed. Directions in Psychiatry, Volume 15. New York, NY:

The Hatherleigh Company; January 1995.

Suppes T. New findings about rapidly cycling bipolars and an atypical antipsychotic medication. The Journal

of the California Alliance for the Mentally Ill. Sacramento, CA: California Alliance for the Mentally Ill

1995; 6(2).

Suppes T, Rush AJ. Evolving clinical characteristics or distinct disorders? In: Shulman K, Tohen M, Kutcher S,

eds. Mood Disorders Across the Life Span. New York: John Wiley & Sons; 1996:3-16.

Baldessarini RJ, Tondo L, Suppes T, Faedda GL, Tohen M. Pharmacological treatment of bipolar disorder

throughout the life cycle. In: Shulman K, Tohen M, Kutcher S, eds. Mood Disorders Across the Life

Span. New York: John Wiley & Sons 1996:299-338.

Suppes T, Baldessarini RJ, Motohashi N, Tondo L, Viguera AC. Special treatment issues: Maintaining and

discontinuing psychotropic medications. In: Rush AJ, ed. Mood Disorders: Systematic Medication

Management. Modern Problems of Pharmacopsychiatry, Vol 25. Basel, Switzerland: S. Karger AG

1997:235-254.

Suppes T. Pharmacotherapy of bipolar disorder, depressed phase. In: Rush AJ, ed. Women's Health Care

Newsletter. Case Conferences on Mood and Anxiety Disorders. St. Louis College of Pharmacy,

Women's Health Platform http://www.stlcop.edu/whp/whp.html, 1997.

Brown S, Suppes T. Bipolar disorders. In: Dunner D, Rosenbaum J eds. Psychiatric Clinics of North America:

Annual of Drug Therapy. Philadelphia, PA: W.B. Saunders 1998:154-160.

Glick ID, Marder S, Janowsky D, Suppes T, DeBattista C. New short- and long-term psychopharmacologic

treatment strategies for schizophrenia, bipolar disorder and depressive disorder. In: Watson SJ, Deutch

A, eds. Psychopharmacology: The Fourth Generation of Progress CD/ROM. Philadelphia, PA:

Lippincott-Raven 1998.


Page 46 of 68

04.17.19

Suppes T, Habermacher E, Potter W. Treatment algorithms and guidelines for bipolar disorder. In: Jobson K,

Stein D, Fawcett J, eds. Treatment Algorithms in Clinical Psychopharmacology. New York: John Wiley

& Sons 1999.

Suppes T. Management of treatment-resistant bipolar and schizoaffective disorders. The Hatherleigh Guide to

Psychopharmacology. The Hatherleigh Guides Series, Vol II. New York, NY: Hatherleigh Press

1999:169-188.

Trivedi M, Suppes T. Nefazodone, mirtazapine and venlafaxine: Clinical use and experience. In: Buckley P,

Waddington J, Baldessarini R, eds. Schizophrenia and Mood Disorders: The New Drug Therapies in

Clinical Practice. Oxford: Butterworth-Heinemann 2000.

Suppes T. Management of treatment-resistant bipolar and schizoaffective disorders. In: Flach F, ed. The

Hatherleigh Guide to Psychiatric Disorders, Part II. The Hatherleigh Guides Series. Long Island City,

NY: Dymock’s Book Arcade 2000:128-144.

Calabrese JR, Goodwin GM, Manji HK, Suppes T, and Zarate CA. Current Options for the Treatment of

Bipolar Disorder. CNS News Special Report. CME Accredited. Dec. 2001: 1-7.

Frye M, Berlant J, Suppes T. Health Learning Systems monograph, Managing Bipolar Disorder and Related

Comorbidities with Anticonvulsant Drugs, June 2002.

Post RM, Chang KD, Suppes T, Ginsberg DL. Treatment of Rapid-Cycling Bipolar Disorder. CME Accredited

Monograph. CNS Spectrums 2004; 9(2):1-12.

Mondimore F, Suppes T, Ketter T. Optimizing Pharmacotherapy in bipolar depression. Euro RSCG Life

Genecom, Johns Hopkins University, 2004.

McIntyre RS, Suppes T. Management of Bipolar Psychosis: Diagnosis and Treatment Strategies. A CME-

Certified Monograph. November 2006.

Hirschfeld RMA, Bowden CL, Ketter TA, Kowatch RA, McIntyre RS, Post RM, Sachs GS, Suppes T, Wagner

K. Bipolar Disorder: A Critical Appraisal of Current Practice. The Proceedings of the Bipolar Summit

2006. CME Accredited Clinical Monograph. December 2006.

Suppes T, Kelly DI. Treatment and Monitoring Guidelines for the Patient with Bipolar Disorder. US Psychiatry

Review. November 2008.

Estevez RF, Suppes T. Maintenance Treatments in Bipolar Disorder. In: Bipolar Disorder: A Clinician's Guide

to Management, 2nd edition. Eds. Yatham L, Kusumakar V. New York, NY: Routledge 2009: 107-152.

Suppes T. Is There a Role for Antidepressants in the Treatment of Bipolar II Depression? Invited Editorial,

American Journal of Psychiatry, 2010; 167(7): 738-40. doi: 10.1176/appi.ajp.2010.10040590.

Cosgrove VE, Seo JS, Yang H, Suppes, T. Clinical utility of clozapine in bipolar disorder. In HS Akiskal & M

Tohen (Ed.), Bipolar Psychopharmacotherapy: Caring for the Patient Second Edition, San Francisco:

John Wiley & Sons, Ltd, 2011.

Kudlow PA, Cha DS, McIntyre RS, Suppes T. Maintenance Treatments in Bipolar Disorder. In: The Bipolar

Book. Oxford University Press, 2015

Suppes T. Fangou Chapter Life. December 2015.

Miller S, Ostacher M, Suppes T. Bipolar and Related Disorders. In APA 7th edition. February 2018.

Cosgrove V, Suppes T, Schaffer A, Baker A, Kramer N. Bipolar Spectrum Disorders. In: Textbook of Suicide

Assessment and Management, 3rd edition, Bipolar spectrum disorders. 2019

Lange, N, Suppes T. Diagnosing Bipolar II Disorder. In: Bipolar II Disorder: Recognition, Understanding,

and Treatment. APA Publishing, In Press 2019

News Releases/Interviews

Suppes T (interview). Anxiety in bipolar disorder: Balancing benefits. Practical Psychopharmacology, C.

Sherman, contributing writer, 2005.

Suppes T (interview). Maintenance Treatment of Bipolar Disorder: An Expert Interview With Trisha Suppes,

MD, PhD. Medscape 2007. http://www.medscape.com/viewarticle/552834

http://www.medscape.com/viewarticle/552834


Page 47 of 68

04.17.19

Parikh AR. Pharmaceutical Industry and Academic Psychiatry: Invited interview with Dr. Suppes. American

Journal of Psychiatry, 2008; 3(5): 1-3. http://ajp.psychiatryonline.org/cgi/data/165/5/A62/DC2/1

Suppes T (interview) Therapeutic Switching in Bipolar Disorder: An Expert Interview with Dr. Trisha Suppes,

M.D., Ph.D. Medscape 2008. http://www.medscape.com/viewprogram/17462

Suppes T (interview) Hope for Alternative Medicine Still to be Validated. Psychiatric News, 2010; 45(2): 10.

http://pn.psychiatryonline.org/content/45/2/10.full

Suppes T (interview) Depression and Bipolar Support Alliance 2009 Klerman Award Winner. National Public

Radio, 2009.

Selected Abstracts

Roth RL, Suppes P. Postembryonic addition of neurons to the nerve cord of the crayfish. Anatomical Record

1973; 175: 430.

Suppes T, O'Lague PH. Electrophysiological properties of isolated sympathetic neurons developing in

microculture. Society for Neurosciences Meeting 1978; 4: 139.5.

Suppes T. In the presence of tetraethylammonium, a late delayed depolarization follows the action potential of

rat sympathetic neurons grown in cell culture. Society for Neurosciences Meeting 1980; 6: 281.8.

Kriegstein AR, Suppes T, Prince DA. Cholinergic enhancement of penicillin-induced epileptiform discharges

in pyramidal neurons of the guinea pig hippocampus. Society for Neuroscience Meeting 1982; 8:259.5.

Kriegstein AR, Suppes T, Prince DA. Cellular physiology of the developing rat neocortex in vitro. Society for

Neurosciences Meeting 1983; 9:178.7

Suppes T, Tohen M, Faedda G, Baldessarini RJ. Risk of discontinuation of lithium in bipolar disorder.

American Psychiatric Association Meeting, 1991. New Research Poster.

Jackson PS, Suppes T, Harris KM. Dramatic differences in the magnitude and temporal development of long-

term potentiation (LTP) in rat hippocampal area CA1 at postnatal days 11 and 15. Society for

Neurosciences Meeting, 1991.

Faedda GL, Strakowski SM, Tohen M, Suppes T, Stoll AL, Mayer PV, Goodwin DC, Kolbrenner ML,

Baldessarini RJ. Mixed and dysphoric states in bipolar patients. American Psychiatric Association

Meeting, 1992. Poster Presentation.

Klein DF, Nierenberg AA, Blater MB, Lasagna L, Lydiard BR, Rush JA, Suppes T. International

Psychopharmacology Algorithm Project. Study Group. 32nd ACNP, 1993. Abstract Published in ACNP

Scientific Abstract 1993.

Tohen M, Strakowski TM, Suppes T, Stoll A, Hegarty J, Centorrino F, Zarate C, Weiss M. The McLean First-

Episode Mania Project. First International Conference on Bipolar Disorder, 1994. Poster Presentation.

Suppes T, Rush AJ, Harrison S, Webb A, Paul B. Toward a treatment algorithm for bipolar disorder. First

International Conference on Bipolar Disorder, 1994. Poster Presentation.

Suppes T, Yurgelen-Todd DA, Tohen M, Faedda G, Kolbrenner M, Weiss M, Strakowski S, Mayer P, Stoll A.

Mixed bipolar states at first hospitalization. First International Conference on Bipolar Disorder, 1994.

Poster Presentation.

Suppes T, Rush AJ, Harrison S, Webb A, Paul B. Treatment algorithm project for bipolar disorder. New

Clinical Drug Evaluation Unit Program (NCDEU) Annual Meeting, 1994. Poster presentation.

Suppes T, Yurgelen-Todd DA, Tohen M, Faedda G, Kolbrenner M, Weiss M, Strakowski S, Mayer P, Stoll A.

Mixed bipolar states at first hospitalization. Biological Psychiatry 1994; 35:478. Poster Presentation.

Suppes T, Rush AJ, Basco M, Webb A, Paul B, Harrison S. A treatment algorithm for bipolar disorder: An

open trial. 33rd American College of Neuropsychopharmacology Annual Meeting, 1994. Poster

Presentation.

Armitage R, Suppes T, Cole D, Rush AJ. The effects of clozapine on sleep EEG in bipolar illness. 34th

American College of Neuropsychopharmacology Annual Meeting, 1995. Poster Presentation.

http://ajp.psychiatryonline.org/cgi/data/165/5/A62/DC2/1

http://www.medscape.com/viewprogram/17462

http://pn.psychiatryonline.org/content/45/2/10.full


Page 48 of 68

04.17.19

Trivedi MH, Suppes T, Devous MD, Harris TS, Rush AJ. Effects of clozapine on rCBF in severe refractory

bipolar disorder. 34th American College of Neuropsychopharmacology Annual Meeting, 1995. Poster

Presentation.

Suppes T, Rush AJ, Webb A. Clozapine to treat severe and persistent bipolar disorder: preliminary results. 34th

American College of Neuropsychopharmacology Annual Meeting, 1995. Poster Presentation.

Basco MR, Kashner TM, Suppes T, Turner M, Orsulak P, Battaglia J, Rush AJ. A research partnership in the

community. Symposium Community Psychiatry: Public Academic Partnership, Joel Feiner, Director.

American Psychiatric Association: Miami, Florida; May 1995. Paper.

Brown ES, Suppes T, Khan DA. Affective symptoms from corticosteroids: A hypothesis for bipolar disorder.

35th American College of Neuropsychopharmacology Annual Meeting, 1996. Poster Presentation.

Suppes T, Rush AJ, Webb A, Carmody T, Kraemer H. A one-year randomized trial of clozapine vs. usual care

in patients with a history of mixed mania. 35th American College of Neuropsychopharmacology Annual

Meeting, 1996. Poster Presentation.

Kowatch RA, Gilfillan SK, Suppes T, Fuentes RM. Clozapine treatment of children and adolescents: A four-

year follow-up. Biological Psychiatry 1996; 39:105.

Trivedi MH, Suppes T, Devous MD, Harris TS, Rush AJ. RCBF changes with clozapine treatment in refractory

bipolar disorder. Biological Psychiatry1996; 39:108.

Armitage R, Suppes T, Cole D, Rush AJ. The effects of clozapine on sleep EEG in bipolar illness. Biological

Psychiatry 1996;39:533.


in bipolar I patients. Biological Psychiatry 1996; 39:107.

Suppes T. New treatments for bipolar disorder - anticonvulsants and beyond. American Psychiatric Association

Annual Meeting, 1996. Symposium.

Brown ES, Suppes T, Khan DA. Affective symptoms from corticosteroids: A hypothesis for bipolar disorder.

American Psychiatric Association Annual Meeting, 1997.

Suppes T, Lee A, Paul B, Sanchez B, Mack R. The atypical antipsychotic sertindole: A case series.

International Congress on Schizophrenia Research, 1997.

Brown ES, Suppes T, Khan DA, Carmody TJ. Affective symptoms with corticosteroids: Preliminary data and

hypothesis. New Clinical Drug Evaluation Unit Annual Meeting, 1997.

Rush AJ, Crismon ML, Miller AL, Suppes T, Trivedi MH, Shon S, Toprac MG, Kashner TM, Altshuler KZ.

The Texas Medication Algorithm Project (TMAP): A status report 1998. New Clinical Drug Evaluation

Unit Annual Meeting, 1997. Poster Presentation.

Brown ES, Suppes T, Khan DA, Carmody TJ. Mood changes during corticosteroid exposure; preliminary data.

American College of Neuropsychopharmacology Annual Meeting, 1997.


in patients with a history of mixed mania. Society for Neuroscience, 1997.

Kowatch RA, Bucci MA, Suppes T, Emslie GJ, Weinberg WA, Rush AJ. A randomized trial of mood

stabilizers in bipolar children and adolescents. American Academy of Child and Adolescent Psychiatry,

1997.

Brown ES, Suppes T, Khan DA, Carmody TJ. Affective symptoms with corticosteroids: Preliminary data and

hypothesis. International Society for Psychoneuroendocrinology Meeting, 1997.


in patients with a history of mixed mania. Second International Conference on Bipolar Disorder, 1997.

Calabrese JR, Bowden CL, McElroy SL, Sachs GS, Suppes T. Treatment of bipolar depression. European

College of Neuropsychopharmacology, 1998.

Rush AJ, Thase M, Bauer M, Nolen WA, Suppes T, Lavori P. Guidelines and algorithms. American College of

Neuropsychopharmacology Annual Meeting, 1998. Study Group Abstract.


Page 49 of 68

04.17.19

Brown ES, Suppes T, Swann A, Rush AJ, Crismon M, Shon S, Toprac M, Kashner TM, Altshuler K. Texas

Medication Algorithm Project bipolar disorder module: A status report. American College

Neuropsychopharmacology Annual Meeting, 1998.

Apter J, Ascher J, Downs J, Goldstein D, Kolin I, Lydiard B, McElroy S, Rudd D, Shiovitz T, Suppes T,

Udelman H, Weisler R, Zarate C. Lamotrigine: Evidence for antidepressant activity in bipolar disorder.

American College of Neuropsychopharmacology Annual Meeting, 1998.

Brown ES, Suppes T, McElroy S, Kmetz G, Frye M, Keck PE, Kupka R, Altshuler L, Rochussen J, Haytef J,

Leverich G, Post R. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder:

Application of the Stanley Foundation Bipolar Network prospective protocol. American College of

Neuropsychopharmacology Annual Meeting, 1998.

Crismon ML, Rush AJ, Toprac MG, Shon SP, Miller AL, Suppes T, Trivedi MH. Texas Medication Algorithm

Project: Feasibility study of implementing medication algorithms in the public mental health sector.

Second Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists:

February 10, 1999.

Khan DA, Brown ES, Suppes P, Carmody TJ. Mood changes during prednisone bursts for asthma. American

Lung Association/American Thoracic Meeting: April 23-28 1999. American Journal of Respiratory

Critical Care Medicine 1999; 159: A919.


Leverich G, Post R. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Biological

Psychiatry 1999; 45: 252.

Brown ES, Suppes T, McElroy S, Kmetz G, Frye M, Denicoff K, Keck PE, Nolen W, Kupka R, Altshuler L,

Rochussen J, Haytef J, Leverich G, Post R. A pilot trial of adjunctive topiramate in the treatment of

bipolar disorder. Society of Biological Psychiatry Annual Meeting, 45: Washington, DC; May 13-15,

1999. Biological Psychiatry 1999; 45: 8S.

Bowden C, Calabrese J, Greene P, McElroy S, Sachs G, Suppes T, Swann A. Lamotrigine in rapid cycling

bipolar disorder. American College of Neuropsychopharmacology (ACNP): Acapulco, Mexico;

December 12-16, 1999.

Suppes T. Clinical evidence on the use of antidepressants for bipolar depression. 38th Annual Meeting,

American College of Neuropsychopharmacology (ACNP): Acapulco, Mexico; December 12-16, 1999.


Leverich G, Post R. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Third

International Conference on Bipolar Disorder: Pittsburgh, PA; June 17, 1999.

Brown ES, Suppes T, Swann A, Rush AJ, Crismon M, Shon S, Toprac M, Kashner TM, Altshuler K. Texas

Medication Algorithm Project bipolar disorder module: A status report. Third International Conference

on Bipolar Disorder: Pittsburgh, PA; June 17, 1999.

Ascher J, Cookson J, Huffman R, Lydiard RB, McElroy S, Monaghan E, Suppes T. Profile of antidepressant

activity of lamotrigine (Lamictal) in bipolar depression: Results from a double- blind, placebo-

controlled study. Third International Conference on Bipolar Disorder: Pittsburgh, PA; June 1999.

Denicoff KD, Brotman MA, Leverich GS, Nolan W, Rush AJ, McElroy SL, Keck PE, Suppes T, Altshuler LL,

Kupka R, Frye MA, Post RM. Validation of the NIMH-Life-Chart Method (NIMH-LCM™). Third

International Conference on Bipolar Disorder: Pittsburgh, PA; June 17-19, 1999.

Suppes T, Cunningham L, Dinan T, Grounds D, Mitchell P, Sokolski K, West S, Ascher J, Babiar D, Cedrone

J, Laurenza A, Monaghan E. Lamotrigine (Lamictal): Safety data from controlled monotherapy trials in

depression. European College of Neuropsychopharmacology (ECNP), 1999.

Denicoff KD, Brotman MA, Leverich GS, Nolan W, Rush AJ, McElroy SL, Keck PE, Suppes T, Altshuler LL,

Kupka R, Frye MA and Post RM. Validation of the NIMH-Life-Chart Method (NIMH-LCM™)

[abstract]. Bipolar Disorders 1999, 1(Suppl. 1):29.


Page 50 of 68

04.17.19

Apter J, Cutler N, Emmanuel N, Goldstein D, Kolin I, Suppes T, Udelman H, Zarate C Jr, Evoniuk G, Huffman

R. Profile of antidepressant activity of lamotrigine in bipolar depression: Results from a double-blind,

placebo–controlled study. New Clinical Drug Evaluation Unit Program (NCDEU) Annual Meeting,

1999.

Greene P, Earl NL, Ascher J, Monahan E, Suppes P, Bowden C, Calabrese J. 488-Mood stabilization with

lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study. American

Psychiatric Association Annual Meeting: Chicago, IL; May 13-18, 2000.

Tohen M, Chengappa KNR, Suppes T, Jacobs TG, Timpe TM, Risser RC, Keeter EL, Feldman PD, Tollefson

GD, Kupfer DJ, Zarate CA, Breier A. Efficacy of olanzapine combined with mood stabilizers in the

treatment of bipolar disorder. Congress of Collegium Internationale Neuropsychopharmacologicum

(CINP): Brussels, Belgium; July 9-13, 2000.

Earl N, Bowden C, Calabrese J, Ketter T, McElroy S, Post R, Sachs G, Suppes P, Swann A, Ascher J, Chang C,

Evoniuk G, Greene P. Mood stabilization with lamotrigine in rapid cycling bipolar disorder. Congress of

Collegium Internationale Neuropsychopharmacologicum (CINP): Brussels, Belgium; July 9-13, 2000.

Greene P, Calabrese J, Ketter T, McElroy S, Post R, Sachs P, Suppes P, Swann A, Ascher J, Earl N, Monaghan

E, Smoot T. Mood stabilization with lamotrigine in rapid cycling bipolar disorder: A double–blind

placebo–controlled study. Congress of Collegium Internationale Neuropsychopharmacologicum (CINP):

Brussels, Belgium; July 9-13, 2000.

Leverich GS, Altshuler LL, McElroy S, Keck PE Jr, Suppes T, Denicoff KD, Nolen WA, Rush AJ, Kupka R,

Frye MA, Autio KA, Post RM. Prevalence of axis II comorbidity in bipolar disorder: Relationship to

mood state and course of illness. Second European Stanley Foundation Conference on Bipolar Disorder:

Amsterdam, Holland; Acta Neuropsychiatrica September 2000; 12: 161-162.

Calabrese J, Suppes P, Post R, Greene P, Ascher RN, Monaghan E. A double–blind placebo-controlled study of

lamotrigine in rapid cycling bipolar disorder. Second European Stanley Foundation Conference on

Bipolar Disorder: Amsterdam, Holland; September, 2000.

Frye MA, Altshuler LL, Denicoff KD, Keck PE, McElroy SL, Suppes T, Nolen W, Kupka R, Pollio C, Colburn

A, Leverich G, Rush AJ. Gender difference in bipolar disorder alcohol abuse comorbidity. Second

European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; September, 2000.

Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE, McElroy SL, Denicoff KD, Leverich GS,

Kupka R, Nolen WA. Low switch rate in bipolar patients prospectively treated with third generation

antidepressants as augmentation to mood stabilizers. Second European Stanley Foundation Conference

on Bipolar Disorder: Amsterdam, Holland; September, 2000.

Denicoff KD, Leverich GS, Nolen WA, McElroy SL, Keck PE Jr, Suppes T, Altshuler LL, Kupka R, Frye MA,

Pollio HC, Post RM. Morbidity in 202 patients followed for one year in the Stanley Foundation Bipolar

Network (SFBN). Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam,

Holland; Acta Neuropsychiatrica 12:157, September, 2000.

Leverich GS, McElroy SL, Suppes T, Keck PE, Jr, Denicoff KD, Nolen WA, Altshuler LL, Rush AJ, Kupka R,

Frye MA, Autio KA, Post RM. Early physical or sexual abuse and the course of bipolar illness. Second


Suppes T, Kupka R, McElroy S, Altshuler L, Frye M, Keck PE, Denicoff K, Nolen W, Rochussen J, Leverich

G, Post R. Stanley Foundation Bipolar Network, USA. Incidence of co-occurrence of hypomania and

depressive symptoms in the Stanley Foundation Bipolar Network. Second European Stanley Foundation

Conference on Bipolar Disorder: Amsterdam, Holland; Acta Neuropsychiatrica September, 2000;

12:170.

Suppes T, Bowden C, Calabrese J, Greene P, McElroy S, Sachs G, Swann A. Mood stabilization with

lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study. Second



Page 51 of 68

04.17.19

Rush JA, Shon SP, Crismon LM, Toprac MG, Miller AL, Trivedi MH, Suppes T, Kashner M, Carmody TJ.

The Texas Medication Algorithm Project (TMAP): Results of a 3-year study. 39th ACNP: Puerto Rico;

December 10-14, 2000.

Crismon LM, Rush JA, Toprac MG, Shon SP, Miller AL, Suppes T, Kashner M, Carmody TJ, Biggs MM,

Shores-Wilson K, Altshuler KZ. Texas Medication Algorithm Project: Study Methodology. 39th ACNP:

Puerto Rico; December 10-15, 2000.

Suppes T, Dennehy EB, Rush AJ, Crismon ML, Toprac MG, Kashner TM, Carmody TJ, Brown ES, Shores-

Wilson K, Biggs MM, Witte B, Shon SP. The Texas Medication Algorithm Project (TMAP): Outcomes

for persons with bipolar disorder. 39th ACNP: Puerto Rico: December 10-15, 2000.

Suppes T, Altshuler L, Apter J, Bowden C, Calabrese J, Ginsberg L, Goldberg J, Gyulai L, Khan A, McElroy

S, Rapport M, Risch S, Sachs G, Swann A, West S, Zajecka J, Ascher J, Barrows C, Earl N, Greene P.

Mood stabilization with lamotrigine in rapid cycling bipolar disorder: A double–blind placebo-

controlled study. American College of Neuropsychopharmacology (ACNP): San Juan, Puerto Rico;

December 10-15, 2000.

Kusumakar V, Greene P, Ascher J, Monaghan E, Smoot T, Fouche N, Bowden C, Calabrese J, Post R, Sachs G,

Suppes P, Gyulai L, Young T, Rapaport M. Mood stabilization with lamotrigine in rapid cycling bipolar

disorder: A double blind placebo-controlled study. European College of Neuropsychopharmacology

(ECNP), 2000.

Gyulai L, Suppes T, Apter J, Zajecka J, Ascher J, Greene P. Lamotrigine in rapid cycling bipolar disorder:

Predictors of response. New Clinical Drug Evaluation Unit Program (NCDEU) sponsored by

GlaxoSmithKline: Phoenix, AZ; May 29-31, 2001, Abstract.

Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE, McElroy SL, Denicoff KD, Leverich GS,

Kupka RW, Nolen WA, Grunze H, Walden J. An Update on the Stanley Foundation Bipolar Disorder

Network (SFBN). Fourth International Conference on Bipolar Disorders: Pittsburgh, PA; June 14-16

2001, Abstract.

Greene P, Suppes T, Bowden CL, Calabrese JR, Gyulai L, Sachs G, Ascher J, Smoot T, Earl N. Lamotrigine in

Rapid Cycling Bipolar Disorder: Predictors of Response. Fourth International Conference on Bipolar

Disorders; Pittsburgh, PA; June 14-16 2001, Abstract.

Chisholm K, Dennehy E, Suppes T. Clinical Response to Quetiapine Add-on for Treatment Refractory Bipolar

Disorder. Fourth International Conference on Bipolar Disorders: Pittsburgh, PA; June 14-16 2001,

Abstract.

Kupka RW, Nolen WA, Drexhage HA, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE, Leverich

GS, Rush AJ, Suppes T, Pollio C, Post RM. High Rate of Autoimmune Thyroiditis in Bipolar Disorder

is Not Associated with Lithium. Fourth International Conference on Bipolar Disorders: Pittsburgh, PA;

June 14-16 2002, Society of Biological Psychiatry 2002; 51: 305-311

Suppes T, Ascher J, Bowden C, Calabrese J, Earl N, Greene P. Lamotrigine in Rapid-Cycling Bipolar

Disorders: Predictors of Response. American Psychiatric Association 154th Annual Meeting: New

Orleans, LA; 2001, Poster Presentation.

Suppes T. Lamotrigine in Rapid-Cycling Bipolar Disorder: Predictors of Response. American Psychiatric

Association 2001 Annual Meeting: New Orleans, LA; May 9, 2001, Abstract.

Calabrese JR, Suppes T, Swann A, Ketter T, Bowden CL, DeVeaugh-Geiss J, Evoniuk G. Lamotrigine and

Rash: A Review of Evidence from Double-Blind, Placebo-Controlled Trials in Bipolar Disorder

Patients. 40th ACNP, December 9-13, 2001.

Suppes T, Kupka R, McElroy SL, Altshuler LL, Frye MA, Keck PE, Denicoff KD, Nolen WA, Rochussen J,

Leverich GS, Post RM. Incidence of Co-Occurrence of Hypomania and Depressive Symptoms in the

Stanley Foundation Bipolar Network Patients. 40th ACNP, December 9-13, 2001.

Dennehy EB, Suppes T, Crismon LM, Rush JA. The Measurement of Adherence to a Treatment Guideline for

Bipolar Disorder. 40th ACNP, December 9-13, 2001.


Page 52 of 68

04.17.19

Tohen M, Chengappa R, Suppes T, Baker RW, Risser RC, Evans AR, Calabrese JR. Olanzapine Combined

with Mood Stabilizers in Prevention of Recurrence in Bipolar Disorder: An 18-month Study. 40th

ACNP, December 9-13, 2001.

Baker RW, Tohen M, Altshuler L, Zarate CA, Suppes T, Ketter TA, Risser RC, Schuh L. Olanzapine versus

Divalproex Sodium for Treatment of Acute Mania and Maintenance of Remission: A 47-week study.

40th ACNP, December 9-13, 2001.

Sachs G, Altshuler L, Ketter T, Suppes T, Rasgon N, Frey M, Collins M. Divalproex versus Placebo for the

Treatment of Bipolar Depression. 40th American College of Neuropsychopharmacology (ACNP):

Waikoloa, Hawaii; December 9-13, 2001.

Bowden C, Suppes T, McElroy S, Goldberg J, Yatham L, Goodwin F, Calabrese J, Leadbetter R, Metz A.

Lamotrigine Control Bipolar Depression Without Destabilizing Mood. American College of

Neuropsychopharmacology (ACNP): San Juan, Puerto Rico; December 8-12, 2002.

Suppes T. Treatment Approaches for Managing Anxiety Disorder in the Bipolar Patient. American Psychiatric

Association: San Francisco, California; May 18-23, 2003.

Suppes T. An Open Add-on Study of Oxcarbazepine Versus Divalproex to Treat Hypomanic Symptoms in

Patients with Bipolar Disorder, NCDEU, Boca Raton, Florida, May 28, 2003.

Mullen JA, Suppes T, Chengappa KNR, Sachs GS. Quetiapine Adjunctive Therapy for Mania Associated with

Bipolar Disorder. Biological Psychiatry, 2004; 55:180S.

Goldberg JF, Malhotra AK, Calabrese JR, Bowden CL, Suppes T, Frye MA, Ketter TA. Weekly Mood

Stability over 6 Months with Lamotrigine or Placebo in Bipolar Rapid Cycling. Biological Psychiatry,

2004; 55:141S-142S.

Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Molay FJ, Hwang CH, Sachs GS, Hall

JE. Valproate Induces Oligomenorrhea with Hyperandrogenism in Women with Bipolar Disorder.

Endocrine Society. New Clinical Drug Evaluation Unit (NCDEU), 44th Annual Meeting, Phoenix, AZ,

June 1-4, 2004. Poster Presentation.

Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Molay FJ, Hwang CH, Sachs GS, Hall

JE. Valproate Induces Oligomenorrhea with Hyperandrogenism in Women with Bipolar Disorder.

Endocrine Society. American Psychiatric Association, 157th American Psychiatric Association Annual

Meeting, New York, NY, May 2-5, 2004. Poster Presentation.

Joffe H, Cohen LS, McLaughlin WL, Adams JM, Molay FJ, Hwang CH, Hall JE, Sachs GS, Suppes T, Lavori

P. Treatment of Mood Disorders Associated with the Reproductive Cycle: Benefits and Risks. New

Clinical Drug Evaluation Unit (NCDEU), 44th Annual Meeting, Phoenix, AZ, June 1-4, 2004.

Goldberg J, Ketter T, Calabrese J, Suppes T, Frye M, White R. Effects of Mood Stabilizer Treatment on Mood

Episode Relapse and Recurrence in Bipolar Disorder. XXIVth CINP Congress, Paris, June 20-24, 2004.

Suppes T, Young A, Bowden C, Paska W, Wilson B, Stewart R. Concomitant use of Lamotrigine and Lithium

as Maintenance Therapy in Patients with Bipolar I Disorder. XXIVth CINP Congress, Paris, June 20-24,

2004.

Ketter T, Suppes T, Goldberg J, Calabrese J, Frye M, White R. Effects of Mood Stabilizer Treatment on Mood

Episode Relapse and Recurrence in Bipolar Disorder. XXIVth CINP Congress, Paris, June 20-24, 2004.

Altshuler LA, Rasgon NL, Elman S, Bitran J, Labarca R, Saad M, Kupka R, Nolen W, Frye MA, Suppes T,

McElroy SL, Keck PE, Leverich GS, Grunze H, Walden J, Post RM, Mintz J. Reproductive endocrine

function in women treated for Bipolar Disorder: reproductive hormone levels. Acta Psychiatrica

Scandinavica 2004; Supplementum 110 (423), 3 Abstract.

Frye MA, Levander E, McElroy S, Suppes T, Keck P, Nolan W, Leverich GS, Grunze H, Walden J, Kupka R,

Altshuler L, Mintz J, Post RM. Additional axis I comorbidity in patients with bipolar disorder and

alcoholism. Acta Psychiatrica Scandinavica 2004; Supplementum 110 (423), 19. Abstract.


Page 53 of 68

04.17.19

Kupka R, Luckenbaugh D, Post RM, Altshuler L, Denicoff K, Frye M, Grunze H, Keck P, Leverich GS,

McElroy S, Suppes T, Walden J, Nolen, W. Rapid Cycling Bipolar Disorder: a Five-Year Prospective

Follow-Up. Acta Psychiatrica Scandinavica 2004; Supplementum 110 (423), 37 Abstract.

Suppes T, Kupka R, McElroy S, Altshuler L, Mintz J, Frye M, Keck P, Leverich GS, Grunze H, Nolen W, Post

RM. Increased incidence of mixed symptoms in hypomania in females. Acta Psychiatrica Scandinavica

2004; Supplementum 110 (423), 36. Abstract.

Grunze H, Dittmann S, Nolen W, Kupka R, Schaerer LO, Bauer M, Frye M, Altshuler LL, Keck PE, Leverich

GS, McElroy SL, Suppes T, Post RM. Acamprosate as adjunctive treatment in rapid cycling bipolar

disorder: an open pilot study. Acta Psychiatrica Scandinavica 2004; Supplementum 110 (423), 25.

Abstract.

Keck P, Hibbeln J, McElroy SL, Freeman M, Suppes T, Nolen W , Kupka R, Grunze H, Mintz J, Frye MA,

Altshuler L, Denicoff K, Walden J, Dittmann S, Leverich GS, Post RM. Omega-3 fatty acid blood

concentrations and response in bipolar depressiont and rapid cycling bipolar disorder. Acta Psychiatrica

Scandinavica 2004; Supplementum 110 (423), 31. Abstract.

Post RM, Altshuler LL, Leverich GS, Frye MS, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck P, Jr,

Denicoff KD, Grunze H, Walden J, Kitchen C. Switch Rate on Venlafaxine Compared with Bupropion

and Sertraline. Acta Psychiatrica Scandinavica 2004; Supplementum 110 (423), 61. Abstract.

Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, Jr, Kupka R, Nolen WA, Grunze H,

Martinez M, Post RM. The Range of Hypo/Manic Severities on Antidepressants; A randomized, double

blind comparison of Bupropion, Sertraline, and Venlafaxine using daily NIMH-LCM ratings. Acta

Psychiatrica Scandinavica 2004; Supplementum 110 (423), 39. Abstract.

Kupka R, Suppes T, McElroy S, Altshuler L, Mintz J, Post R. The Incidence of Mixed Symptoms of during

Hypomania may be Gender Specific. Fourth European Stanley Conference on Bipolar Disorder,

Scandinavian Congress Center, Aarhus, Denmark, September 23-25, 2004.

Suppes T, Kupka R, McElroy S, Altshuler L, Mintz J, Frye M, Keck PE, Leverich G, Grunze H, Nolen W, Post

R. Increased Incidence of Mixed Symptoms in Hypomania in Females, Fourth European Stanley

Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus, Denmark, September 23-25,

2004.

Kupka R, Luckenbaugh D, Post R, Altshuler L, Denicoff K, Frye M, Grunze H, Keck PE, Leverich G, McElroy

S, Suppes T, Walden J, Nolen W. Rapid-Cycling Bipolar Disorder: A Five-Year Prospective Follow-up.

Fourth European Stanley Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus,

Denmark, September 23-25, 2004.

Grunze H, Dittmann S, Nolen W, Kupka R, Schaerer L, Bauer M, Frye M, Altshuler L, Keck PE, Leverich G,

McElroy SL, Suppes T, Post R. Acamprosate as Adjunctive Treatment in Rapid-cycling Bipolar

Disorder: An Open Pilot Study. Fourth European Stanley Conference on Bipolar Disorder, Scandinavian

Congress Center, Aarhus, Denmark, September 23-25, 2004.

Post R, Altshuler L, Leverich G, Frye M, Nolen W, Kupka R, Suppes T, McElroy S, Keck PE, Denicoff K,

Grunze H, Walden J, Kitchen C. Switch Rate on Venlafaxine Compared with Bupropion and Sertraline.

Fourth European Stanley Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus,

Denmark, September 23-25, 2004.

Leverich G, Altshuler L, Suppes T, McElroy S, Keck PE, Kupka R, Nolen W, Grunze H, Martinez M, Post R.

The Range of Hypo/Manic Severities on Antidepressants by the Daily LCM. Fourth European Stanley

Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus, Denmark, September 23-25,

2004.

Mitchell P, McElroy S, Cookson J, Suppes T, Huffman RF, Paska W, Ascher J. Open-label Use of Lamotrigine

Maintenance Treatment in Bipolar Depression: Combination Therapy Experience. 17th European

College of Neuropsychopharmacology, Stockholm, Sweden, October 9-13, 2004, Abstract.


Page 54 of 68

04.17.19

Grunze H, Calabrese J, Ketter T, Suppes T, Frye M, White R. Effects of Mood Stabilizer Treatment on Mood

Episode Relapse and Recurrence in Bipolar Disorder. 43rd Annual Meeting of the American College of

Neuropsychopharmacology, Nashville, TN, December 12-16, 2004, Abstract.

Yatham L, Bowden C, Calabrese J, Suppes T, Ketter T, Frye M, Thompson T, Adams B, DeVeaugh-Geiss A.

The Impact of Lamotrigine Treatment on Depression in Bipolar I Disorder (5). 43rd Annual Meeting of

the American College of Neuropsychopharmacology, Nashville, TN, December 12-16, 2004.

Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter T,

Sachs G, Swann AC. The Texas Implementation of Medication Algorithms: Update to the Algorithms

for Treatment of Bipolar 1 Disorder. 45th Annual New Clinical Drug Evaluation Unit (NCDEU), Boca

Raton, FL, June 6-9, 2005, Poster Presentation.

Suppes T, Dennehy EB, Fischer EG, Schnyer RN, Allen JJ, Kelly DI. Acupuncture to Treatment Depression in

Bipolar Disorder. 45th Annual New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, June 6-9,

2005, Poster Presentation.

Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter T,

Sachs G, Swann AC. The Texas Implementation of Medication Algorithms: Update to the Algorithms

for Treatment of Bipolar 1 Disorder. 6th International Conference on Bipolar Disorder, Pittsburgh, PA,

June 16-18, 2005, Poster Presentation.

Fischer EG, Dennehy EB, Schnyer RN, Allen JJ, Kelly DI, Suppes T. Acupuncture to Treatment Depression in

Bipolar Disorder. 6th International Conference on Bipolar Disorder, Pittsburgh, PA, June 16-18, 2005,

Poster Presentation.

Shivakumar G, Suppes T. Bipolar Disorder Symptoms and Relationship of Menstrual Cycle. 6th International

Conference on Bipolar Disorder, Pittsburgh, PA, June 16-18, 2005, Poster Presentation.

Suppes T, Keck PE Jr, Macfadden W, Calabrese JR, McCoy R, Minkwitz M, Wilson E, Mullen J. Quetiapine

in Bipolar I Depression: Double-Blind, Placebo-Controlled Study. 8th World Congress of Biological

Psychiatry, Vienna, Austria, July 1, 2005, Poster Presentation.

Suppes T, Vieta E, Raines S, Macfadden W. Quetiapine for the Treatment of Bipolar II Depression. 8th World

Congress of Biological Psychiatry, Vienna, Austria, July 1, 2005, Poster Presentation.

Crismon ML, Kashner M, Rush AJ, Suppes T, Toprac M, Carmody TJ, Wicker A. TMAP Cost Outcomes for

Patients with Bipolar Disorder. 18th NIMH Conference on Mental Health Services Research (MHSR),

Bethesda, MD, July 18-19, 2005.

Marangell L, Suppes T, Zboyan H, Fischer EG, Martinez J, Snow D, Sureddi S. Vagus Nerve Stimulation for

the Treatment of Rapid Cycling Bipolar Disorder. 44th American College of Neuropsychopharmacology

(ACNP) Annual Meeting, Waikoloa, Hawaii, December 11-15, 2005. Poster Presentation.

Kelly DI, Marangell L, Suppes T, Zboyan H, Fischer EG, Martinez J, Snow D, Sureddi S. Vagus Nerve

Stimulation for the Treatment of Rapid Cycling Bipolar Disorder. Australasian Society for Bipolar

Disorders Conference 2006, Melbourne, Australia, February 24-25, 2006. Poster Presentation.

Suppes T, Hirschfeld RMA, Vieta E, Carlsson A, Stening G, Macfadden W. Quetiapine Monotherapy for

Bipolar II Depression: Pooled Results from Two Placebo-controlled Studies. 46th Annual Meeting New

Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006. Abstract.

Shivakumar GN, Bernstein IH, Suppes T. Bipolar Disorder and Menstrual Cycle Mood Changes: Are They

Related? 46th annual Meeting New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida,

June 12-15, 2006. Abstract.

Suppes T, Kupfer D, McElroy S, Hirschfeld RMA. Metabolic Syndrome Awareness Among Psychiatrists

Treating Bipolar Disorder: Results of a National Harris Interactive Survey. 46th Annual Meeting New

Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006. Abstract.

Suppes T, Kupfer D, McElroy SL, Hirschfeld R. Metabolic syndrome awareness among psychiatrists treating

bipolar disorder: Results of a national Harris Interactive survey. Second Biennial Conference of the

International Society for Bipolar Disorders, Edinburgh, Scotland, August 2-4, 2006. Abstract.


Page 55 of 68

04.17.19

Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA,

Sachs G, Swann AC. The Texas Implementation of Medication Algorithms: Update to the algorithms for

treatment of bipolar I disorder. Fifth European Stanley Conference on Bipolar Disorder, Barcelona,

Spain, October 5-7, 2006. Abstract.

Perla J, Marangell L, Suppes T, Zboyan H, Fischer EG, Martinez J, Snow D, Sureddi S. Vagus Nerve

Stimulation for the Treatment of Rapid Cycling Bipolar Disorder. Fifth European Stanley Conference on

Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.

Suppes T, Mintz J, McElroy SL, Altshuler LL, Kupka RW, Frye MA, Keck PE Jr, Nolen WA, Leverich GS,

Grunze H, Rush AJ, Post RM. Sex Differences in Mixed Hypomania: Results from 908 Patients

Evaluated Prospectively in the Stanley Foundation Bipolar Treatment Network. Fifth European Stanley

Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.

Suppes T, Altshuler LL, Frye MA, Grunze H, Keck PE Jr, Kupka RW, Leverich GS, McElroy SL, Mintz J,

Nolen WA, Luckenbaugh D, Kelly DI, Post RM. Add-on quetiapine for the treatment of bipolar

disorder: Results from the Stanley Foundation Bipolar Network. Fifth European Stanley Conference on

Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.

Grunze H, Frye M, Suppes T, McElroy SL, Altshuler L, Leverich G, Keck PE. Modafinil in the Treatment of

Bipolar Depression. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October

5-7, 2006. Abstract.

Frye M, McElroy S, Hellemann G, Suppes T. Mixed Depression and Antidepressant-related Mania. Fifth

European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.

Kupka R, Altshuler L, Nolen W, Suppes T, Luckenbaugh D, Leverich G, Frye M, Keck P Jr, McElroy S,

Grunze H, Post R. Three Times More Days Depressed Than Manic in Both Bipolar I and Bipolar II

Disorder. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006.

Abstract.

Schaerer L, Grunze H, Suppes T, McElroy SL, Altshuler L, Leverich G. Treatment Dependent Interepisode

Residual Symptoms. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October

5-7, 2006. Abstract.

Schaerer L, Langosh, Altshuler LL, Frye M, Grunze H, Keck PE Jr, Kupka R, Leverich GS, Nolen W, McElroy

S, Suppes T, Post RM. Detection of significant differences in interepisode residual symptoms between

olanzapine and lamotrigine. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain,

October 5-7 2006. Abstract.

Suppes T, Kupfer D, McElroy SL, Hirschfeld R. Metabolic syndrome awareness among psychiatrists treating

bipolar disorder: Results of a national Harris Interactive survey. Poster Fifth European Stanley

Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.

Kupka R, Altshuler LL, Nolen W, Suppes T, Luckenbaugh D, Leverich GS, Frye M, Keck PE Jr, McElroy S,

Grunze H, Post RM. Three times more days depressed than manic in both bipolar I and bipolar II

disorder. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-7 2006.

Abstract.

Grunze H, Frye M, Suppes T, McElroy S, Altshuler LL, Leverich GS, Post RM. Modafanil in the treatment of

bipolar depression. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-

7 2006. Abstract.

Frye M, McElroy S, Hellman, Nolen W, Suppes T, Grunze H, Altshuler LL, Leverich GS, Keck PE Jr, Kupka

R, Mintz J, Post RM. Clinical correlates associated with treatment emergent mania. Fifth European

Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-7 2006. Abstract.

Post RM, Leverich GS, Luckenbaugh D, Altshuler LL, Frye M, Nolen W, Kupka R, Suppes T, Keck PE Jr,

Grunze H, Walden. An excess of childhood-onset bipolar illness in the United States compared with

Europe. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-7 2006.

Abstract.


Page 56 of 68

04.17.19

Bauer M, Lecrubier Y, Suppes T, Courat J-M. Assessing European Practicing Psychiatrists’ Awareness of

Metabolic Syndrome Among Patients with Bipolar Disorder. Sixth International Forum on Mood and

Anxiety Disorders, Vienna, Austria, November 29-December 1, 2006. Abstract.

Bauer M, Lecrubier Y, Suppes T. Metabolic Syndrome Among Patients with Bipolar Disorder: Current

Perspectives of European Psychiatrists. 15th European Congress of Psychiatry, Madrid, Spain, March

17-21, 2007. Abstract.

Suppes T, Bauer M, Hirschfeld R, Lecrubier Y, McElroy S. Awareness of metabolic syndrome in patients with

bipolar disorder: A comparison of US and European psychiatrists. Annual Meeting of the American

Psychiatric Association, San Diego, CA, May 19-24, 2007. Abstract.

Sheehan DV, McElroy SL, Suppes T, Keck PE, Sheehan KH, Janavs J, Raj BA. The efficacy of risperidone in

bipolar anxiety. Annual Meeting of the American Psychiatric Association, San Diego, CA, May 19-24,

2007. Abstract.

Bauer M, Suppes T, Hirschfeld R, Lecrubier Y, McElroy S. Awareness of metabolic syndrome in patients with

bipolar disorder: Comparison of US and European Psychiatrists. Bipolar Disorders 2007; 9(Suppl.

1):18. Abstract.

Kelly DI, Suppes T, Keck PE Jr, McElroy SL, Altshuler LL, Frye MA, Nolen WA, Kupka RW, Grunze H,

Leverich GS; Mintz J, Luckenbaugh DA, Fischer EG, Post RM. Quetiapine for the continuation

treatment of bipolar depression: Naturalistic prospective case series from the Stanley Bipolar Treatment

Network. Bipolar Disorders 2007; 9(Suppl. 1):57. Abstract.

Abulseoud OA, Hellemann G, Frye MA, Altshuler LL, Keck PE Jr, McElroy SL, Suppes T, Nolen WA, Kupka

RW, Grunze H, Leverich GS, Post RM. Mood stabilizer and subsequent need for adjunctive

antidepressant: naturalistic follow up of the SFBN. Bipolar Disorders 2007; 9(Suppl. 1):13. Abstract.

Gonzalez R, Tamminga C, Ivleva E, Ghose S, Suppes T. A pilot study examining the association between clock

genes and course of illness in bipolar I disorder. Bipolar Disorders 2007; 9(Suppl. 1):48. Abstract.

Suppes T, Marangell LB, Fischer EG, Zboyan H, Peck RM, Snow DE, Martinez M, Sureddi S. Acute treatment

of bipolar II depression with monotherapy lithium versus lamotrigine: an open randomized trial of 102

patients. Bipolar Disorders 2007; 9(Suppl. 1):101. Abstract.

Suppes T, Marangell LB, Fischer EG, Zboyan H, Peck RM, Snow DE, Martinez M, Sureddi S. Acute treatment

of bipolar II depression with monotherapy lithium versus lamotrigine: an open randomized trial of 102

patients. The 47th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL,


Gonzalez R, Tamminga C, Ivleva E, Ghose S, Suppes T. A pilot study examining the association between clock

genes and course of illness in bipolar I disorder. The 47th Annual New Clinical Drug Evaluation Unit

(NCDEU) Meeting, Boca Raton, FL, June 11-14, 2007. Abstract.

Sheehan D, McElroy S, Suppes T, Sheehan KH, Keck P, Janavs J. In Search of a Treatment for Bipolar

Anxiety. The 47th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL,


Gonzalez R, Ivleva E, Ghose S, Gonzalez S, Tamminga C, Suppes T. A Pilot Study Examining the Association

Between Clock Genes and Course of Illness in Bipolar I Disorder. The 46th Annual Meeting of the

American College of Neuropsychopharmacology, Boca Raton, FL, December 12, 2007. Abstract.

Suppes T, Liu S, Paulsson B, Brecher M. Maintenance treatment in bipolar I disorder with quetiapine

concomitant with lithium or divalproex: A North American placebo-controlled, randomized multicenter

trial (Trial 127). The 46th Annual Meeting of the American College of Neuropsychopharmacology,

Boca Raton, FL, December 9-13, 2007. Abstract.


concomitant with lithium or divalproex: A placebo-controlled, randomized multicenter trial. The

International Society for Bipolar Disorders, Delhi and Agra, India, January 27-30, 2008. Abstract.


Page 57 of 68

04.17.19



European Congress of Psychiatry, Nice, France, April 5-9, 2008. Abstract.

Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment in bipolar I disorder with quetiapine


International Review of Bipolar Disorders, Copenhagen, Denmark, April 14-16, 2008. Abstract.

Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in

combination with lithium or divalproex as maintenance treatment for bipolar I disorder. The


Brecher M, Suppes T, Vieta E, Liu S, Paulsson B. Quetiapine in the maintenance treatment of bipolar I

disorder: Combined data from two long-term, phase III studies. The International Review of Bipolar

Disorders, Copenhagen, Denmark, April 14-16, 2008. Abstract.

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release

formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. The



disorder: Combined data from two long-term phase III studies. The Society of Biological Psychiatry,

Washington, DC, May 1-3, 2008. Abstract.

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the new extended release


D144CC00002). The American Psychiatric Association, Washington, DC, May 3-8, 2008. Abstract.


disorder: Combined data from two long-term phase III studies. The American Psychiatric Association,

Washington, DC, May 3-8, 2008. Abstract.

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the new extended release


D144CC00002). The New Clinical Drug Evaluation Unit, Phoenix, AZ, May 27-30, 2008. Abstract.


disorder: combined data from two long-term phase III studies. The New Clinical Drug Evaluation Unit,

Phoenix, AZ, May 27-30, 2008. Abstract.

Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment in bipolar I disorder with quetiapine

concomitant with lithium or divalproex: A North American placebo-controlled, randomized multicenter

trial (Trial 127). The Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany, July

13-17, 2008. Abstract.

Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in

combination with lithium/divalproex as maintenance treatment for bipolar I disorder. The Collegium

Internationale Neuro-Psychopharmacologicum, Munich, Germany, July 13-17, 2008. Abstract.


disorder: combined data from two long-term, phase III studies. The Collegium Internationale Neuro-

Psychopharmacologicum, Munich, Germany, July 13-17, 2008. Abstract.

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the new extended-release


D144CC00002). The Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany,

July 13-17, 2008. Abstract.

Swann A, Suppes T, Eudicone J, Tran Q, Pikalov A, and Carlson B. Factor analysis of bipolar mania:

Retrospectively-assessed structure of mixed mania from randomized clinical trial subjects. Bipolar

Disorders 2009; 11(Suppl. 1):84. Abstract.

Suppes T , Hellemann G, Frye M, McElroy S, Nolen W, Kupka R, Leverich G, Grunze H, Altshuler L, Keck P,


Page 58 of 68

04.17.19

and Post R. Mixed Depression in Bipolar Disorder: Prevalence rate and clinical correlates during

naturalistic follow up. Bipolar Disorders 2009; 11(Suppl. 1):83. Abstract.

Altshuler LL, Kupka RW, Hellemann G, Frye MA, Grunze H, Keck Jr PE, Leverich GS, McElroy SL, Nolen

WA, Sugar CA, Zermeno M, Post RM, Suppes T. Gender and depressive symptoms in 711 patients

with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network.

Bipolar Disorders 2009; 11(Suppl. 1):15. Abstract.

Biernacka J, Veldic M, McElroy SL, Crow S, Sharp A, Benitez J, Rummans T, Krahn L, Mrazek D, Post RM,

Altshuler LL, Suppes T, Frye MA. The genomics of treatment emergent mania: The Mayo Clinic

Individualized Medicine Biobank for Bipolar Disorder. Bipolar Disorders 2009; 11(Suppl. 1):20.

Abstract.

Frye M, Hellemann G, Suppes T, McElroy S, Grunze H, Altshuler L, Keck P, Kupka R, Nolen W, Leverich G,

Post R. Prevalence rate of mixed depression and its impact on remission: a controlled evaluation.

Bipolar Disorders 2009; 11(Suppl. 1):40. Abstract.

Kupka RW, Post RM, Altshuler LL, Frye MA, Grunze H, Keck Jr PE, Leverich GS, McElroy SL, Suppes T,

Nolen WA. Borderline personality features in rapid cycling bipolar disorder in relationship to episode

frequency. Bipolar Disorders 2009; 11(Suppl. 1):55. Abstract.

Post RM, Leverich GS, Kupka R, Keck Jr P, McElroy S, Altshuler L, Frye M, Luckenbaugh DA, Rowe M,

Grunze H, Suppes T, Nolen WA. Delay to first treatment is inversely related to age of onset of bipolar

disorder and an independent contributor to a poor outcome in adulthood. Bipolar Disorders 2009;

11(Suppl. 1):70. Abstract.

Vieta E, Suppes T, Gustafsson U, Paulsson B. Maintenance treatment with quetiapine added to either lithium or

divalproex in bipolar I disorder. European College of Neuropsychopharmacology Annual Meeting 2009,

Istanbul, Turkey, September 12-16. Poster.

Suppes T. Update from the Mood Disorders Workgroup, Bipolar Disorder Subcommittee. Bipolar Disorders

2010; 12(Suppl. 1): 51. Abstract.

Vieta E, Suppes T, Gustafsson U, Paulsson B. Long-term efficacy of quetiapine in combination with lithium or

divalproex on mixed symptoms in bipolar I disorder. Bipolar Disorders 2010; 12(Suppl. 1): 56. Abstract.

Tohen M, Frank E, Bowden CL, Colom F, Ghaemi NS, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta

E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KNR, Grunze H, Mitchell PB, Kanba

S, Berk M. The International Society for Bipolar Disorders (ISBD) Task Force on the Nomenclature of

Course and Outcome in Bipolar Disorders. Bipolar Disorders 2010; 12(Suppl. 1): 53. Abstract.

Suppes T, Vieta E, Gustafsson U, Paulsson B. Maintenance treatment with quetiapine added to either lithium or

divalproex in bipolar I disorder. Bipolar Disorders 2010; 12(Suppl. 1): 52. Abstract.

Suppes T, Hellemann G, Frye MA, McElroy S, Nolen W, Kupka R, Leverich G, Grunze H. Mixed depression

in bipolar disorder: prevalence rate and clinical correlates during naturalistic follow up. Bipolar

Disorders 2010; 12(Suppl. 1): 52. Abstract.

Frye MA, Suppes T, Swann A. The International Society for Bipolar Disorders (ISBD) work group on mixed

states and treatment response. Bipolar Disorders 2010; 12(Suppl. 1): 21. Abstract.

Post RM, Nolen WA, Kupka RW, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, Grunze H, Rowe

M, Leverich GS. Increased risk factors and poor long-term outcome in the U.S. compared to Holland

and Germany. Bipolar Disorders 2010; 12(Suppl. 1): 62. Abstract.

Suppes T. Update from the mood disorders workgroup, Bipolar Disorder Subcommittee. American Psychiatric

Association Annual Meeting 2010, New Orleans, LA, May 25, 2010. Symposium.

Suppes T. An update from the DSM-5 workgroup on mood disorders – a focus on bipolar symptoms.

American Psychiatric Association Annual Meeting 2010, New Orleans, LA, May 25, 2010. Symposium.

Suppes T, Ketter T. A Double-Blind, Placebo-Controlled Trial of Quetiapine for the Treatment of Mixed

Hypomania in Bipolar II Patients. New Research Approaches for Mental Health Interventions (NCDEU)

Scientific Meeting, Boca Raton, FL, June 14-17, 2010. Poster.


Page 59 of 68

04.17.19

Suppes T, Ketter T. A Double-Blind, Placebo-Controlled Trial of Quetiapine for the Treatment of Mixed

Hypomania in Bipolar II Patients. American College of Neuropsychopharmacology (ACNP) Annual

Meeting, Miami Beach, FL, December 5-9, 2010. Poster.

Cosgrove, VE, Suppes, TS, & Chang, KD. Life Stress and Bipolar Disorders across the Life Span. Society of

Biological Psychiatry (SOBP), San Francisco, C.A, May 12-14, 2011. Panel.

Suppes T. The debate on duration criteria of hypomanic episodes: agreements, disagreements, and proposed

solutions in DSM-5. International Conference on Bipolar Disorder (ICBD), Pittsburgh, PA, June 9-11,

2011. Symposium.

Suppes T. Debates in bipolar disorder: Are atypical antipsychotics overused in bipolar disorder. International

Conference on Bipolar Disorder (ICBD), Pittsburgh, PA, June 9-11, 2011. Concurrent Session.

Seo JS, Jamieson K, Cosgrove V, Gwizdowski IS, Yang H, Sheehan DV, McElroy SL, Suppes T.

Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring

bipolar disorder and anxiety disorder. World Psychiatric Association Thematic Conference, Istanbul,

Turkey, June 9-12, 2011. Poster.

Raudabaugh BJ, Hernandez JM, Seo JS, Jamieson K, Cosgrove V, Gwizdowski IS, Yang H, Sheehan DV,

McElroy SL, Suppes T. Clinical predictors of response versus non-response to risperidone: CGI-21

scores after one week of treatment in a bipolar disorder population with co-occurring panic disorder or

generalized anxiety disorder. 5th Biennial Conference of the International Society for Bipolar Disorders

(ISBD), Istanbul, Turkey, March 14-17, 2012. Poster.

Feldman NS, Gwizdowski IS, Fischer EG, Yang H, Suppes T. Co-occurrence of serious or undiagnosed

medical conditions with bipolar disorder preventing clinical trial randomization: A case series. 165th

Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 5-9, 2012. Poster.

Suppes T, Cosgrove V. Update from the Mood Disorders Workgroup for DSM-5: Boundaries of bipolar and

schizophrenia disorders. 165th Annual Meeting of the American Psychiatric Association (APA),

Philadelphia, PA, May 5-9, 2012. Symposium.

Suppes T. Update from the Mood Disorders Workgroup for DSM-5: Bipolar Disorder. 165th Annual Meeting of

the American Psychiatric Association (APA), Philadelphia, PA, May 5-9, 2012. Symposium.

Suppes T, Cucchiaro J, Pikalov A, Werner P, Targum S, Loebel A. Major depressive disorder with mixed

features: interim baseline characteristics of subjects enrolled in a 6 week, double-blind, placebo-

controlled trial of lurasidone. 51st Annual Meeting of the American College of

Neuropsychopharmacology (ACNP), Hollywood, FL, December 3, 2012. Poster.

Suppes T, McElroy SL, Sheehan DV, Hidalgo RB, Cosgrove VE, Gwizdowski IS, Feldman NS. A randomized,

double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-

occurring lifetime panic or generalized anxiety disorder. 166th Annual Meeting of the American

Psychiatric Association, San Francisco, CA, May 18-88, 2013. Poster.

Cosgrove VE, Lauder S, Berk L, Gwizdowski IS, Fischer EG, Castle D, Gliddon E, Dodd S, Feldman N, Berk

M, Suppes T. MoodSwings 2.0 online intervention for bipolar disorder: www.moodswings.net.au. 166th

Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 18-88, 2013. Poster.

Suppes T, Frank E, DePaulo JR, Davis L, Fawcett J. DSM-5 Bipolar Disorders: Update on Revised Criteria and

the Clinical Implications. Suppes T. Bipolar and related disorders: Changes to criteria A and issues of

duration. 166th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 18-

88, 2013. Symposium.

Swann A, Suppes T. Mixed Features in Bipolar Disorder: What is an Episode and How are Episodes and

Illness-course Characteristics Related? Suppes T. How can Mixed Features be Diagnosed and

Quantified, and what do they tell us about Episodes of Bipolar Disorder? 10th International Conference

on Bipolar Disorders, A Meeting of the International Society for Bipolar Disorders, Miami Beach, FL,

June 13-16, 2013. Brainstorming Session.


Page 60 of 68

04.17.19

Suppes T (Chair). Beyond Traditional Approaches: Alternative Mechanisms to Approach Biological

Treatments in Mood Disorder. 10th International Conference on Bipolar Disorders, A Meeting of the

International Society for Bipolar Disorders, Miami Beach, FL, June 13-16, 2013. Symposium.

Cosgrove V, Fischer E, Lauder S, Gwizdowski I, Feldman N, Berk M, Gliddon E, Suppes T. An Online

Intervention for Bipolar Disorder MoodSwings 2.0: www.moodswings.net.au. 10th International

Conference on Bipolar Disorders, A Meeting of the International Society for Bipolar Disorders, Miami

Beach, FL, June 13-16, 2013. Poster.

Suppes T, McElroy S, Cosgrove V, Gwizdowski I, Feldman N. A Randomized, Double-Blind, Placebo-

Controlled Study of Ziprasidone in Bipolar Disorder with Co-Occurring Lifetime Panic or Generalized

Anxiety Disorder. 10th International Conference on Bipolar Disorders, A Meeting of the International

Society for Bipolar Disorders, Miami Beach, FL, June 13-16, 2013. Poster.

Suppes T, Gustafsson U. Maintenance Treatment with Quetiapine when Combined with either Lithium or

Divalproex in Bipolar I Disorder: Analysis of 2 Large Randomized, Placebo-controlled Trials. 10th

International Conference on Bipolar Disorders, A Meeting of the International Society for Bipolar

Disorders, Miami Beach, FL, June 13-16, 2013. Poster.

Suppes T. Presentation and Prevalence of PTSD in a Population with Bipolar Disorder. 2013 APA Annual

Meeting, San Francisco, CA, May 18, 2013. Poster.

Suppes T A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder with

Co-Occurring Panic or Generalized Anxiety Disorder. APA Annual Meeting, San Francisco, CA,

May 18, 2013. Poster.

Suppes T Major Depressive Disorder with Mixed Features: Interim Baseline Characteristics of Subjects in a

Double-Blind, Placebo-Controlled Trial of Lurasidone. APA Annual Meeting, San Francisco, CA,

May 18, 2013. Poster.

Suppes T Maintenance Treatment with Quetiapine when Combined with either Lithium or Divalproex in

Bipolar I Disorder: Analysis of 2 Large Randomized, Placebo-controlled Trials. APA Annual

Meeting, San Francisco, CA, May 18, 2013. Poster.

Suppes T DSM-5: Update to Bipolar Disorders. Columbia, symposium, August 23-24, 2013.

Suppes T Mixed States?.Columbia symposium, August 23-24, 2013

Suppes T Evidence-based Treatment of Bipolar Disorder, April 2014 Australia

Suppes T DSM-5 Criteria for bipolar disorder with mixed features. Are anxiety, irritability and agitation

gateway symptoms for patients suffering from mania with depressive symptoms? WCP Madrid 2014

Suppes T Towards diagnosis of depressive symptoms during manic episodes: the DSM-5 mixed specifier

ECNP Berlin 2014

Fischer EG, Cosgrove V, Suppes T, Lange N, Gwizdowski I, Hambro B, Ostacher M. Efficacy and tolerability

of divalproex sodium plus adjunctive quetiapine, lithium, or placebo for hypomanic or manic episodes

in outpatients with bipolar I disorder. ISBD Annual Meeting, Mexico City, March 6-9, 2018. Poster.

Earley W, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese J, Yatham LN. A Pooled

Post Hoc Analysis Evaluating the Safety of Cariprazine in Bipolar Depression. ISBD Annual Meeting,

Sydney, March 19-23, 2019. Abstract.

Selected CDs and Videos

Suppes T. CD-ROM Educational Program: Zyprexa in Bipolar Mania. Dallas, Texas: Eli Lilly and Company;

January 11, 2000.

Suppes T, Dennehy ED. Video: Recent Studies on the Treatment of Bipolar Disorder. Dallas, Texas: Distance

Learning Center; March 28, 2000.

Rush AJ, Suppes T, Swann Alan. Audio: Biological Therapies for Bipolar & Schizoaffective Disorders. ACNP

Psychiatric Update.


Page 61 of 68

04.17.19

Bowden C, Calabrese J, Goodwin F, Keck PE, Jusumakar V, Suppes T. Long-Term Use of Mood Stabilizers in

Bipolar Disorder. Journal of Clinical Psychiatry Audiograph Series, Vol. 5, No. 6, July 2002.

Suppes T, Genecom Slide Kit: Optimizing the Treatment of Bipolar Depression, 2002, CME provided by Johns

Hopkins Medical School. Co-Chair with Dr. Terry Ketter.

Suppes T. CME, Inc. Slide Kit: Using Antipsychotics in Treating Mania: Key Factors for Successful

Outcomes, 2002, Co-Chair with Steve Strakowski.

Suppes T, Glazer W, Strakowski S. Video: New Developments in the Treatment of Bipolar Mania. Dallas,

Texas: PsychLINK, January 28, 2004.

Suppes T, Altman C. Video: Bipolar 360 Degrees Experience. Dallas, Texas: Cadient Group, March 10, 2004.

Suppes T. Video: Battling Bipolar Disorder: Evidence for New Treatments and Tactics. Dallas, Texas:

psychCME, March 10, 2004.

Selected Invited Presentations

1991 “Discontinuation of Lithium in Bipolar Patients: How Safe is It?” Psychopharmacology Lunch

Program, McLean Hospital, October 10th.

1991 “Risk of Discontinuation of Lithium in Bipolar Disorder.” Scientific Advisory Committee Research

Symposium, McLean Hospital, November 18th -19th.

1992 “New Generation of Programs to Treat Mental Illness – Newly Refined Community Approaches.”

National Alliance for the Mentally Ill, Texas Chapter, May.

1992 “Bipolar, Depressive and Manic-Depressive Illnesses.” National Alliance for the Mentally Ill, Texas

Chapter, May.

1992 “Risk of Recurrence with Lithium Discontinuation.” Physician’s Evening Seminar, Zale Lipshy

University Hospital, UT Southwestern Medical Center, August 20th.

1992 “Clinical Risks and Scientific Issues in Discontinuing Psychotic Agents.” American College of

Neuropsychopharmacology 30th Meeting, December.

1993 “Day Hospitalization/Pharmacology.” Mental Health Connections Didactic Seminar, St. Paul

University, January 14th.

1993 “Maintenance Treatment and Risk of Relapse with Discontinuation.” Dallas, Texas, Abbott, January

16th.

1993 “Clozapine in Treatment of Dysphoric Mania, Psychotic Mood Disorders, S-A and Schizophrenia.”

UT Southwestern Medical Center, February 8th.

1993 Case Conference. Mental Health Connections, March 31st.

1993 “Pharmacological Treatment of Bipolar Disorder.” Terrell State Hospital, April 15th.

1993 “New Treatment in Bipolar Disorders.” UT Southwestern Medical Center, July 15th.

1993 “In Your Interest.” “Manic Depression.” KHSX-TV, Dallas, Texas, July 29th.

1993 “Bipolar Disorder.” Dallas Area Women Psychiatrists, October 16th.

1993 “Update on Bipolar Disorder: Should Medications be Continued Indefinitely?” Austin, Texas, Texas

Psychological Association, November 6th.

1993 “Maintenance Treatment in Bipolar Disorder: Risks and Implications.” Dallas, Texas, St. Paul

Medical Center, November 13th.

1993 “New Management Options in Bipolar Disorder.” Terrell, Texas, Terrell State Hospital, November

18th.

1993 The Mental Health Forum with Gary Lefkof, M.D. KGBS Talk Radio, Dallas, Texas, December 8th.

1993 International Psychopharmacology Algorithm Project Study Group, American College of

Neuropsychopharmacology (ACNP), December 13th.

1994 “Schizophrenia.” Health Matters, WFAA-TV. Dallas, Texas, January 16th.

1994 “New Management Options in Bipolar Disorder.” Waco, Texas, Heart of Texas Pharmacy

Association, January 20th.


Page 62 of 68

04.17.19

1994 “Treatment-Resistant Bipolar Disorder.” UT Southwestern Medical Center Grand Rounds, Dallas,

Texas, January 28th.

1994 “Can Medications Change Personality?” Texas State Network Radio Program, 1080 AM, Dallas,

Texas, February 10th.

1994 “New Management Options in Bipolar Disorder.” Vernon State Hospital, Vernon, Texas, February

17th.

1994 “Bipolar Disorder: Diagnostic Challenges, Treatment Optimization.” Discovery International,

Dallas, Texas, April 28th.

1994 “New Management Options in Bipolar Disorder.” Mississippi State Hospital, Whitfield, Mississippi,

May 24th.

1994 “Medications and Miracles: Advances in Treating Severe Mental Illness.” TEXAMI, UT

Southwestern Medical Center, Dallas, Texas, May 28th.

1994 “New Management Options in Bipolar Disorder.” Central Oklahoma Psychiatric Society, Oklahoma

City, Oklahoma, July 12th.

1994 “Recent Advances and Innovations in the Treatment of Bipolar Disorder.” Zale Lipshy University

Hospital Grand Rounds, Dallas, Texas, August 4th.

1994 “Clozapine Treatment of Schizoaffective and Bipolar Disorder Patients.” Texas State Alliance for

Mentally Ill, Fort Worth, Texas, September 23rd.

1994 “New Management Options in Bipolar Disorder.” Southern Psychiatric Association, New Orleans,

Louisiana, September 29th.

1994 “Petition of the Psychiatrist.” AMI Candlelight Vigil for Mental Awareness Week, Dallas, Texas,

October 2nd.

1995 Grand Rounds Presentation. Terrell State Hospital, Terrell, Texas, January 26th.

1995 Grand Rounds Presentation. Texas Tech University, Amarillo, Texas, March 23rd.

1995 “Bipolar Depression.” Terrell State Hospital Grand Rounds, Terrell, Texas, May 4th.

1995 “Changing Medications.” Dallas AMI, Dallas, Texas, May 4th.

1995 “Treatment Update on Bipolar Disorder: Focus on Bipolar Depression.” UT Health Science Center,

San Antonio, Texas, May 9th.

1995 Grand Rounds Presentation, Texas Tech Health Science Center, Lubbock, Texas, May 26th.

1995 “Treatment and Management of Bipolar Patients: The Old and the New.” Maricopa Medical Center,

Phoenix, Arizona, August 30th.

1995 “Critical Clinical Issues in Bipolar Disorder.” UT Southwestern Medical Center, Dallas, Texas,

September 30th.

1995 “Treatment of Bipolar Disorder.” University of New Mexico Grand Rounds, New Mexico, October

6th.

1996 “New Management Options in Bipolar Disorder.” St. Vincent Hospital, Santa Fe, New Mexico,

January 30th.

1996 “Risk and Implications of Interrupting Long-term Maintenance Treatment with Lithium and Other

Psychotropic Drugs. UT Southwestern Medical Center, February 7th.

1996 “Treatment and Management of Bipolar Patients: The Old and the New.” Griffin Memorial Hospital,

Norman, Oklahoma, February 22nd.

1996 “Treatment-Resistant Schizoaffective Illness and Bipolar Disorder.” Laureate Psychiatric Clinic and

Hospital, Tulsa, Oklahoma, March 20th.

1996 “Treatment-Resistant Schizoaffective Illness and Bipolar Disorder.” Community Mental Health

Center, Tulsa, Oklahoma, March 20th.

1996 “Advancing the Treatment of Mania Associated with Bipolar Disorder.” Big Spring State Hospital,

Big Spring, Texas, March 27th.


Page 63 of 68

04.17.19

1996 “New and Innovative Ways of Examining Treatment Strategies.” Stanford University Medical

Center, Stanford, California, April 5th.

1996 “Lifetime Treatment of Manic-Depressive Illness.” American Psychiatric Association, New York

City, New York, May.

1996 “Treatment and Management of Bipolar Patients: The Old and the New.” Texas Alliance for Mental

Illness, Dallas, Texas, September 28th.

1996 “The Early Detection for Bipolar Disorder.” UT Southwestern Medical Center, Dallas, Texas,

October 10th.

1996 “Treatment-Resistant Schizoaffective Illness with an Overview of Antipsychotics.” Texas Tech

University, Lubbock, Texas, October 18th.

1996 “Bipolar Disorder.” Brigham and Women’s Hospital, Boston, Massachusetts, October 22nd.

1997 “Bipolar Disorder.” Fort Worth DMDA, Fort Worth, Texas, March 7th.

1997 “Update on Schizophrenia: A Specialist’s Perspective.” Kerrville State Hospital Grand Rounds,

Kerrville, Texas, March 12th.

1997 “Update in the Diagnosis and Treatment of Bipolar Disorder.” St. Elizabeth’s Hospital, Washington

D.C., May 1st.

1997 “Better Treatments: Subtypes and Outcomes, Bipolar Depression and Comorbid Substance Abuse.”

Dallas, Texas, May 31st.

1997 Suppes T, Swann A, Crismon ML, Shon S, Rush AJ, Altshuler KZ. Will medication algorithms

provide adequate information on treatment response in bipolar disorder? New Clinical Drug

Evaluation Unit Annual Meeting, June.

1997 “Better Treatments: Subtypes and Outcomes, Bipolar Depression, and Comorbid Substance Abuse.”

Chicago, Illinois, June 29th.

1997 UCLA Bipolar Disorder Intensive Workshop, Redondo Beach, California, September 11th-13th.

1997 “Bipolar Disorder: Its Course and Consequences for Treatment.” Psychiatric University of Utrecht

(PUK), Utrecht, Netherlands, October 10th.

1997 “An Intensive Educational Experience for Psychiatrists.” Stanford University, Stanford, California,

November 13th-15th.

1998 “Bipolar Disorder and use of the Texas Medication Algorithm.” TMAP, Houston, Texas, February

13th.

1998 “Bipolar Disorders.” Dallas Area Women Psychiatrists, Dallas, Texas, March 14th.

1998 “Better Diagnosis of Bipolar Disorder and Enhanced Treatment for Bipolar Depression.” U.S.

Bipolar Disorders Update, San Diego, California, April 19th.

1998 “Better Diagnosis of Bipolar Disorder and Enhanced Treatment for Bipolar Depression.” U.S.

Bipolar Disorders Update, Los Angeles, California, May 9th.

1998 “Managing Treatment Resistant Patients Using Combination Medication.” UT Southwestern

Medical Center, Dallas, Texas, May 15th-16th.

1998 “Treatment Options for Acute Mania.” Consultant Meeting, Newport Beach, California, June 26th-

28th.

1998 “New Options in Bipolar Disorders.” Houston, Texas, July 18th.

1998 “New Options in Bipolar Disorders.” New Orleans, Louisiana, July 25th.

1998 “New Treatment Options in Bipolar Disorder.” Depressive and Manic Depressive Association,

Dallas, Texas, September 17th.

1998 “The Use of Anticonvulsants and Atypical Antipsychotics in Bipolar Disorder.” Texas Society of

Psychiatric Physicians Annual Convention, Houston, Texas, November 14th.

1998 “Update on Treatment of Bipolar Disorder.” Abbott Laboratories, Little Rock, Arkansas, November

19th.

1998 “New Options in Bipolar Disorders.” Austin, Texas, December 5th.


Page 64 of 68

04.17.19

1999 “New Options in Bipolar Disorders.” Tucson, Arizona, February 20th.

1999 “Use of Mood Stabilizers in the Treatment of Bipolar Disorder.” Menninger Clinic, Incorporated,

Kansas City, Missouri, March 20th.

1999 “Anticonvulsant Drugs in Psychiatry: Bipolar Disorders and Beyond.” Medical Education Systems,

April 15th.

1999 “Diagnosis and Treatment of Bipolar Depression.” SCP Communications, San Francisco, California,

April 30th.

1999 “Bipolar Disorder.” Scott and White Hospital Grand Rounds, Temple, Texas, June 4th.

1999 “Bipolar Treatment Update.” Glaxo Wellcome, Dallas, Texas, June 24th.

1999 “Bipolar Disorders and Substance Abuse: Toward Improved Outcomes.” St. Louis, Missouri, July

10th.

1999 “Anticonvulsant Drugs in Psychiatry: Bipolar Disorders and Beyond.” The Mansion on Turtle

Creek, Dallas, Texas, August 10th.

1999 “Update on Treatment of Bipolar Disorder.” NARSAD Symposium, Dallas, Texas, September 14th.

1999 “Update on Treatment of Bipolar Disorder.” National DMDA Conference, Houston, Texas, October

3rd.

1999 “Bipolar Depression: Clinical Physiologic, and Therapeutic Specificity.” ACNP, Acapulco, Mexico,

December 12th-16th.

2000 “Treatment Update on Bipolar Disorder.” Dallas Area Women Psychiatrists, Dallas, Texas, January

28th.

2000 “Balancing Treatment Alternatives for Bipolar Disorder: Maximizing Efficacy, Minimizing Side

Effects.” Dallas, Texas, April 15th.

2000 “Bipolar Depression: Clinical, Biological, and Treatment Specificity.” American Psychiatric

Association, Chicago, Illinois, May 15th.

2000 “Clinical Evidence on Antidepressants for Bipolar Disorder.” American Psychiatric Association,

Chicago, Illinois, May 15th.

2000 “How Useful are Third-Generation Anticonvulsants?” American Psychiatric Association, Chicago,

Illinois, May 17th.

2000 “Restoring Balance: Long-Term Mood Stabilization in the Bipolar Patient.” San Francisco,

California, April 28th.

2000 “Differential Diagnosis of Bipolar Disorder vs Unipolar Depression.” Dallas, Texas, June 28th.

2000 “Efficacy of Topiramate in Bipolar Disorder: First Clinical Results.” Collegium Internationale

Neuro-Psychopharmacologicum Congress, Brussels, Belgium, July 10th.

2000 “Clinical Update on Novel Treatment for Rapid Cycling Bipolar Disorder.” Collegium Internationale

Neuro-Psychopharmacologicum Congress, Brussels, Belgium, July 11th.

2001 “Minimizing the Impact of Adverse Reactions from Medications Used to Treat Bipolar Disorder.”

Genecom, Dallas, Texas, February 9th.

2001 “Treatment of Bipolar Disorder with Atypical Antipsychotics.” International Congress Centre,

Berlin, Germany, July 3rd.

2001 “Prevention 2001: Crisis in Changing Times.” Suicide and Crisis Center, Dallas, Texas, September

21st.

2001 “Bipolar Disorder.” Mental Illness Awareness Week, UT Southwestern Medical Center, Dallas,

Texas, October 6th.

2001 “Novel Treatments for Bipolar Disorder.” Texas Society of Psychiatric Physicians, Galveston,

Texas, November 3rd.

2002 “Exploring Novel Treatment Strategies for Bipolar Disorder.” Psychiatric Nursing Symposium,

Arlington, Texas, March 8th.


Page 65 of 68

04.17.19

2002 “Practical Considerations in Stabilizing Mania Associated with Bipolar Disorder.”

GlaxoSmithKline, Arlington, Texas, March 15th.

2002 “The Management of Mania Associated with Bipolar Disorder.” GlaxoSmithKline, Arlington,

Texas, April 12th.

2002 “Medication Strategies for Treatment of Refractory Patients with Bipolar Disorder.” American

Psychiatric Association, Philadelphia, Pennsylvania, May 19th.

2002 “Customizing Care for Patients with Bipolar Disorder.” American Psychiatric Association,

Philadelphia, Pennsylvania, May 19th.

2002 “The Role of Atypicals in Mania.” Seroquel Standalone Meeting, Seville, Spain, September 5th.

2002 “The Role of Atypicals in Mania.” International Forum on Mood and Anxiety, Monte Carlo,

November 28th.

2002 “Clinical Effectiveness in Bipolar Disorder.” International Forum on Mood and Anxiety, Monte

Carlo, November 28th.

2003 “Optimizing Drug Treatment in Bipolar Depression,” Johns Hopkins University and

GlaxoSmithKline Training, UT Southwestern Medical Center, February 10th.

2003 “Antipsychotic Use in Special Populations,” Dallas, Texas, AstraZeneca, April 2nd.

2003 “Bipolar II Disorder: The Concept of Dysphoric Hypomania”, UCLA Neuropsychiatric Institute and

Hospital, UCLA School of Medicine, Grand Rounds. April 15th

2003 “Evolving Treatment Strategies for Bipolar Disorder,” Bristol-Myers Squibb, Dallas, Texas, May

7th.

2003 “Treatment Approaches for Managing Anxiety Disorder in the Bipolar Patient,” American

Psychiatric Association, May 19th-22nd.

2003 “Clinical Predictors of Response to Maintenance Treatment in Bipolar I Disorder,” American

Psychiatric Association, May 19th-22nd.

2003 “Service Utilization Among Patients with Bipolar Disorder in the Texas Medication Algorithm

Project,” NCDEU, Boca Raton, Florida, May 29, 2003.

2003 “Assessing the Efficacy of Antipsychotics in Acute Mania,” CME, Dallas, Texas, June 7th.

2003 “Practical Considerations in Stabilizing Mania Associated with Bipolar Disorder,”

GlaxoSmithKline, Dallas, Texas, August 20th.

2003 “Stabilization for the Long Term,” GlaxoSmithKline, Dallas, Texas, August 23rd.

2003 “Long-Term Management of Bipolar Disorder,” GlaxoSmithKline, Dallas, Texas, August 25th.

2004 “Bipolar I Disorder: Stabilization for the Long-Term.” GlaxoSmithKline, Dallas, Texas, January

13th.

2004 “Antipsychotic Use in Special Populations.” AstraZeneca, Dallas, Texas, January 15th.

2004 “Stabilizing Bipolar Disorder: Key Factors in Achieving Patient Acceptance.” CME, Inc., Las

Vegas, Nevada, January 24th.

2004 “Practical Considerations for Choosing Long-Term Agents for the Management of Bipolar I

Disorder.” GlaxoSmithKline, Dallas, Texas, January 27th.

2004 “Antipsychotic Use in Special Populations.” AstraZeneca, Tulsa, Oklahoma, March 1st.

2004 “Antipsychotic Use in Special Populations.” Laureate Psychiatric Clinic and Hospital, Tulsa,

Oklahoma, March 1st.

2004 “Antipsychotic Use in Special Populations.” The Polo Grill, Tulsa, Oklahoma, March 1st.

2004 “Antipsychotic Use in Special Populations.” AstraZeneca, Muskogee, Oklahoma, March 2nd.

2004 “Antipsychotic Use in Special Populations.” Jasper’s, Muskogee, Oklahoma, March 2nd.

2004 “Stabilizing Bipolar Disorder: Key Factors in Achieving Successful Outcomes.” AstraZeneca,

Terrell State Hospital, Terrell, Texas, April 19th.

2004 “Bipolar Disorder.” University of Texas Medical Branch, Grand Rounds, Galveston, Texas,

September 14th.


Page 66 of 68

04.17.19

2004 "Latest Advances in the Multi-dimensional Assessment and Treatment of Bipolar Disorder."

Stanford University School of Medicine and GlaxoSmithKline, Oklahoma City, Oklahoma,

November 4th.

2005 "Update on Maintenance Treatment of Bipolar Disorder." Depression Bipolar Support Alliance of

Dallas, Dallas, Texas, January 20th.

2005 "Latest Advances in the Multi-dimensional Assessment and Treatment of Bipolar Disorder,"

Stanford University and GlaxoSmithKline, Dallas, TX, February 22nd.

2005 “Diagnosis of Bipolar II Disorder and Mixed Hypomania: Prevalence and Gender Specificity.”

University of Mexico School of Medicine, Grand Rounds, Albuquerque, NM, April 29th.

2005 “Diagnosis of Bipolar II Disorder and Mixed Hypomania: Prevalence and Gender Specificity.”

McLean Hospital, Harvard Medical School, Grand Rounds, Boston, MA, May 5th.

2005 “Treatment and Monitoring Guidelines and the Management of Patients with Psychiatric

Comorbidities in Bipolar Disorder.” American Psychiatric Association, Atlanta, GA, May 21st.

2005 “The Acute Setting: Achieving Stabilization.” American Psychiatric Association, Atlanta, GA, May

22nd.

2005 “Treatment Algorithms of Bipolar Disorder.” Sixth International Conference on Bipolar Disorder,

Pittsburgh, PA, June 16th.

2005 “The Role of Complementary and Alternative Medicine (CAM) in Bipolar Disorder.” Sixth

International Conference on Bipolar Disorder, Pittsburgh, PA, June 17th.

2005 “Bipolar Depression.” Psychopharmacology Update Series: Foundations and Innovations in the

Treatment of Bipolar Disorder, UT Health Science Center, San Antonio, TX, August 26th.

2005 “Management of Rapid Cycling in Patients with Bipolar Disorder.” Psychopharmacology Update

Series: Foundations and Innovations in the Treatment of Bipolar Disorder, UT Health Science

Center, San Antonio, TX, August 26th.

2005 “Treating Bipolar Disorder: Clinical Applications of the Texas Medication Algorithm Project

(TMAP), Dallas Group Psychotherapy Society for Continuing Education, Dallas, TX, October 28th.

2005 “Optimizing Treatment of Bipolar Disorder: Guideline-Driven Pharmacotherapy,” The Center for

Medical Knowledge CME Teleconference, November 15 – December 15.

2006 “The Impact of Bipolar Illness,” Foundations and Innovations in the Treatment of Bipolar Disorder,

Arizona Psychopharmacology Update Series, Scottsdale, AZ, April 28.

2006 “Psychopharmacologic Treatment of Mania,” Foundations and Innovations in the Treatment of

Bipolar Disorder, Arizona Psychopharmacology Update Series, Scottsdale, AZ, April 28.

2006 “Mixed Hypomania: Prevalence and Gender Specificity,” University of Arizona Grand Rounds,

Tucson, AZ, April 29.

2006 “Mood Disorders in Women,” Texas Medical Association, TexMed 2006, Houston, TX, May 5.

2006 “Diagnostic Dilemmas in Mixed States in Bipolar Disorder,” Understanding the Complexity of

Bipolar Mixed Episodes, psychCME and Postgraduate Institute for Medicine CME Program, San

Francisco, CA, May 13.

2006 “Bipolar Summit 2006: A Critical Appraisal of Current Practice,” Statement 8, Medical Summit

Series, San Diego, CA, June 19-20.

2006 “Examining Options and Issues in the Treatment of Bipolar Disorder,” Life Long Learning Initiative

Bipolar Disorder, CME, LLC program, San Jose, CA, June 22.

2006 “Introduction: Bipolar Disorder Clinical Challenges,” Bipolar Disorder Think Tank, Novartis

Pharmaceuticals Corporation, Philadelphia, PA, July 26.

2006 The Future of Psychiatric Diagnosis: Refining the Research Agenda, Dimensional Psychiatry,

National Institutes of Health, Bethesda, MD, July 26-28.


Page 67 of 68

04.17.19

2006 “Gender differences in bipolar disorder and a recent Stanley Bipolar network study on mixed

hypomania,” Management of Women with Bipolar Disorder, 2nd Biennial Conference of the

International Society for Bipolar Disorders, Edinburgh, Scotland, August 4.

2006 “Bipolar Guidelines, Algorithms, Consensus Statements –

Are They Worth the Paper They Are Written On?” Global Expert Forum, Eli Lilly Co., Barcelona,

Spain, October 4.

2006 “Efficacy for depressive episodes in patients with bipolar II disorder: Quetiapine monotherapy,”

Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5.

2006 “The Current Essentials in Diagnosing Bipolar Disorder Today,” Texas Society of Psychiatric

Physicians (CME), Austin, Texas, November 4.

2007 “Update on the Diagnosis and Treatment of Bipolar Disorder,” Medical University of South

Carolina, Grand Rounds, Charleston, South Carolina, March 23.

2007 “Diagnosis and Update to the Treatment Algorithms,” University of Oklahoma Health Sciences

Center, Grand Rounds, Oklahoma City, Oklahoma, April 12.

2007 “Managing Mixed Mania: Diagnostic Dilemmas and Therapeutic Challenges,” US Psychiatric and

Mental Health Congress, Regional Extension, CME LLC, San Franciso, CA, April 21.

2007 “Recent Research Findings in Bipolar Disorder,” NAMI-Dallas Coalition Advocates in Action,

Dallas, Texas, May 10.

2007 “Categories and Dimensions in Clinical & Research Contexts of Diagnostic Classifications of DSM-

V,” Invited Symposium, Annual Meeting of the American Psychiatric Association, San Diego, CA,

May 21.

2007 “Treatment of bipolar II disorder and consideration of the bipolar spectrum,” Invited Symposium:

The Bipolar Spectrum and Bipolar II Disorder; chair: Joseph Calabrese, MD. International

Conference on Bipolar Disorders, Pittsburgh, PA, June 7.

2007 “New trends for outpatient treatment of bipolar disorder,” NAMI Mental Illness Awareness Week

Conference, Plano, Texas, October 4.

2008 “Diagnosis and Treatment of Bipolar II Disorder,” University of Michigan, Grand Rounds, Ann

Arbor, Michigan, April 9.

2008 Chair, Invited Symposium: Mood Disorders II: Neural and Genetic Mechanisms; Annual Meeting

for Society of Biological Psychiatry, Washington, DC, May 2.

2008 “Quetiapine As Maintenance Therapy in Bipolar I Disorder,” Oral Report, Annual Meeting of the

American Psychiatric Association, Washington, DC, May 3-8.

2008 “Clinical trial design in the long-term treatment of bipolar disorder: patient considerations,” Invited

Symposium, 21st European College of Neuropsychopharmacology Congress, Barcelona, Spain,

September 2nd.

2008 “Sample Selection and Inclusion Criteria for Generalizability in Studies of Bipolar I & II” Bipolar

Statistical Summit, Bethesda, MD, October 29.

2009 “Evidence-Based Care for a Complex Illness: Treatment Guidelines for Bipolar Disorder,” Stanford

University School of Medicine, Grand Rounds, Palo Alto, CA, March 26th.

2009 “Depression/Bipolar Disorder and its Impact on the Family” Department of Veterans Affairs Support

and Family Education, Palo Alto, CA, April 23rd.

2009 “Bipolar Disorder and Treatment Guidelines” Santa Clara County Psychological Association, Santa

Clara, CA June 11th.

2009 “Sample Selection and Inclusion Criteria for Generalizability in Studies of Bipolar Disorder,” 49th

Annual Meeting New Clinical Drug Evaluation Unit (NCDEU), Hollywood, FL, June 29th.

2009 “Bipolar Spectrum and Bipolar II Disorders,” Eighth International Conference on Bipolar Disorder,

Pittsburgh, PA, June 27.


Page 68 of 68

04.17.19

2009 “Diagnosis Roundtable,” Eighth International Conference on Bipolar Disorder, Pittsburgh, PA, June

27th.

2009 “Applying Novel Methodologies to Long-Term Intervention Trials in Bipolar Disorder,” 49th Annual

NCDEU Meeting, Hollywood, FL, June 29th.

2009 “Klerman Award Presentation” and “Ask the Doctor” Q&AQ Panel, DBSA 2009 National

Conference, Indianapolis, IN, September 11th.

2009 “New APA Guidelines for Bipolar Disorder,” DBSA 2009 National Conference, Indianapolis, IN,

September 12th.

2010 “VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults,” Department

of Veterans Affairs, VA National PTSD Center educational series, Palo Alto, CA, August 17, 2010.

2010 “Bipolar Disorder: A Complex Illness” and Ask the Expert, Depression and Bipolar Support

Alliance (DBSA) support group meeting, Palo Alto, CA, November 17, 2010.

2011 “Proposed Changes to DSM 5 for Bipolar Disorder: Will it Matter?,” Grand Rounds, Department of

Psychiatry, University of New Mexico, Albuquerque, NM, April 8, 2011.

2011 “What do we know about Veterans with bipolar disorder?” Research Seminar Series, VA Palo Alto

Health Care System, Palo Alto, CA, May 6, 2011.

2012 “Update on DSM-5 Mood Disorders,” 8th Annual Mood Disorders Education Day, Stanford School

of Medicine, Stanford, CA, July 28, 2012.

2012 “VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults,” Department

of Veterans Affairs, Employee Education System and Office of Public Health and Environmental

Hazards, VA Palo Alto Health Care System, Palo Alto, CA September 20, 2012.

2013 “Mixed States?” International Society of Bipolar Disorders. Columbia. August 22, 2013

2013 “SSM-5 Criteria for Bipolar Disorder: What HAs Changed?” Florida Medicaid Drug Guideline.

September 20, 2013.

2013 “Challenging new perspectives in Mania” Expert Focus Meeting, Barcelona. October 13, 2013

2014 “DSM-5: Update to Bipolar Disorders” Stanford Psychiatry Grand Rounds. February 27, 2014

2014 “DSM-5: Update to Bipolar Disorders” Aztra Zeneca Speaker Tour. April 2014. Australia: Perth,

Melbourne, Sydney, and Brisbane

2014 “DSM-5: Update to Bipolar Disorders” Global Medical Education. May 2014. Rhode Island.

2015 “DSM-5: Update to Bipolar Disorders” INNOPSY. November 2015. Milan.

2015 “Diagnosis in Bipolar Disorders?” MQ Health. November 2015. London.

2017 “Recent Guideline Developments in the Veterans Administration – How Far Do Guidelines Take

Us?” ADDA. April 2017. San Francisco.

2017 “Discussion forum engagement within an internet-based program for bipolar disorder: impacts on

social support, stigma, quality of life and mood severity.” ISBD 2017. Washington D.C.

2017 “Efficacy and Safety of Lurasidone in Bipolar Depression: Treatment Review” WFSBP Congress,

June 18-22, 2017

2018 “Controversies in Bipolar Depression Across the Lifespan.” ASCP Annual Meeting May 29 – June

1, 2018

2018 “Treatment of Bipolar Depression: Is there more to do?” 2018 International Society of Affective

Disorders Conference, being held in conjunction with the Houston Mood Disorders Conference, on

September 20-22, 2018

2019 “Update on Treatment of Bipolar Disorder” ASCP-ISBD Workshop at the 2019 Annual ASCP

Meeting, May 28-31, 2019

2019 “What's Up with Mixed States in Bipolar Disorder and Major Depression” and “What’s New in

Innovative Medications and Approaches to Identify New Therapies for Mood Disorders” WFSBP

Congress Vancouver June 2019.

Documents

Curriculum Vitae Trisha Suppes, M.D., Ph.D. BIOGRAPHICAL